


**CUMULATIVE  
SUPPLEMENT 3  
March 2025**



**APPROVED  
DRUG PRODUCTS**

**WITH  
THERAPEUTIC EQUIVALENCE EVALUATIONS**

**45th EDITION**

**Department of Health and Human Services**

**Food and Drug Administration  
Office of Medical Products and Tobacco  
Center for Drug Evaluation and Research  
Office of Generic Drugs  
Office of Generic Drug Policy**

Prepared By  
Food and Drug Administration  
Office of Medical Products and Tobacco  
Center for Drug Evaluation and Research  
Office of Generic Drugs  
Office of Generic Drug Policy

**APPROVED DRUG PRODUCTS  
with  
THERAPEUTIC EQUIVALENCE EVALUATIONS**

**45<sup>th</sup> EDITION**

**Cumulative Supplement 3  
March 2025**

**CONTENTS**

*PAGE*

**Contents**

1.0	INTRODUCTION.....	v
1.1	HOW TO USE THE CUMULATIVE SUPPLEMENT.....	vi
1.2	CUMULATIVE SUPPLEMENT CONTENT.....	vi
1.3	APPLICANT NAME CHANGES.....	vii
1.4	LEVOTHYROXINE SODIUM.....	viii
1.5	AVAILABILITY OF THE EDITION.....	ix
1.6	REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST.....	ix
1.7	CUMULATIVE SUPPLEMENT LEGEND.....	xi
<b>DRUG PRODUCT LISTS</b>		
	Prescription Drug Product List .....	1-1
	OTC Drug Product List .....	2-1
	Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research List .....	3-1
	Orphan Products Designations and Approvals List .....	4-1
	Drug Products Which Must Demonstrate in vivo Bioavailability Only if Product Fails to Achieve Adequate Dissolution .....	5-1
<b>PATENT AND EXCLUSIVITY INFORMATION ADDENDUM</b>		
A.	Patent and Exclusivity Lists .....	A-1
B.	Patent and Exclusivity Terms .....	B-1

**APPROVED DRUG PRODUCTS  
with  
THERAPEUTIC EQUIVALENCE EVALUATIONS**

**45<sup>th</sup> EDITION**

**CUMULATIVE SUPPLEMENT 3  
March 2025**

**1.0 INTRODUCTION**

This Cumulative Supplement is one of a series of monthly updates to the *Approved Drug Products with Therapeutic Equivalence Evaluations* (the List, commonly known as the Orange Book). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; approved over-the-counter (OTC) drug products for those drugs that may not be marketed without NDAs or ANDAs because they are not covered under existing OTC monographs; drug products with approval under Section 505 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) administered by the Center for Biologics Evaluation and Research; and approved products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons, or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, Discontinued Drug Product, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of this Edition List will then be added to the "Discontinued Drug

Product List" appearing in the next Edition. The current Annual Edition Section 2., How To Use The Drug Product Lists, describes the layout and usage of the List.

## 1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity List new additions are indicated by the symbol >A> to the left of Patent Number or Exclusivity Code. The >A> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

## 1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month's second work week (e.g., November's supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.
- All product changes received and processed as of the date of publication.
  - Refer to CS Section 1.7 Cumulative Supplement Legend for types of changes
- New Drug Application (NDA) approvals appear in the CS month they were approved.

- Patent information, also updated daily in the EOB, is current to the date of publication.
- Exclusivity information is updated monthly and is current as of the date of publication.

Every effort is made to ensure the Cumulative Supplement is accurate. Applicant holders are requested to inform the FDA Division of Orange Book Publication and Regulatory Assessment (DOB/PRA) of any changes or corrections. The DOB/PRA can be contacted by email at [orangebook@fda.hhs.gov](mailto:orangebook@fda.hhs.gov).

### 1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each, and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

<u>FORMER APPLICANT NAME</u> <u>(FORMER ABBREVIATED NAME)</u>	<u>NEW APPLICANT NAME</u> <u>(NEW ABBREVIATED NAME)</u>
MYLAN INSTITUTIONAL LLC (MYLAN INSTITUTIONAL)	NORVIUM BIOSCIENCE LLC (NORVIUM BIOSCIENCE)
MYLAN LABORATORIES LTD (MYLAN LABS LTD)	NORVIUM BIOSCIENCE LLC (NORVIUM BIOSCIENCE)
MYLAN PHARMACEUTICALS INC (MYLAN)	NORVIUM BIOSCIENCE LLC (NORVIUM BIOSCIENCE)
MYLAN PHARMACEUTICALS INC (MYLAN PHARMS INC)	NORVIUM BIOSCIENCE LLC (NORVIUM BIOSCIENCE)
MYLAN TECHNOLOGIES INC (MYLAN TECHNOLOGIES)	NORVIUM BIOSCIENCE LLC (NORVIUM BIOSCIENCE)

## 1.4 LEVOTHYROXINE SODIUM<sup>1</sup>

Because there are multiple reference listed drugs for levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character therapeutic equivalence codes may be potentially confusing and inadequate for these drug products. Looking at the Orange Book listing alone for a product identified as a reference listed drug or reference standard, it may be difficult to determine to which therapeutic equivalence code the reference listed drugs and/or reference standard designation corresponds. For example, Unithroid 0.3 mg strength has been assigned the therapeutic equivalence codes AB1, AB2, and AB3 and it is identified as the reference listed drug and reference standard, but it is unclear that the reference listed drug and reference standard designations are associated with the AB1 therapeutic equivalence code.

Accordingly, FDA provides the following chart, which identifies (1) a reference listed drug for each therapeutic equivalence code in the Orange Book and (2) and the reference standard products in the Active Section of the Orange Book.<sup>2</sup>

- Therapeutic equivalence has been established between products that have the same AB+number therapeutic equivalence code (i.e. AB1, AB2, AB3 or AB4).
- More than one therapeutic equivalence code may apply to some products. One common therapeutic equivalence code indicates therapeutic equivalence between products. For example, Unithroid has been assigned therapeutic equivalence codes AB1, AB2, and AB3 therefore Unithroid tablets are considered therapeutically equivalent to other levothyroxine sodium products of the same strength with these therapeutic equivalence codes.

TE Code	Proprietary Name	Applicant	Strength	Appl No	RLD	RS
AB1	UNITHROID	STEVENS J	0.3MG	N021210	RLD	RS
AB2	SYNTHROID	ABBVIE	0.3MG	N021402	RLD	RS
AB3	LEVOXYL	KING PHARMS	0.2MG	N021301	RLD	RS
AB4	THYRO-TABS	ALVOGEN INC	0.3MG	N021116	RLD	-
AB4	LEVOTHYROXINE SODIUM <sup>3</sup>	MYLAN	0.3MG	A076187	-	RS

<sup>1</sup> In previous editions of the Orange Book, FDA provided a chart outlining therapeutic equivalence codes for all .025 mg levothyroxine sodium drug products in the Active Section of the Orange Book. FDA has decided, for ease of review, to revise the chart to identify the NDAs for the reference listed drugs for each therapeutic equivalence code (i.e., AB1, AB2, AB3, and AB4), and their corresponding reference standards, which are identified in 0.2 and 0.3 mg strengths.

<sup>2</sup> Please consult the Active Section of the Orange Book for information on other strengths.

<sup>3</sup> Lloyd's Thyro-Tabs tablets (NDA 021116) (previously known as Levothroid) previously was listed in the Discontinued Drug Product List section of the Orange Book. It is the RLD for therapeutic equivalents identified with the AB4 code. During this time, Mylan's levothyroxine product (ANDA 076187) was selected

## 1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) <http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm>, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions.

There are historical lists of Orange Book cumulative supplement product monthly changes at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm>. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm>. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket \*95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List,  
Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket \*95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List,  
<https://www.fda.gov/about-fda/reports-manuals-forms/forms>.

The current listing of the Orphan Product Designations and Approvals is available at <https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products>.

## 1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

### DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors;

---

as the reference standard for ANDA applicants to use to establish bioequivalence to Thyro-Tabs. It remains the reference standard for ANDA applicants to use to establish bioequivalence to Thyro-Tabs. If an ANDA that uses Mylan's levothyroxine product as its reference standard is approved, the ANDA will receive an AB4 rating. The ANDA applicant also may obtain an AB rating for its product to the other reference listed drugs (i.e., Unithroid, Synthroid, and Levoxyl) by submitting supplements that demonstrate that the generic product is bioequivalent to these other reference listed drugs and satisfies all other therapeutic equivalence criteria with respect to these reference listed drugs. See Letter from Janet Woodcock, M.D., Director, Center for Drug Evaluation and Research, FDA to Teri Nataline, Principal Consultant, Lachman Consultant Services, Inc., Docket No. FDA-2015-P-0403 (May 27, 2016).



those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (December of the previous Annual Edition) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST  
COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES</u> <u>COUNTED</u>	<u>DEC</u> <u>2024</u>	<u>MAR</u> <u>2025</u>	<u>JUN</u> <u>2025</u>	<u>SEP</u> <u>2025</u>	<u>DEC</u> <u>2025</u>
DRUG PRODUCTS LISTED SINGLE SOURCE	23856 2772 (11.8%)	23679 2740 (11.6%)			
MULTISOURCE	20814 (88.2%)	20939 (88.4%)			
THERAPEUTICALLY EQUIVALENT	20741 (87.9%)	20826 (88%)			
NOT THERAPEUTICALLY EQUIVALENT	73 (0.3%)	113 (0.5%)			
EXCEPTIONS <sup>4</sup>	47 (0.2%)	47 (0.2%)			
NEW MOLECULAR ENTITIES APPROVED	43	13			
NUMBER OF APPLICANTS	1197	1209			

<sup>4</sup> Amino acid containing products of varying composition (see Introduction, page xx of the List).

## 1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route of Administration and then by trade name (or established name of the active ingredient, if no trade name exists).

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, Reference Standard symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by "N" is a New Drug Application (NDA or innovator). The application number preceded by an "A" is an Abbreviated New Drug Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form, new route(s) of administration, new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be preceded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval
NFTG	New first-time generic approval
CAHN <sup>5</sup>	Applicant holder firm name has changed
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration
CFTG	Change. A TE Code is added when a first time generic for an innovator is approved.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMKT	Change. RX to OTC marketing status switch.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug
CHRS	Change. Reference Standard
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will appear in the discontinued section in the next edition.

---

<sup>5</sup> The Cumulative Supplement (CS) currently displays a condensed 20 character collapsed applicant holder firm name and the Electronic Orange Book (EOB) query may display up to a 250-character full applicant holder firm name. An applicant holder firm name change usually changes both the collapsed name and long name. On occasion, only the long name is changed resulting in the CS displaying only the collapsed name for the >D> and >A> action. The new firm long name will display in the EOB query.

ABIRATERONE ACETATE

TABLET;ORAL

ABIRATERONE ACETATE

>D>	AB	TEVA PHARMS USA	250MG	A208432	001	Oct 31, 2018	Mar	DISC
>A>	@		250MG	A208432	001	Oct 31, 2018	Mar	DISC
>D>	AB		500MG	A210726	001	Jan 26, 2023	Mar	DISC
>A>	@		500MG	A210726	001	Jan 26, 2023	Mar	DISC

ACAMPROSATE CALCIUM

TABLET, DELAYED RELEASE;ORAL

ACAMPROSATE CALCIUM

>D>	@	GLENMARK PHARMS LTD	333MG	A202229	001	Jul 16, 2013	Mar	CMFD
>A>	AB		333MG	A202229	001	Jul 16, 2013	Mar	CMFD

ACETAMINOPHEN

SOLUTION;INTRAVENOUS

ACETAMINOPHEN

>D>	AP	ASPIRO	1GM/100ML (10MG/ML)	A216617	001	Jul 27, 2022	Mar	CTEC
>A>	AP1		1GM/100ML (10MG/ML)	A216617	001	Jul 27, 2022	Mar	CTEC
>D>	+	B BRAUN MEDICAL INC	500MG/50ML (10MG/ML)	N204957	001	Feb 18, 2021	Mar	CFTG
>A>	AP	+	500MG/50ML (10MG/ML)	N204957	001	Feb 18, 2021	Mar	CFTG
>D>	+		1GM/100ML (10MG/ML)	N204957	002	Feb 18, 2021	Mar	CFTG
>A>	AP2	+	1GM/100ML (10MG/ML)	N204957	002	Feb 18, 2021	Mar	CFTG
>D>	AP	BAXTER HLTHCARE CORP	1GM/100ML (10MG/ML)	A214331	001	Sep 17, 2021	Mar	CTEC
>A>	AP1		1GM/100ML (10MG/ML)	A214331	001	Sep 17, 2021	Mar	CTEC
>D>	AP	EUGIA PHARMA	1GM/100ML (10MG/ML)	A210969	001	Oct 21, 2020	Mar	CTEC
>A>	AP1		1GM/100ML (10MG/ML)	A210969	001	Oct 21, 2020	Mar	CTEC
>A>	AP	GLAND	500MG/50ML (10MG/ML)	A219215	001	Apr 02, 2025	Mar	NFTG
>A>	AP2		1GM/100ML (10MG/ML)	A219215	002	Apr 02, 2025	Mar	NFTG
>D>	AP	HIKMA	1GM/100ML (10MG/ML)	A202605	001	Jun 13, 2016	Mar	CTEC
>A>	AP1		1GM/100ML (10MG/ML)	A202605	001	Jun 13, 2016	Mar	CTEC
>D>	AP	INFORLIFE	1GM/100ML (10MG/ML)	A215403	001	May 03, 2023	Mar	CTEC
>A>	AP1		1GM/100ML (10MG/ML)	A215403	001	May 03, 2023	Mar	CTEC
>D>	AP	MYLAN	1GM/100ML (10MG/ML)	A213255	001	Aug 07, 2020	Mar	CTEC
>A>	AP1		1GM/100ML (10MG/ML)	A213255	001	Aug 07, 2020	Mar	CTEC
>D>	AP	! SANDOZ	1GM/100ML (10MG/ML)	A204052	001	Mar 22, 2016	Mar	CTEC
>A>	AP1	!	1GM/100ML (10MG/ML)	A204052	001	Mar 22, 2016	Mar	CTEC
>D>	AP	WOCKHARDT BIO AG	1GM/100ML (10MG/ML)	A205746	001	Apr 18, 2023	Mar	CTEC
>A>	AP1		1GM/100ML (10MG/ML)	A205746	001	Apr 18, 2023	Mar	CTEC

ACETAMINOPHEN; CODEINE PHOSPHATE

SOLUTION;ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

	@	CHARTWELL	120MG/5ML;12MG/5ML	A089450	001	Oct 27, 1992	Feb	DISC
	!	GENUS LIFESCIENCES	120MG/5ML;12MG/5ML	A087508	001		Feb	CTEC
	@	XTTRIUM LABS INC	120MG/5ML;12MG/5ML	A087006	001		Feb	CAHN

ACETAMINOPHEN; HYDROCODONE BITARTRATE

SOLUTION;ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

	@	CHARTWELL	325MG/15ML;7.5MG/15ML	A040482	001	Sep 25, 2003	Feb	DISC
AA	!	WES PHARMA INC	325MG/15ML;7.5MG/15ML	A211023	001	Mar 08, 2019	Feb	CHRS

TABLET;ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

	@	CHARTWELL	300MG;5MG	A040658	001	Jan 19, 2006	Feb	DISC
	@		300MG;7.5MG	A040658	002	Mar 24, 2006	Feb	DISC
	@		300MG;10MG	A040658	003	Jun 23, 2004	Feb	DISC
	@		325MG;7.5MG	A040432	001	Jan 22, 2003	Feb	DISC
	@	RHODES PHARMS	300MG;5MG	A207808	001	Mar 30, 2018	Jan	DISC
	@		300MG;7.5MG	A207808	002	Mar 30, 2018	Jan	DISC
	@		300MG;10MG	A207808	003	Mar 30, 2018	Jan	DISC
AA	!	SPECGX LLC	300MG;5MG	A206718	001	Mar 31, 2017	Feb	CHRS
AA	!		300MG;7.5MG	A206718	002	Mar 31, 2017	Feb	CHRS
AA	!		300MG;10MG	A206718	003	Mar 31, 2017	Feb	CHRS

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

TABLET; ORAL

OXYCODONE AND ACETAMINOPHEN

@	CHARTWELL	325MG; 5MG	A207834	001	Aug 15, 2019	Feb	DISC
@		325MG; 7.5MG	A207834	002	Aug 15, 2019	Feb	DISC
@		325MG; 10MG	A207834	003	Aug 15, 2019	Feb	DISC

ACETAZOLAMIDE

TABLET; ORAL

DIAMOX

+	@	TEVA BRANDED PHARM	125MG	N008943	001		Feb	CAHN
+	@		250MG	N008943	002		Feb	CAHN

ACETYLCYSTEINE

SOLUTION; INHALATION, ORAL

ACETYLCYSTEINE

>A>	AN	CONBA USA	10%	A214177	001	Mar 14, 2025	Mar	NEWA
>A>	AN		20%	A214177	002	Mar 14, 2025	Mar	NEWA
	AN	SOMERSET THERAPS LLC	10%	A219194	001	Feb 12, 2025	Jan	NEWA
	AN		20%	A219194	002	Feb 12, 2025	Jan	NEWA

ACYCLOVIR

CREAM; TOPICAL

ACYCLOVIR

>D>	AB	ZYDUS LIFESCIENCES	5%	A206770	001	Feb 28, 2023	Mar	CTEC
>A>	BX		5%	A206770	001	Feb 28, 2023	Mar	CTEC

OINTMENT; TOPICAL

ACYCLOVIR

	@	APOTEX	5%	A210774	001	Sep 06, 2019	Jan	DISC
	@	CHARTWELL MOLECULAR	5%	A206437	001	Jul 31, 2017	Feb	CAHN
>D>	AB	CIPLA	5%	A211794	001	Jan 18, 2019	Mar	CTEC
>A>	BX		5%	A211794	001	Jan 18, 2019	Mar	CTEC

ACYCLOVIR SODIUM

INJECTABLE; INJECTION

ACYCLOVIR SODIUM

@	FRESENIUS KABI USA	EQ 50MG BASE/ML	A215404	001	Jun 25, 2024	Feb	DISC
---	--------------------	-----------------	---------	-----	--------------	-----	------

ALBUTEROL SULFATE

AEROSOL, METERED; INHALATION

ALBUTEROL SULFATE

>D>	@	PADAGIS US	EQ 0.09MG BASE/INH	A203760	001	Feb 24, 2020	Mar	CMFD
>A>	AB2		EQ 0.09MG BASE/INH	A203760	001	Feb 24, 2020	Mar	CMFD

POWDER, METERED; INHALATION

PROAIR DIGIHALER

+	@	TEVA BRANDED PHARM	EQ 0.09MG BASE/INH	N205636	002	Dec 21, 2018	Feb	CAHN
---	---	--------------------	--------------------	---------	-----	--------------	-----	------

+	!	TEVA BRANDED PHARM	EQ 0.09MG BASE/INH	N205636	001	Mar 31, 2015	Feb	CAHN
---	---	--------------------	--------------------	---------	-----	--------------	-----	------

SOLUTION; INHALATION

ALBUTEROL SULFATE

AN		RITEDOSE CORP	EQ 0.5% BASE	A218386	001	Mar 12, 2025	Feb	NEWA
----	--	---------------	--------------	---------	-----	--------------	-----	------

SYRUP; ORAL

ALBUTEROL SULFATE

@	COSETTE	EQ 2MG BASE/5ML	A074454	001	Sep 25, 1995	Jan	DISC
---	---------	-----------------	---------	-----	--------------	-----	------

ALENDRONATE SODIUM

TABLET; ORAL

ALENDRONATE SODIUM

>D>	AB	APOTEX	EQ 5MG BASE	A077982	001	Aug 04, 2008	Mar	DISC
>A>		@	EQ 5MG BASE	A077982	001	Aug 04, 2008	Mar	DISC
>D>	AB		EQ 10MG BASE	A077982	002	Aug 04, 2008	Mar	DISC
>A>		@	EQ 10MG BASE	A077982	002	Aug 04, 2008	Mar	DISC
>D>	AB		EQ 35MG BASE	A077982	003	Aug 04, 2008	Mar	DISC
>A>		@	EQ 35MG BASE	A077982	003	Aug 04, 2008	Mar	DISC
>D>	AB		EQ 70MG BASE	A077982	004	Aug 04, 2008	Mar	DISC
>A>		@	EQ 70MG BASE	A077982	004	Aug 04, 2008	Mar	DISC

ALPRAZOLAM

## TABLET; ORAL

## ALPRAZOLAM

>D>	AB	APOTEX INC	0.25MG	A 077741	001	Jan 19, 2007	Mar	DISC
>A>		@	0.25MG	A 077741	001	Jan 19, 2007	Mar	DISC
>D>	AB		0.5MG	A 077741	002	Jan 19, 2007	Mar	DISC
>A>		@	0.5MG	A 077741	002	Jan 19, 2007	Mar	DISC
>D>	AB		1MG	A 077741	003	Jan 19, 2007	Mar	DISC
>A>		@	1MG	A 077741	003	Jan 19, 2007	Mar	DISC
>D>	AB		2MG	A 077741	004	Jan 19, 2007	Mar	DISC
>A>		@	2MG	A 077741	004	Jan 19, 2007	Mar	DISC

## TABLET, EXTENDED RELEASE; ORAL

## ALPRAZOLAM

>D>	AB	APOTEX INC	0.5MG	A 078449	001	Nov 12, 2008	Mar	DISC
>A>		@	0.5MG	A 078449	001	Nov 12, 2008	Mar	DISC
>D>	AB		1MG	A 078449	004	Dec 23, 2015	Mar	DISC
>A>		@	1MG	A 078449	004	Dec 23, 2015	Mar	DISC
>D>	AB		2MG	A 078449	002	Nov 12, 2008	Mar	DISC
>A>		@	2MG	A 078449	002	Nov 12, 2008	Mar	DISC
>D>	AB		3MG	A 078449	003	Nov 12, 2008	Mar	DISC
>A>		@	3MG	A 078449	003	Nov 12, 2008	Mar	DISC

ALPROSTADIL

## SUPPOSITORY; URETHRAL

## MUSE

+	@	VIATRIS	0.125MG	N 020700	001	Nov 19, 1996	Feb	CAHN
+	@		0.25MG	N 020700	002	Nov 19, 1996	Feb	CAHN
+	@		0.5MG	N 020700	003	Nov 19, 1996	Feb	CAHN
+	@		1MG	N 020700	004	Nov 19, 1996	Feb	CAHN

AMANTADINE HYDROCHLORIDE

## SYRUP; ORAL

## AMANTADINE HYDROCHLORIDE

>A>		@	BAJAJ	50MG/5ML	A 075819	001	Sep 11, 2002	Mar	CAHN
>D>		@	CMP PHARMA INC	50MG/5ML	A 075819	001	Sep 11, 2002	Mar	CAHN

AMCINONIDE

## LOTION; TOPICAL

## AMCINONIDE

!		SOLUBIOMIX	0.1%	A 076329	001	Nov 06, 2002	Feb	CAHN
---	--	------------	------	----------	-----	--------------	-----	------

AMINOCAPROIC ACID

## SOLUTION; ORAL

## AMINOCAPROIC ACID

AA		AJENAT PHARMS	0.25GM/ML	A 213825	001	Apr 08, 2021	Jan	CAHN
----	--	---------------	-----------	----------	-----	--------------	-----	------

AMITRIPTYLINE HYDROCHLORIDE

## TABLET; ORAL

## AMITRIPTYLINE HYDROCHLORIDE

>D>	AB	RUBICON	10MG	A 215376	001	May 01, 2023	Mar	CTEC
>A>	BX		10MG	A 215376	001	May 01, 2023	Mar	CTEC
>D>	AB		25MG	A 215376	002	May 01, 2023	Mar	CTEC
>A>	BX		25MG	A 215376	002	May 01, 2023	Mar	CTEC
>D>	AB		50MG	A 215376	003	May 01, 2023	Mar	CTEC
>A>	BX		50MG	A 215376	003	May 01, 2023	Mar	CTEC
>D>	AB		75MG	A 215376	004	May 01, 2023	Mar	CTEC
>A>	BX		75MG	A 215376	004	May 01, 2023	Mar	CTEC
>D>	AB		100MG	A 215376	005	May 01, 2023	Mar	CTEC
>A>	BX		100MG	A 215376	005	May 01, 2023	Mar	CTEC
>D>	AB		150MG	A 215376	006	May 01, 2023	Mar	CTEC
>A>	BX		150MG	A 215376	006	May 01, 2023	Mar	CTEC

AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM

## TABLET; ORAL

## AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM

AB		APDM PHARMS	EQ 2.5MG BASE;EQ 10MG BASE	A 207762	001	Jan 11, 2019	Feb	CAHN
AB			EQ 2.5MG BASE;EQ 20MG BASE	A 207762	002	Jan 11, 2019	Feb	CAHN
AB			EQ 2.5MG BASE;EQ 40MG BASE	A 207762	003	Jan 11, 2019	Feb	CAHN
AB			EQ 5MG BASE;EQ 10MG BASE	A 207762	004	Jan 11, 2019	Feb	CAHN
AB			EQ 5MG BASE;EQ 20MG BASE	A 207762	005	Jan 11, 2019	Feb	CAHN
AB			EQ 5MG BASE;EQ 40MG BASE	A 207762	006	Jan 11, 2019	Feb	CAHN

## TABLET;ORAL

## AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM

AB		EQ 5MG BASE;EQ 80MG BASE	A207762	007	Jan 11, 2019	Feb CAHN
AB		EQ 10MG BASE;EQ 10MG BASE	A207762	008	Jan 11, 2019	Feb CAHN
AB		EQ 10MG BASE;EQ 20MG BASE	A207762	009	Jan 11, 2019	Feb CAHN
AB		EQ 10MG BASE;EQ 40MG BASE	A207762	010	Jan 11, 2019	Feb CAHN
AB		EQ 10MG BASE;EQ 80MG BASE	A207762	011	Jan 11, 2019	Feb CAHN

AMLODIPINE BESYLATE; OLMESARTAN MEDOXOMIL

## TABLET;ORAL

## AMLODIPINE AND OLMESARTAN MEDOXOMIL

AB	HETERO LABS LTD V	EQ 5MG BASE;20MG	A209591	001	Feb 14, 2025	Feb NEWA
AB		EQ 5MG BASE;40MG	A209591	002	Feb 14, 2025	Feb NEWA
AB		EQ 10MG BASE;20MG	A209591	003	Feb 14, 2025	Feb NEWA
AB		EQ 10MG BASE;40MG	A209591	004	Feb 14, 2025	Feb NEWA

AMMONIA N-13

## INJECTABLE;INTRAVENOUS

## AMMONIA N 13

>D>	AP	DECATUR	30mCi-300mCi/8ML (3.75-37.5mCi/ML)	A204465	001	Oct 23, 2014	Mar CAHN
>A>	AP	SOFIE	30mCi-300mCi/8ML (3.75-37.5mCi/ML)	A204465	001	Oct 23, 2014	Mar CAHN

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

## TABLET;ORAL

## DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB	CEDIPROF INC	1.25MG;1.25MG;1.25MG;1.25MG	A210754	001	Jul 05, 2022	Jan CMFD
AB		2.5MG;2.5MG;2.5MG;2.5MG	A210754	002	Jul 05, 2022	Jan CMFD
AB		3.75MG;3.75MG;3.75MG;3.75MG	A210754	003	Jul 05, 2022	Jan CMFD
AB		5MG;5MG;5MG;5MG	A210754	004	Jul 05, 2022	Jan CMFD
AB		7.5MG;7.5MG;7.5MG;7.5MG	A210754	005	Jul 05, 2022	Jan CMFD

AMPHETAMINE SULFATE

## TABLET;ORAL

## AMPHETAMINE SULFATE

	@ RHODES PHARMS	5MG	A213852	001	Sep 07, 2021	Jan DISC
	@	10MG	A213852	002	Sep 07, 2021	Jan DISC

AMPICILLIN SODIUM; SULBACTAM SODIUM

## INJECTABLE;INJECTION

## AMPICILLIN AND SULBACTAM

>D>	AP	HIKMA	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A065074	001	Mar 19, 2002	Mar DISC
>A>		@	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A065074	001	Mar 19, 2002	Mar DISC
>D>	AP		EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A065074	002	Mar 19, 2002	Mar DISC
>A>		@	EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A065074	002	Mar 19, 2002	Mar DISC

ANAGRELIDE HYDROCHLORIDE

## CAPSULE;ORAL

## ANAGRELIDE HYDROCHLORIDE

>D>		@ BARR	EQ 0.5MG BASE	A076530	001	Apr 18, 2005	Mar CAHN
>D>		@	EQ 1MG BASE	A076530	002	Apr 18, 2005	Mar CAHN
>A>		@ BARR LABS	EQ 0.5MG BASE	A076530	001	Apr 18, 2005	Mar CAHN
>A>		@	EQ 1MG BASE	A076530	002	Apr 18, 2005	Mar CAHN

APALUTAMIDE

## TABLET;ORAL

## APALUTAMIDE

>A>	AB	ZYDUS	60MG	A217113	001	Mar 17, 2025	Mar NFTG
		ERLEADA					
>D>		+ JANSSEN BIOTECH	60MG	N210951	001	Feb 14, 2018	Mar CFTG
>A>	AB	+	60MG	N210951	001	Feb 14, 2018	Mar CFTG

APIXABAN

## TABLET;ORAL

## APIXABAN

AB	IMPAX	2.5MG	A209810	001	Feb 14, 2025	Feb NEWA
AB		5MG	A209810	002	Feb 14, 2025	Feb NEWA
AB	MACLEODS PHARMS LTD	2.5MG	A210067	001	Feb 27, 2025	Feb NEWA
AB		5MG	A210067	002	Feb 27, 2025	Feb NEWA

APOMORPHINE HYDROCHLORIDESOLUTION;SUBCUTANEOUS  
ONAPGO

+! MDD US 98MG/20ML (4.9MG/ML) N214056 001 Feb 03, 2025 Feb NEWA

ARFORMOTEROL TARTRATESOLUTION;INHALATION  
ARFORMOTEROL TARTRATEAN AUCTA EQ 0.015MG BASE/2ML A218380 001 Feb 03, 2025 Jan NEWA  
AN MICRO LABS EQ 0.015MG BASE/2ML A218555 001 Mar 07, 2025 Feb NEWAARGATROBANINJECTABLE;INTRAVENOUS  
ARGATROBAN IN SODIUM CHLORIDE>A> AP +! PLANO PHARMS 125MG/125ML (1MG/ML) N022485 001 May 09, 2011 Mar CAHN  
>D> AP +! SANDOZ 125MG/125ML (1MG/ML) N022485 001 May 09, 2011 Mar CAHNARIPIPIRAZOLEFOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR  
ABILIFY MAINTENA KIT+ OTSUKA PHARM CO LTD 300MG/VIAL N202971 001 Feb 28, 2013 Jan CTEC  
+! 400MG/VIAL N202971 002 Feb 28, 2013 Jan CTEC

ARIPIPIRAZOLE

@ MYLAN 300MG/VIAL A216608 001 Dec 03, 2024 Jan DISC

@ 400MG/VIAL A216608 002 Dec 03, 2024 Jan DISC

SOLUTION;ORAL

ARIPIPIRAZOLE

AA VISTAPHARM LLC 1MG/ML A212870 001 Dec 26, 2019 Jan CAHN

ARMODAFINILTABLET;ORAL  
NUVIGILAB + NUVO PHARMS 50MG N021875 001 Jun 15, 2007 Jan CAHN  
+ @ 100MG N021875 002 Mar 26, 2009 Jan CAHN  
AB + 150MG N021875 003 Jun 15, 2007 Jan CAHN  
AB + 200MG N021875 005 Mar 26, 2009 Jan CAHN  
AB +! 250MG N021875 004 Jun 15, 2007 Jan CAHNATORVASTATIN CALCIUMTABLET;ORAL  
ATORVASTATIN CALCIUM>D> AB SUN PHARM INDS LTD EQ 10MG BASE A076477 001 Nov 30, 2011 Mar DISC  
>A> @ EQ 10MG BASE A076477 001 Nov 30, 2011 Mar DISCATOVAQUONESUSPENSION;ORAL  
ATOVAQUONE>D> AB APOTEX 750MG/5ML A209750 001 Oct 11, 2017 Mar DISC  
>A> @ 750MG/5ML A209750 001 Oct 11, 2017 Mar DISCAVIBACTAM SODIUM; AZTREONAMPOWDER;INTRAVENOUS  
EMBLAVEO

+! ABBVIE EQ 0.5GM BASE/VIAL;1.5GM/VIAL N217906 001 Feb 07, 2025 Feb NEWA

AZELASTINE HYDROCHLORIDESPRAY, METERED;NASAL  
ASTEPRO+ @ NORVIUM BIOSCIENCE 0.137MG/SPRAY N022203 001 Oct 15, 2008 Jan CAHN  
@ 0.2055MG/SPRAY N022203 002 Aug 31, 2009 Jan CAHN

AZELASTINE HYDROCHLORIDE

@ BIONPHARMA 0.137MG/SPRAY A090176 001 Jul 28, 2015 Jan DISC

AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATESPRAY, METERED;NASAL  
AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE

&gt;A&gt; AB TEVA PHARMS USA INC 0.137MG/SPRAY;0.05MG/SPRAY A208436 001 Apr 08, 2025 Mar NEWA

AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE

TABLET;ORAL

AZILSARTAN MEDOXOMIL AND CHLORTHALIDONE

AB	ALKEM LABS LTD	EQ 40MG MEDOXOMIL;12.5MG	A217490	001	Jan 21, 2025	Jan NFTG
AB		EQ 40MG MEDOXOMIL;25MG	A217490	002	Jan 21, 2025	Jan NFTG
	EDARBYCLOR					
AB	+ AZURITY	EQ 40MG MEDOXOMIL;12.5MG	N202331	001	Dec 20, 2011	Jan CFTG
AB	+	EQ 40MG MEDOXOMIL;25MG	N202331	002	Dec 20, 2011	Jan CFTG

AZITHROMYCIN

FOR SUSPENSION;ORAL

AZITHROMYCIN

AB	CHARTWELL RX	EQ 100MG BASE/5ML	A065488	001	May 15, 2015	Feb CMFD
AB		EQ 200MG BASE/5ML	A065488	002	May 15, 2015	Feb CMFD
>D>	HAINAN POLY	EQ 100MG BASE/5ML	A217036	001	Jul 27, 2023	Mar CAHN
>D>		EQ 200MG BASE/5ML	A217036	002	Jul 27, 2023	Mar CAHN
>A>	ZHEJIANG POLY PHARM	EQ 100MG BASE/5ML	A217036	001	Jul 27, 2023	Mar CAHN
>A>		EQ 200MG BASE/5ML	A217036	002	Jul 27, 2023	Mar CAHN

BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC

LUMI-SPORYN

AT	+ CASPER PHARMA LLC	400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM	N050417	001		Feb CPOT
----	---------------------	--	---------	-----	--	----------

BACLOFEN

TABLET;ORAL

BACLOFEN

AB	APPCO	5MG	A090334	003	Jan 31, 2025	Jan NEWA
----	-------	-----	---------	-----	--------------	----------

BALSALAZIDE DISODIUM

CAPSULE;ORAL

BALSALAZIDE DISODIUM

>A>	AB	CARNEGIE	750MG	A219422	001	Apr 03, 2025	Mar NEWA
-----	----	----------	-------	---------	-----	--------------	----------

BECLOMETHASONE DIPROPIONATE

AEROSOL, METERED;INHALATION

QVAR 40

>D>	+ @	TEVA BRANDED PHARM	0.04MG/INH	N020911	002	Sep 15, 2000	Mar CAHN
>A>	+ @		0.04MG/INH	N020911	002	Sep 15, 2000	Mar CAHN
		QVAR 80					
>D>	+ @	TEVA BRANDED PHARM	0.08MG/INH	N020911	001	Sep 15, 2000	Mar CAHN
>A>	+ @		0.08MG/INH	N020911	001	Sep 15, 2000	Mar CAHN

AEROSOL, METERED;NASAL

QNASL

	+	TEVA BRANDED PHARM	0.04MG/ACTUATION	N202813	002	Dec 17, 2014	Feb CAHN
	+		0.08MG/ACTUATION	N202813	001	Mar 23, 2012	Feb CAHN

BENZTROPINE MESYLATE

TABLET;ORAL

BENZTROPINE MESYLATE

AA	QUAGEN	0.5MG	A212694	001	Feb 11, 2025	Jan NEWA
AA		1MG	A212694	002	Feb 11, 2025	Jan NEWA
AA		2MG	A212694	003	Feb 11, 2025	Jan NEWA

BETAMETHASONE DIPROPIONATE

CREAM, AUGMENTED;TOPICAL

BETAMETHASONE DIPROPIONATE

@	CHARTWELL MOLECULAR	EQ 0.05% BASE	A076603	001	Jan 23, 2004	Feb CAHN
---	---------------------	---------------	---------	-----	--------------	----------

BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE

SUSPENSION;TOPICAL

CALCIPOTRIENE AND BETHAMETHASONE DIPROPIONATE

@	PADAGIS ISRAEL	0.064%;0.005%	A212367	001	Sep 11, 2020	Jan DISC
---	----------------	---------------	---------	-----	--------------	----------

BEXAROTENE

CAPSULE;ORAL

BEXAROTENE

@	CIPLA	75MG	A210352	001	Dec 10, 2024	Jan DISC
---	-------	------	---------	-----	--------------	----------



BICALUTAMIDETABLET; ORAL  
BICALUTAMIDE

>D>	AB	APOTEX	50MG	A200274	001	May 21, 2015	Mar	DISC
>A>		@	50MG	A200274	001	May 21, 2015	Mar	DISC

BIMATOPROSTSOLUTION/DROPS; OPHTHALMIC  
BIMATOPROST

>A>	AB	MANKIND PHARMA	0.01%	A218196	001	Mar 17, 2025	Mar	NFTG
		LUMIGAN						
>D>	+	ABBVIE	0.01%	N022184	001	Aug 31, 2010	Mar	CFTG
>A>	AB	+	0.01%	N022184	001	Aug 31, 2010	Mar	CFTG

BISOPROLOL FUMARATETABLET; ORAL  
BISOPROLOL FUMARATE

>A>		RUBICON	2.5MG	A075643	003	Mar 07, 2025	Mar	NEWA
-----	--	---------	-------	---------	-----	--------------	-----	------

BOSENTANTABLET, FOR SUSPENSION; ORAL  
BOSENTAN

AB		NATCO PHARMA LTD	32MG	A213154	001	Feb 05, 2025	Jan	NFTG
		TRACLEER						
AB	+	ACTELION	32MG	N209279	001	Sep 05, 2017	Jan	CFTG

BREXANOLONESOLUTION; INTRAVENOUS  
ZULRESSO

+	@	SAGE THERAP	100MG/20ML (5MG/ML)	N211371	001	Jun 17, 2019	Jan	DISC
---	---	-------------	---------------------	---------	-----	--------------	-----	------

BREXPIPIRAZOLETABLET; ORAL  
BREXPIPIRAZOLE

AB		ALEMBIC	0.25MG	A213683	001	Jan 13, 2025	Jan	NEWA
AB			0.5MG	A213683	002	Jan 13, 2025	Jan	NEWA
AB			1MG	A213683	003	Jan 13, 2025	Jan	NEWA
AB			2MG	A213683	004	Jan 13, 2025	Jan	NEWA
AB			3MG	A213683	005	Jan 13, 2025	Jan	NEWA
AB			4MG	A213683	006	Jan 13, 2025	Jan	NEWA
>D>	AB	APOTEX	0.25MG	A213731	001	Feb 24, 2025	Mar	DISC
>A>		@	0.25MG	A213731	001	Feb 24, 2025	Mar	DISC
	AB		0.25MG	A213731	001	Feb 24, 2025	Feb	NEWA
>D>	AB		0.5MG	A213731	002	Feb 24, 2025	Mar	DISC
>A>		@	0.5MG	A213731	002	Feb 24, 2025	Mar	DISC
	AB		0.5MG	A213731	002	Feb 24, 2025	Feb	NEWA
>D>	AB		1MG	A213731	003	Feb 24, 2025	Mar	DISC
>A>		@	1MG	A213731	003	Feb 24, 2025	Mar	DISC
	AB		1MG	A213731	003	Feb 24, 2025	Feb	NEWA
>D>	AB		2MG	A213731	004	Feb 24, 2025	Mar	DISC
>A>		@	2MG	A213731	004	Feb 24, 2025	Mar	DISC
	AB		2MG	A213731	004	Feb 24, 2025	Feb	NEWA
>D>	AB		3MG	A213731	005	Feb 24, 2025	Mar	DISC
>A>		@	3MG	A213731	005	Feb 24, 2025	Mar	DISC
	AB		3MG	A213731	005	Feb 24, 2025	Feb	NEWA
		REXULTI						
AB	+	OTSUKA	0.25MG	N205422	001	Jul 10, 2015	Jan	CTEC
AB	+		0.5MG	N205422	002	Jul 10, 2015	Jan	CTEC
AB	+		1MG	N205422	003	Jul 10, 2015	Jan	CTEC
AB	+		2MG	N205422	004	Jul 10, 2015	Jan	CTEC
AB	+		3MG	N205422	005	Jul 10, 2015	Jan	CTEC
AB	+		4MG	N205422	006	Jul 10, 2015	Jan	CTEC

BRIMONIDINE TARTRATE; TIMOLOL MALEATESOLUTION/DROPS; OPHTHALMIC  
BRIMONIDINE TARTRATE AND TIMOLOL MALEATE

AB		@ AMNEAL	0.2%;EQ 0.5% BASE	A217288	001	Dec 30, 2024	Jan	DISC
AB		CAPLIN	0.2%;EQ 0.5% BASE	A219093	001	Feb 25, 2025	Feb	NEWA

BROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

SYRUP; ORAL  
BROMFED-DM

AA	+	XTTRIUM LABS INC	2MG/5ML; 10MG/5ML; 30MG/5ML	A088811	001	Jun 07, 1985	Feb	CAHN
----	---	------------------	-----------------------------	---------	-----	--------------	-----	------

BUDESONIDE

SUSPENSION; INHALATION  
BUDESONIDE

	@	SANDOZ	0.25MG/2ML	A201966	003	Sep 27, 2013	Feb	DISC
	@		0.5MG/2ML	A201966	002	Sep 27, 2013	Feb	DISC
	@		1MG/2ML	A201966	001	Sep 27, 2013	Feb	DISC

BUMETANIDE

INJECTABLE; INJECTION  
BUMETANIDE

AP		ASPIRO	0.25MG/ML	A218746	001	Feb 27, 2025	Feb	NEWA
----	--	--------	-----------	---------	-----	--------------	-----	------

TABLET; ORAL  
BUMETANIDE

>A>	AB	MANKIND PHARMA	0.5MG	A219291	001	Apr 03, 2025	Mar	NEWA
>A>	AB		1MG	A219291	002	Apr 03, 2025	Mar	NEWA
>A>	AB		2MG	A219291	003	Apr 03, 2025	Mar	NEWA

BUPRENORPHINE HYDROCHLORIDE

INJECTABLE; INJECTION  
BUPRENORPHINE HYDROCHLORIDE

AP		SOMERSET THERAPS LLC	EQ 0.3MG BASE/ML	A219302	001	Jan 30, 2025	Jan	NEWA
----	--	----------------------	------------------	---------	-----	--------------	-----	------

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE

FILM; BUCCAL, SUBLINGUAL  
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE

AB		DIFGEN PHARMS	EQ 2MG BASE; EQ 0.5MG BASE	A212756	003	Feb 13, 2025	Feb	NEWA
AB			EQ 4MG BASE; EQ 1MG BASE	A212756	004	Feb 13, 2025	Feb	NEWA

BUPROPION HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL  
BUPROPION HYDROCHLORIDE

	@	SUN PHARM	150MG	A200216	001	Nov 30, 2020	Feb	DISC
	@		300MG	A203650	001	Dec 31, 2020	Feb	DISC

BUSPIRONE HYDROCHLORIDE

CAPSULE; ORAL  
BUSPIRONE HYDROCHLORIDE

		EPIC PHARMA LLC	7.5MG	A218628	001	Mar 13, 2025	Feb	NEWA
			10MG	A218628	002	Mar 13, 2025	Feb	NEWA
			15MG	A218628	003	Mar 13, 2025	Feb	NEWA

TABLET; ORAL

BUSPIRONE HYDROCHLORIDE

>D>	AB	EPIC PHARMA LLC	5MG	A208972	001	Apr 16, 2019	Mar	CTEC
>A>	BX		5MG	A208972	001	Apr 16, 2019	Mar	CTEC
>D>	AB		7.5MG	A208972	002	Apr 16, 2019	Mar	CTEC
>A>	BX		7.5MG	A208972	002	Apr 16, 2019	Mar	CTEC
>D>	AB		10MG	A208972	003	Apr 16, 2019	Mar	CTEC
>A>	BX		10MG	A208972	003	Apr 16, 2019	Mar	CTEC
>D>	AB		15MG	A208972	004	Apr 16, 2019	Mar	CTEC
>A>	BX		15MG	A208972	004	Apr 16, 2019	Mar	CTEC
>D>	AB		30MG	A208972	005	Apr 16, 2019	Mar	CTEC
>A>	BX		30MG	A208972	005	Apr 16, 2019	Mar	CTEC
>D>	AB	INVENTIA HLTHCARE	5MG	A209696	001	May 03, 2018	Mar	CTEC
>A>	BX		5MG	A209696	001	May 03, 2018	Mar	CTEC
>D>	AB		7.5MG	A209696	002	May 03, 2018	Mar	CTEC
>A>	BX		7.5MG	A209696	002	May 03, 2018	Mar	CTEC
>D>	AB		10MG	A209696	003	May 03, 2018	Mar	CTEC
>A>	BX		10MG	A209696	003	May 03, 2018	Mar	CTEC
>D>	AB		15MG	A209696	004	May 03, 2018	Mar	CTEC
>A>	BX		15MG	A209696	004	May 03, 2018	Mar	CTEC
>D>	AB		30MG	A209696	005	May 03, 2018	Mar	CTEC
>A>	BX		30MG	A209696	005	May 03, 2018	Mar	CTEC

BUSULFAN

INJECTABLE; INJECTION

BUSULFAN

@ APOTEX

6MG/ML

A210448 001 May 07, 2019 Jan DISC

CAFFEINE CITRATE

SOLUTION; ORAL

CAFFEINE CITRATE

@ SUN PHARM

EQ 30MG BASE/3ML (EQ 10MG BASE/ML)

A090357 001 Sep 30, 2009 Feb DISC

CALCIUM CHLORIDE; DEXTROSE; LACTIC ACID; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

PRISMASOL B22GK 2/0 IN PLASTIC CONTAINER

+ @ VANTIVE US HLTHCARE	N/A/1000ML; 20GM/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; 0.157GM/1000ML; 2.21GM/1000ML; 7.07GM/1000ML (5000ML)	N021703	010	Oct 10, 2008	Feb CAHN
-------------------------	---	---------	-----	--------------	----------

PRISMASOL B22GK 2/2.5 IN PLASTIC CONTAINER

@ VANTIVE US HLTHCARE	3.68GM/1000ML; 20GM/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; 0.157GM/1000ML; 2.21GM/1000ML; 7.07GM/1000ML (5000ML)	N021703	012	Oct 10, 2008	Feb CAHN
-----------------------	--	---------	-----	--------------	----------

PRISMASOL B22GK 4/0 IN PLASTIC CONTAINER

+! VANTIVE US HLTHCARE	N/A/1000ML; 20GM/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; 0.314GM/1000ML; 2.21GM/1000ML; 7.07GM/1000ML (5000ML)	N021703	011	Oct 10, 2008	Feb CAHN
------------------------	---	---------	-----	--------------	----------

PRISMASOL B22GK 4/2.5 IN PLASTIC CONTAINER

+ @ VANTIVE US HLTHCARE	3.68GM/1000ML; 20GM/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; 0.314GM/1000ML; 2.21GM/1000ML; 7.07GM/1000ML (5000ML)	N021703	013	Oct 10, 2008	Feb CAHN
-------------------------	--	---------	-----	--------------	----------

PRISMASOL BGK 0/2.5 IN PLASTIC CONTAINER

+! VANTIVE US HLTHCARE	3.68GM/1000ML; 20GM/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; N/A/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	006	Oct 25, 2006	Feb CAHN
------------------------	--	---------	-----	--------------	----------

PRISMASOL BGK 2/0 IN PLASTIC CONTAINER

+! VANTIVE US HLTHCARE	N/A/1000ML; 20GM/1000ML; 5.4GM/1000ML; 2.03GM/1000ML; 0.157GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	002	Oct 25, 2006	Feb CAHN
------------------------	---	---------	-----	--------------	----------

PRISMASOL BGK 2/3.5 IN PLASTIC CONTAINER

+! VANTIVE US HLTHCARE	5.15GM/1000ML; 20GM/1000ML; 5.4GM/1000ML; 2.03GM/1000ML; 0.157GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	003	Oct 25, 2006	Feb CAHN
------------------------	--	---------	-----	--------------	----------

PRISMASOL BGK 4/0 IN PLASTIC CONTAINER

@ VANTIVE US HLTHCARE	N/A/1000ML; 20GM/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; 0.314GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	005	Oct 25, 2006	Feb CAHN
-----------------------	---	---------	-----	--------------	----------

PRISMASOL BGK 4/0/1.2 IN PLASTIC CONTAINER

+! VANTIVE US HLTHCARE	N/A/1000ML; 20GM/1000ML; 5.4GM/1000ML; 2.44GM/1000ML; 0.314GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	015	Oct 10, 2008	Feb CAHN
------------------------	---	---------	-----	--------------	----------

PRISMASOL BGK 4/2.5 IN PLASTIC CONTAINER

+! VANTIVE US HLTHCARE	3.68GM/1000ML; 20GM/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; 0.314GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	004	Oct 25, 2006	Feb CAHN
------------------------	--	---------	-----	--------------	----------

PRISMASOL BGK 4/3.5 IN PLASTIC CONTAINER

@ VANTIVE US HLTHCARE	5.15GM/1000ML; 20GM/1000ML; 5.4GM/1000ML; 2.03GM/1000ML; 0.314GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	008	Oct 25, 2006	Feb CAHN
-----------------------	--	---------	-----	--------------	----------

PRISMASOL BK 0/0 IN PLASTIC CONTAINER

@ VANTIVE US HLTHCARE	N/A/1000ML; N/A/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; N/A/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	007	Oct 25, 2006	Feb CAHN
-----------------------	--	---------	-----	--------------	----------

PRISMASOL BK 0/0/1.2 IN PLASTIC CONTAINER

+! VANTIVE US HLTHCARE	N/A/1000ML; N/A/1000ML; 5.4GM/1000ML; 2.44GM/1000ML;	N021703	014	Oct 10, 2008	Feb CAHN
------------------------	--	---------	-----	--------------	----------

## INJECTABLE; INJECTION

	PRISMASOL BK 0/0/1.2 IN PLASTIC CONTAINER	N/A/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)						
	PRISMASOL BK 0/3.5 IN PLASTIC CONTAINER							
+ @	VANTIVE US HLTHCARE	5.15GM/1000ML; N/A/1000ML; 5.4GM/1000ML; 2.03GM/1000ML; N/A/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	001	Oct 25, 2006	Feb	CAHN	
	PRISMASOL BK 4/2.5 IN PLASTIC CONTAINER							
@	VANTIVE US HLTHCARE	3.68GM/1000ML; N/A/1000ML; 5.4GM/1000ML; 3.05GM/1000ML; 0.314GM/1000ML; 3.09GM/1000ML; 6.46GM/1000ML (5000ML)	N021703	009	Oct 25, 2006	Feb	CAHN	

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

## SOLUTION; INTRAPERITONEAL

	DELFLX W/ DEXTROSE 1.5% IN PLASTIC CONTAINER							
+!	FRESENIUS MEDCL	25.7MG/100ML; 1.5GM/100ML; 15.2MG/100ML; 567MG/100ML; 392MG/100ML	N018883	001	Nov 30, 1984	Feb	CTEC	
	DELFLX W/ DEXTROSE 2.5% IN PLASTIC CONTAINER							
+!	FRESENIUS MEDCL	25.7MG/100ML; 2.5GM/100ML; 15.2MG/100ML; 567MG/100ML; 392MG/100ML	N018883	002	Nov 30, 1984	Feb	CTEC	
	DELFLX W/ DEXTROSE 4.25% IN PLASTIC CONTAINER							
+!	FRESENIUS MEDCL	25.7MG/100ML; 4.25GM/100ML; 15.2MG/100ML; 567MG/100ML; 392MG/100ML	N018883	003	Nov 30, 1984	Feb	CTEC	
	DIANEAL 137 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER							
@	VANTIVE US HLTHCARE	25.7MG/100ML; 1.5GM/100ML; 15.2MG/100ML; 567MG/100ML; 392MG/100ML	N017512	001		Feb	CAHN	
	DIANEAL 137 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER							
@	VANTIVE US HLTHCARE	25.7MG/100ML; 2.5GM/100ML; 15.2MG/100ML; 567MG/100ML; 392MG/100ML	N017512	003		Feb	CAHN	
	DIANEAL 137 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER							
@	VANTIVE US HLTHCARE	25.7MG/100ML; 4.25GM/100ML; 15.2MG/100ML; 567MG/100ML; 392MG/100ML	N017512	002		Feb	CAHN	
	DIANEAL LOW CALCIUM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER							
AT +	VANTIVE US HLTHCARE	18.3MG/100ML; 1.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	N020183	001	Dec 04, 1992	Feb	CAHN	
	DIANEAL LOW CALCIUM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER							
AT +	VANTIVE US HLTHCARE	18.3MG/100ML; 2.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	N020183	002	Dec 04, 1992	Feb	CAHN	
	DIANEAL LOW CALCIUM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER							
+ @	VANTIVE US HLTHCARE	18.3MG/100ML; 3.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	N020183	003	Dec 04, 1992	Feb	CAHN	
	DIANEAL LOW CALCIUM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER							
AT +	VANTIVE US HLTHCARE	18.3MG/100ML; 4.25GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	N020183	004	Dec 04, 1992	Feb	CAHN	
	DIANEAL LOW CALCIUM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER							
AT +	VANTIVE US HLTHCARE	18.3MG/100ML; 1.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	N017512	012	Jan 10, 1989	Feb	CAHN	
	DIANEAL LOW CALCIUM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER							
AT +	VANTIVE US HLTHCARE	18.3MG/100ML; 2.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	N017512	013	Jul 11, 1990	Feb	CAHN	
	DIANEAL LOW CALCIUM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER							
+ @	VANTIVE US HLTHCARE	18.3MG/100ML; 3.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	N017512	014	Jul 11, 1990	Feb	CTEC	
	DIANEAL LOW CALCIUM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER							
AT +	VANTIVE US HLTHCARE	18.3MG/100ML; 4.25GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	N017512	015	Jul 11, 1990	Feb	CAHN	
	DIANEAL PD-1 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER							
@	VANTIVE US HLTHCARE	25.7MG/100ML; 1.5GM/100ML; 15.2MG/100ML; 567MG/100ML; 392MG/100ML	N017512	007	Jul 09, 1984	Feb	CAHN	
	DIANEAL PD-1 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER							
@	VANTIVE US HLTHCARE	25.7MG/100ML; 2.5GM/100ML; 15.2MG/100ML; 567MG/100ML; 392MG/100ML	N017512	008	Jul 09, 1984	Feb	CAHN	
	DIANEAL PD-1 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER							
@	VANTIVE US HLTHCARE	25.7MG/100ML; 3.5GM/100ML; 15.2MG/100ML; 567MG/100ML; 392MG/100ML	N017512	010	Nov 18, 1985	Feb	CAHN	
	DIANEAL PD-1 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER							
@	VANTIVE US HLTHCARE	25.7MG/100ML; 4.25GM/100ML; 15.2MG/100ML; 567MG/100ML; 392MG/100ML	N017512	009	Jul 09, 1984	Feb	CAHN	
	DIANEAL PD-2 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER							
AT +	VANTIVE US HLTHCARE	25.7MG/100ML; 1.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	N017512	004		Feb	CAHN	
AT +		25.7MG/100ML; 1.5GM/100ML; 5.08	N020163	001	Dec 04, 1992	Feb	CAHN	

SOLUTION;INTRAPERITONEAL

		DIANEAL PD-2 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER							
		MG/100ML;538MG/100ML;448MG/100ML							
		DIANEAL PD-2 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER							
AT	+	VANTIVE US HLTHCARE	25.7MG/100ML;2.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N017512	005				Feb CAHN
AT	+		25.7MG/100ML;2.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N020163	002	Dec 04, 1992			Feb CAHN
		DIANEAL PD-2 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER							
	+	@ VANTIVE US HLTHCARE	25.7MG/100ML;3.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N017512	011	Nov 18, 1985			Feb CAHN
		DIANEAL PD-2 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER							
AT	+	VANTIVE US HLTHCARE	25.7MG/100ML;4.25GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N017512	006				Feb CAHN
AT	+		25.7MG/100ML;4.25GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML	N020163	003	Dec 04, 1992			Feb CAHN

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATEINJECTABLE;INJECTION

		PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER							
	+	!	VANTIVE US HLTHCARE	N/A/1000ML;3.05GM/1000ML;0.314GM/1000ML;2.21GM/1000ML;6.95GM/1000ML;0.187GM/1000ML (5000ML)	N207026	002	Jan 13, 2015		Feb CAHN
		PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER							
	+	!	VANTIVE US HLTHCARE	3.68GM/1000ML;3.05GM/1000ML;0.314GM/1000ML;3.09GM/1000ML;6.34GM/1000ML;0.187	N207026	001	Jan 13, 2015		Feb CAHN

CANDESARTAN CILEXETILTABLET;ORAL

		CANDESARTAN CILEXETIL							
AB		ZYDUS LIFESCIENCES	4MG	A091390	001	Aug 23, 2017			Jan CMFD
AB			8MG	A091390	002	Aug 23, 2017			Jan CMFD
AB			16MG	A091390	003	Aug 23, 2017			Jan CMFD
AB			32MG	A091390	004	Aug 23, 2017			Jan CMFD

CAPECITABINETABLET;ORAL

		CAPECITABINE							
>D>	AB	TEYRO LABS	150MG	A217237	001	Oct 23, 2023			Mar CTEC
>A>	BX		150MG	A217237	001	Oct 23, 2023			Mar CTEC
>D>	AB		500MG	A217237	002	Oct 23, 2023			Mar CTEC
>A>	BX		500MG	A217237	002	Oct 23, 2023			Mar CTEC

CARBAMAZEPINETABLET, EXTENDED RELEASE;ORAL

		CARBAMAZEPINE							
AB		ALKEM LABS LTD	100MG	A217277	001	Jan 14, 2025			Jan NEWA
AB			200MG	A217277	002	Jan 14, 2025			Jan NEWA
AB			400MG	A217277	003	Jan 14, 2025			Jan NEWA
AB		TORRENT	100MG	A212524	001	Jan 13, 2025			Jan NEWA
AB			200MG	A212524	002	Jan 13, 2025			Jan NEWA
AB			400MG	A212524	003	Jan 13, 2025			Jan NEWA
AB		YICHANG HUMANWELL	100MG	A219072	001	Jan 16, 2025			Jan NEWA
AB			200MG	A219072	002	Jan 16, 2025			Jan NEWA
AB			400MG	A219072	003	Jan 16, 2025			Jan NEWA

CARBIDOPA; LEVODOPATABLET;ORAL

		CARBIDOPA AND LEVODOPA							
>D>	AB	APOTEX INC	10MG;100MG	A077120	001	Jun 02, 2008			Mar DISC
>A>	@		10MG;100MG	A077120	001	Jun 02, 2008			Mar DISC
>D>	AB		25MG;100MG	A077120	002	Jun 02, 2008			Mar DISC
>A>	@		25MG;100MG	A077120	002	Jun 02, 2008			Mar DISC
>D>	AB		25MG;250MG	A077120	003	Jun 02, 2008			Mar DISC
>A>	@		25MG;250MG	A077120	003	Jun 02, 2008			Mar DISC
AB		ASCENT PHARMS INC	10MG;100MG	A218939	001	Jan 14, 2025			Jan NEWA
AB			25MG;100MG	A218939	002	Jan 14, 2025			Jan NEWA
AB			25MG;250MG	A218939	003	Jan 14, 2025			Jan NEWA
		TABLET, EXTENDED RELEASE;ORAL							
		CARBIDOPA AND LEVODOPA							
>D>	AB	APOTEX	25MG;100MG	A076212	001	Jun 16, 2004			Mar DISC
>A>	@		25MG;100MG	A076212	001	Jun 16, 2004			Mar DISC

TABLET, EXTENDED RELEASE;ORAL  
CARBIDOPA AND LEVODOPA

>D>	AB		50MG;200MG	A076212	002	Jun 16, 2004	Mar DISC
>A>	@		50MG;200MG	A076212	002	Jun 16, 2004	Mar DISC

CARBINOXAMINE MALEATE

TABLET;ORAL  
CARBINOXAMINE MALEATE  
@ SENORES PHARMS

		4MG	A090435	001	Apr 15, 2010	Jan CAHN
--	--	-----	---------	-----	--------------	----------

CARISOPRODOL

TABLET;ORAL  
CARISOPRODOL

AA	FOSUN WANBANG	350MG	A081025	001	Apr 13, 1989	Jan CAHN
----	---------------	-------	---------	-----	--------------	----------

CARVEDILOL

TABLET;ORAL  
CARVEDILOL

AB	GRAVITI PHARMS	3.125MG	A076649	001	Sep 05, 2007	Feb CAHN
AB		6.25MG	A076649	002	Sep 05, 2007	Feb CAHN
AB		12.5MG	A076649	003	Sep 05, 2007	Feb CAHN
AB		25MG	A076649	004	Sep 05, 2007	Feb CAHN
>D>	@ NORVIUM BIOSCIENCE	3.125MG	A077316	001	Sep 05, 2007	Feb CAHN
>A>	@	6.25MG	A077316	002	Sep 05, 2007	Mar DISC
AB		6.25MG	A077316	002	Sep 05, 2007	Feb CAHN
AB		12.5MG	A077316	003	Sep 05, 2007	Feb CAHN
AB		25MG	A077316	004	Sep 05, 2007	Feb CAHN

CEDAZURIDINE; DECITABINE

TABLET;ORAL  
INQOVI

+!	TAIHO ONCOLOGY	100MG;35MG	N212576	001	Jul 07, 2020	Feb CAHN
----	----------------	------------	---------	-----	--------------	----------

CEFAZOLIN SODIUM

INJECTABLE;INJECTION  
CEFAZOLIN SODIUM

AP	QILU ANTIBIOTICS	EQ 3GM BASE/VIAL	A203661	003	Jan 24, 2024	Jan CAHN
		EQ 1GM BASE/VIAL	A203661	001	Dec 28, 2015	Jan CAHN
		EQ 2GM BASE/VIAL	A203661	002	Mar 11, 2022	Jan CAHN
AP	!	EQ 10GM BASE/VIAL	A209217	001	Oct 17, 2018	Jan CAHN

CEFEPIME HYDROCHLORIDE

INJECTABLE;INJECTION  
CEFEPIME HYDROCHLORIDE

AP	!	QILU ANTIBIOTICS	EQ 500MG BASE/VIAL	A203704	001	Feb 01, 2016	Jan CAHN
AP	!		EQ 1GM BASE/VIAL	A203704	002	Feb 01, 2016	Jan CAHN
AP	!		EQ 2GM BASE/VIAL	A203704	003	Feb 01, 2016	Jan CAHN

CEFPODOXIME PROXETIL

FOR SUSPENSION;ORAL  
VANTIN

>A>	+ @ PFIZER	EQ 50MG BASE/5ML	N050675	001	Aug 07, 1992	Mar CAHN
>A>	+ @	EQ 100MG BASE/5ML	N050675	002	Aug 07, 1992	Mar CAHN
>D>	+ @ PHARMACIA AND UPJOHN	EQ 50MG BASE/5ML	N050675	001	Aug 07, 1992	Mar CAHN
>D>	+ @	EQ 100MG BASE/5ML	N050675	002	Aug 07, 1992	Mar CAHN
>A>	+ @ PFIZER	EQ 100MG BASE	N050674	001	Aug 07, 1992	Mar CAHN
>A>	+ @	EQ 200MG BASE	N050674	002	Aug 07, 1992	Mar CAHN
>D>	+ @ PHARMACIA AND UPJOHN	EQ 100MG BASE	N050674	001	Aug 07, 1992	Mar CAHN
>D>	+ @	EQ 200MG BASE	N050674	002	Aug 07, 1992	Mar CAHN

CEFPROZIL

FOR SUSPENSION;ORAL  
CEFPROZIL

>D>	AB	APOTEX INC	125MG/5ML	A065351	001	Feb 29, 2012	Mar DISC
>A>	@		125MG/5ML	A065351	001	Feb 29, 2012	Mar DISC
>D>	AB		250MG/5ML	A065351	002	Feb 29, 2012	Mar DISC
>A>	@		250MG/5ML	A065351	002	Feb 29, 2012	Mar DISC

		TABLET;ORAL							
		CEFPROZIL							
>D>	AB	APOTEX INC	250MG	A065327	001	Mar 26, 2008	Mar	DISC	
>A>		@	250MG	A065327	001	Mar 26, 2008	Mar	DISC	
>D>	AB		500MG	A065327	002	Mar 26, 2008	Mar	DISC	
>A>		@	500MG	A065327	002	Mar 26, 2008	Mar	DISC	
<u>CEFTOBIPROLE MEDOCARIL SODIUM</u>									
		POWDER;INTRAVENOUS							
		ZEVTERA							
>D>		+ @ BASILEA PHARM ALLSCH	667MG/VIAL	N218275	001	Apr 03, 2024	Mar	CAHN	
>A>		+ @ ISTX	667MG/VIAL	N218275	001	Apr 03, 2024	Mar	CAHN	
<u>CEFTRIAZONE SODIUM</u>									
		INJECTABLE;INJECTION							
		CEFTRIAZONE							
AP		QILU ANTIBIOTICS	EQ 10GM BASE/VIAL	A209218	001	Oct 17, 2018	Jan	CAHN	
		INJECTABLE;INTRAMUSCULAR, INTRAVENOUS							
		CEFTRIAZONE							
AP		QILU ANTIBIOTICS	EQ 250MG BASE/VIAL	A203702	001	Jun 29, 2016	Jan	CAHN	
AP			EQ 500MG BASE/VIAL	A203702	002	Jun 29, 2016	Jan	CAHN	
AP			EQ 1GM BASE/VIAL	A203702	003	Jun 29, 2016	Jan	CAHN	
AP			EQ 2GM BASE/VIAL	A203702	004	Jun 29, 2016	Jan	CAHN	
<u>CEFUROXIME AXETIL</u>									
		TABLET;ORAL							
		CEFUROXIME AXETIL							
>D>	AB	APOTEX	EQ 250MG BASE	A065069	001	Oct 02, 2002	Mar	DISC	
>A>		@	EQ 250MG BASE	A065069	001	Oct 02, 2002	Mar	DISC	
>D>	AB		EQ 500MG BASE	A065069	002	Oct 02, 2002	Mar	DISC	
>A>		@	EQ 500MG BASE	A065069	002	Oct 02, 2002	Mar	DISC	
<u>CELECOXIB</u>									
		CAPSULE;ORAL							
		CELECOXIB							
		@ PANGEA	200MG	A212925	001	Dec 09, 2020	Feb	CAHN	
		@	400MG	A212925	002	Dec 09, 2020	Feb	CAHN	
<u>CETIRIZINE HYDROCHLORIDE</u>									
		SOLUTION;ORAL							
		ZYRTEC							
		+ @ J AND J CONSUMER INC	5MG/5ML	N020346	001	Sep 27, 1996	Feb	CRLD	
<u>CEVIMELINE HYDROCHLORIDE</u>									
		CAPSULE;ORAL							
		CEVIMELINE HYDROCHLORIDE							
>D>	AB	RUBICON	30MG	A216682	001	Apr 06, 2023	Mar	CTEC	
>A>	BX		30MG	A216682	001	Apr 06, 2023	Mar	CTEC	
<u>CHENODIOL</u>									
		TABLET;ORAL							
		CTEXLI							
		+! MIRUM	250MG	N219488	001	Feb 21, 2025	Feb	NEWA	
<u>CHLORPROMAZINE HYDROCHLORIDE</u>									
		TABLET;ORAL							
		CHLORPROMAZINE HYDROCHLORIDE							
AB		ZAMEER PHARMS	10MG	A212630	001	Nov 29, 2021	Feb	CAHN	
AB			25MG	A212630	002	Nov 29, 2021	Feb	CAHN	
AB			50MG	A212630	003	Nov 29, 2021	Feb	CAHN	
AB			100MG	A212630	004	Nov 29, 2021	Feb	CAHN	
AB			200MG	A212630	005	Nov 29, 2021	Feb	CAHN	
<u>CHLORTHALIDONE</u>									
		TABLET;ORAL							
		CHLORTHALIDONE							
		@ AIPING PHARM INC	25MG	A087380	001		Jan	CAHN	
		@	50MG	A087381	001		Jan	CAHN	
>A>		HEMICLOR							
>A>		+! PRM PHARMA	12.5MG	N218647	001	Mar 17, 2025	Mar	NEWA	

CHLORZOXAZONE

TABLET; ORAL

CHLORZOXAZONE

AA	AJENAT PHARMS	250MG	A215540	001	Jan 24, 2023	Jan	CAHN
>A>	AB	APPCO	A212047	001	Jan 27, 2023	Mar	CAHN
>A>	AB		A212047	002	Jan 27, 2023	Mar	CAHN
>D>	AB	UPSHER SMITH LABS	A212047	001	Jan 27, 2023	Mar	CAHN
>D>	AB		A212047	002	Jan 27, 2023	Mar	CAHN

CICLOPIROX

SHAMPOO; TOPICAL

CICLOPIROX

>D>	AT	PADAGIS US	1%	A078594	001	Feb 16, 2010	Mar	CHRS
>A>	AT	!	1%	A078594	001	Feb 16, 2010	Mar	CHRS
>D>		LOPROX						
>D>	AT	+! BAUSCH	1%	N021159	001	Feb 28, 2003	Mar	DISC
>A>		+ @	1%	N021159	001	Feb 28, 2003	Mar	DISC

CINACALCET HYDROCHLORIDE

TABLET; ORAL

CINACALCET HYDROCHLORIDE

AB	PIRAMAL	EQ 30MG BASE	A210207	001	Aug 01, 2018	Jan	CAHN
AB		EQ 60MG BASE	A210207	002	Aug 01, 2018	Jan	CAHN
AB		EQ 90MG BASE	A210207	003	Aug 01, 2018	Jan	CAHN

CISATRACURIUM BESYLATE

INJECTABLE; INJECTION

CISATRACURIUM BESYLATE

>A>	AP	GLAND	EQ 2MG BASE/ML	A215516	001	May 24, 2022	Mar	CAHN
>A>	AP		EQ 2MG BASE/ML	A215516	003	Dec 14, 2022	Mar	CAHN
>A>	AP		EQ 10MG BASE/ML	A215516	002	May 24, 2022	Mar	CAHN
		@ HAINAN POLY	EQ 2MG BASE/ML	A216538	001	Mar 08, 2024	Feb	DISC
	AP	HENGRUI PHARMA	EQ 2MG BASE/ML	A204960	003	Aug 30, 2017	Feb	CMS1
>D>	AP	PIRAMAL CRITICAL	EQ 2MG BASE/ML	A215516	001	May 24, 2022	Mar	CAHN
>D>	AP		EQ 2MG BASE/ML	A215516	003	Dec 14, 2022	Mar	CAHN
>D>	AP		EQ 10MG BASE/ML	A215516	002	May 24, 2022	Mar	CAHN
		CISATRACURIUM BESYLATE PRESERVATIVE FREE						
		@ HAINAN POLY	EQ 2MG BASE/ML	A216539	001	Aug 27, 2024	Feb	DISC
		@	EQ 10MG BASE/ML	A216539	002	Aug 27, 2024	Feb	DISC

CITALOPRAM HYDROBROMIDE

TABLET; ORAL

CITALOPRAM HYDROBROMIDE

>D>	AB	APOTEX	EQ 10MG BASE	A077046	001	Nov 24, 2004	Mar	DISC
>A>		@	EQ 10MG BASE	A077046	001	Nov 24, 2004	Mar	DISC
>D>	AB		EQ 20MG BASE	A077046	002	Nov 24, 2004	Mar	DISC
>A>		@	EQ 20MG BASE	A077046	002	Nov 24, 2004	Mar	DISC
>D>	AB		EQ 40MG BASE	A077046	003	Nov 24, 2004	Mar	DISC
>A>		@	EQ 40MG BASE	A077046	003	Nov 24, 2004	Mar	DISC

CLINDAMYCIN PHOSPHATE

INJECTABLE; INJECTION

CLINDAMYCIN PHOSPHATE

	@ ALMAJECT	EQ 150MG BASE/ML	A062800	001	Jul 24, 1987	Feb	DISC
	@	EQ 150MG BASE/ML	A062943	001	Sep 29, 1988	Feb	DISC

CLOBAZAM

SUSPENSION; ORAL

CLOBAZAM

	@ VISTAPHARM LLC	2.5MG/ML	A210746	001	Jul 10, 2019	Jan	CAHN
--	------------------	----------	---------	-----	--------------	-----	------

TABLET; ORAL

CLOBAZAM

	@ ESJAY PHARMA	5MG	A209308	003	Oct 19, 2021	Feb	CAHN
AB		10MG	A209308	001	Oct 22, 2018	Feb	CAHN
	@	20MG	A209308	002	Oct 22, 2018	Feb	CAHN



CLOBETASOL PROPIONATE

LOTION; TOPICAL  
IMPEKLO

+ @ NORVIUM BIOSCIENCE 0.05% N213691 001 May 19, 2020 Jan CAHN

SUSPENSION/DROPS; OPHTHALMIC  
CLOBETASOL PROPIONATE

+! FORMOSA 0.05% N218158 001 Mar 04, 2024 Feb CAHN

CLONAZEPAM

TABLET, ORALLY DISINTEGRATING; ORAL  
CLONAZEPAM

@ SUN PHARM INDS INC 0.125MG A078654 001 Aug 27, 2014 Jan DISC

@ 0.25MG A078654 002 Aug 27, 2014 Jan DISC

@ 0.5MG A078654 003 Aug 27, 2014 Jan DISC

@ 1MG A078654 004 Aug 27, 2014 Jan DISC

@ 2MG A078654 005 Aug 27, 2014 Jan DISC

CLONIDINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL  
CLONIDINE HYDROCHLORIDE

>D> @ SOMERSET THERAPS LLC 0.1MG A211433 001 Oct 12, 2018 Mar CMFD

>A> ABI 0.1MG A211433 001 Oct 12, 2018 Mar CMFD

COBICISTAT; DARUNAVIR

TABLET; ORAL  
PREZCOBIX

>D> +! JANSSEN PRODS 150MG; 800MG N205395 001 Jan 29, 2015 Mar CAIN

COBICISTAT; DARUNAVIR ETHANOLATE

TABLET; ORAL  
PREZCOBIX

>A> + JANSSEN PRODS 150MG; EQ 675MG BASE N205395 002 Mar 21, 2025 Mar NEWA

>A> +! 150MG; 800MG N205395 001 Jan 29, 2015 Mar CAIN

>A> +! 150MG; EQ 800MG BASE N205395 001 Jan 29, 2015 Mar CPOT

CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE

AA XTTRIUM LABS INC 10MG/5ML; 6.25MG/5ML A088875 001 Dec 17, 1984 Feb CAHN

PROMETHAZINE WITH CODEINE

@ PHARM ASSOC 10MG/5ML; 6.25MG/5ML A040650 001 Jan 31, 2006 Jan DISC

COPPER

SYSTEM; INTRAUTERINE  
MIUDELLA

+! SEBELA WOMENS HLTH N/A N218201 001 Feb 24, 2025 Feb NEWA

COPPER CU-64 DOTATATE

SOLUTION; INTRAVENOUS  
DETECTNET

+! CURIUM 4mL (1mCi/ML) N213227 001 Sep 03, 2020 Jan CAHN

CROMOLYN SODIUM

CONCENTRATE; ORAL  
GASTROCROM

AA +! VIATRIS SPECIALTY 100MG/5ML N020479 001 Feb 29, 1996 Feb CAHN

CUPRIC SULFATE

INJECTABLE; INJECTION  
CUPRIC SULFATE

! AM REGENT EQ 0.4MG COPPER/ML A216324 001 Dec 16, 2022 Jan CTEC

@ APOTEX CORP EQ 0.4MG COPPER/ML A218745 001 Aug 19, 2024 Jan DISC

CYANOCOBALAMIN

INJECTABLE; INJECTION  
DODEX

@ ACCORD HLTHCARE 1MG/ML A083022 001 Jan DISC

CYCLOSPORINEEMULSION;OPHTHALMIC  
CYCLOSPORINE

>D>	AB	APOTEX	0.05%	A207606	001	Jan 12, 2023	Mar CTEC
>A>	BX		0.05%	A207606	001	Jan 12, 2023	Mar CTEC

SOLUTION;ORAL  
CYCLOSPORINE

	@	ABBVIE	100MG/ML	A065025	001	Mar 03, 2000	Feb DISC
--	---	--------	----------	---------	-----	--------------	----------

DABIGATRAN ETEXILATE MESYLATE

CAPSULE;ORAL

DABIGATRAN ETEXILATE MESYLATE

AB	DR REDDYS	EQ 75MG BASE	A208048	001	Jan 28, 2025	Jan NEWA
AB		EQ 110MG BASE	A208048	002	Jan 28, 2025	Jan NEWA
AB		EQ 150MG BASE	A208048	003	Jan 28, 2025	Jan NEWA
AB	MYLAN	EQ 75MG BASE	A208067	001	Feb 03, 2025	Jan NEWA
AB		EQ 150MG BASE	A208067	002	Feb 03, 2025	Jan NEWA

DACARBAZINE

INJECTABLE;INJECTION

DACARBAZINE

>D>	AP	HOSPIRA	200MG/VIAL	A075940	001	Oct 18, 2001	Mar DISC
>A>		@	200MG/VIAL	A075940	001	Oct 18, 2001	Mar DISC

DALFAMPRIDINE

TABLET, EXTENDED RELEASE;ORAL

AMPYRA

AB	+!	MERZ	10MG	N022250	001	Jan 22, 2010	Feb CAHN
----	----	------	------	---------	-----	--------------	----------

DAPSONE

GEL;TOPICAL

DAPSONE

>A>	AB	AUROBINDO PHARMA LTD	5%	A218457	001	Apr 04, 2025	Mar NEWA
-----	----	----------------------	----	---------	-----	--------------	----------

DAPTOMYCIN

POWDER;INTRAVENOUS

DAPTOMYCIN

	@	FRESENIUS KABI USA	350MG/VIAL	A213396	001	Aug 01, 2024	Jan DISC
--	---	--------------------	------------	---------	-----	--------------	----------

DARUNAVIR

TABLET;ORAL

DARUNAVIR

AB	ANNORA PHARMA	600MG	A216168	001	Jan 21, 2025	Jan NEWA
AB		800MG	A216168	002	Jan 21, 2025	Jan NEWA

DASATINIB

TABLET;ORAL

DASATINIB

AB	BIOCON PHARMA	20MG	A217217	001	Mar 03, 2025	Feb NEWA
AB		50MG	A217217	002	Mar 03, 2025	Feb NEWA
AB		70MG	A217217	003	Mar 03, 2025	Feb NEWA
AB		80MG	A217217	004	Mar 03, 2025	Feb NEWA
AB		100MG	A217217	005	Mar 03, 2025	Feb NEWA
AB		140MG	A217217	006	Mar 03, 2025	Feb NEWA
AB	DR REDDYS	20MG	A213383	001	Mar 03, 2025	Feb NEWA
AB		50MG	A213383	002	Mar 03, 2025	Feb NEWA
AB		70MG	A213383	003	Mar 03, 2025	Feb NEWA
AB		80MG	A213383	004	Mar 03, 2025	Feb NEWA
AB		100MG	A213383	005	Mar 03, 2025	Feb NEWA
AB		140MG	A213383	006	Mar 03, 2025	Feb NEWA
AB	ZYDUS PHARMS	20MG	A218719	001	Mar 03, 2025	Feb NEWA
AB		50MG	A218719	002	Mar 03, 2025	Feb NEWA
AB		70MG	A218719	003	Mar 03, 2025	Feb NEWA
AB		80MG	A218719	004	Mar 03, 2025	Feb NEWA
AB		100MG	A218719	005	Mar 03, 2025	Feb NEWA
AB		140MG	A218719	006	Mar 03, 2025	Feb NEWA

PHYRAGO

+	HANDA THERAP	20MG	N216099	001	Dec 05, 2023	Jan CAHN
+		50MG	N216099	002	Dec 05, 2023	Jan CAHN
+		70MG	N216099	003	Dec 05, 2023	Jan CAHN
+		80MG	N216099	004	Dec 05, 2023	Jan CAHN

TABLET;ORAL  
PHYRAGO

+!		100MG	N216099	005	Dec 05, 2023	Jan CAHN
+		140MG	N216099	006	Dec 05, 2023	Jan CAHN

DEFLAZACORT

## TABLET;ORAL

## DEFLAZACORT

>A>	AB	SUN PHARM	6MG	A217741	001	Mar 18, 2025	Mar NEWA
>A>	AB		18MG	A217741	002	Mar 18, 2025	Mar NEWA
>A>	AB		30MG	A217741	003	Mar 18, 2025	Mar NEWA
>A>	AB		36MG	A217741	004	Mar 18, 2025	Mar NEWA
		JAYTHARI					
>A>	AB	ZYDUS LIFESCIENCES	6MG	A219254	001	Apr 08, 2025	Mar NEWA
>A>	AB		18MG	A219254	002	Apr 08, 2025	Mar NEWA
>A>	AB		30MG	A219254	003	Apr 08, 2025	Mar NEWA
>A>	AB		36MG	A219254	004	Apr 08, 2025	Mar NEWA

DESLORATADINE

## TABLET;ORAL

## DESLORATADINE

AB		AJENAT PHARMS	5MG	A078355	001	Apr 19, 2012	Jan CAHN
----	--	---------------	-----	---------	-----	--------------	----------

DESVENLAFAXINE SUCCINATE

## TABLET, EXTENDED RELEASE;ORAL

## DESVENLAFAXINE SUCCINATE

AB		MACLEODS PHARMS LTD	EQ 50MG BASE	A211427	001	Jan 15, 2025	Jan NEWA
AB			EQ 100MG BASE	A211427	002	Jan 15, 2025	Jan NEWA
AB		MEDICAP LABS	EQ 50MG BASE	A204805	001	May 07, 2019	Feb CAHN
AB			EQ 100MG BASE	A204805	002	May 07, 2019	Feb CAHN

DEUTETRABENAZINE

## TABLET;ORAL

## AUSTEDO

+		TEVA BRANDED PHARM	6MG	N208082	001	Apr 03, 2017	Feb CAHN
+			6MG	N208082	001	Apr 03, 2017	Jan CTEC
+			9MG	N208082	002	Apr 03, 2017	Feb CAHN
+			9MG	N208082	002	Apr 03, 2017	Jan CTEC
+!			12MG	N208082	003	Apr 03, 2017	Feb CAHN
+!			12MG	N208082	003	Apr 03, 2017	Jan CTEC

## DEUTETRABENAZINE

@		AUROBINDO PHARMA LTD	6MG	A215971	001	Dec 26, 2024	Jan DISC
@			9MG	A215971	002	Dec 26, 2024	Jan DISC
@			12MG	A215971	003	Dec 26, 2024	Jan DISC

DEXCHLORPHENIRAMINE MALEATE

## SYRUP;ORAL

## POLMON

>A>	!	CARWIN PHARM ASSOC	2MG/5ML	A202520	001	Jul 16, 2018	Mar CAHN
>D>	!	CARWIN PHARMS	2MG/5ML	A202520	001	Jul 16, 2018	Mar CAHN
	!		2MG/5ML	A202520	001	Jul 16, 2018	Feb CAHN

DEXMETHYLPHENIDATE HYDROCHLORIDE

## CAPSULE, EXTENDED RELEASE;ORAL

## DEXMETHYLPHENIDATE HYDROCHLORIDE

AB		MEDICAP LABS	5MG	A078992	001	Nov 23, 2021	Feb CAHN
AB			10MG	A078992	002	Nov 23, 2021	Feb CAHN
AB			15MG	A078992	003	Nov 18, 2013	Feb CAHN
AB			30MG	A078992	004	Nov 18, 2013	Feb CAHN
AB			20MG	A078992	005	Nov 23, 2021	Feb CAHN
AB			40MG	A078992	006	Nov 23, 2021	Feb CAHN

## TABLET;ORAL

## DEXMETHYLPHENIDATE HYDROCHLORIDE

@		RHODES PHARMS	2.5MG	A208756	001	Nov 20, 2017	Jan DISC
@			5MG	A208756	002	Nov 20, 2017	Jan DISC
@			10MG	A208756	003	Nov 20, 2017	Jan DISC

DEXRAZOXANE HYDROCHLORIDE

INJECTABLE; INJECTION  
DEXRAZOXANE HYDROCHLORIDE

>A>	AP	MSN	EQ 250MG BASE/VIAL	A216748	001	Mar 26, 2025	Mar	NEWA
>A>	AP		EQ 500MG BASE/VIAL	A216748	002	Mar 26, 2025	Mar	NEWA

DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL  
PROMETHAZINE W/ DEXTROMETHORPHAN

AA		XTTRIUM LABS INC	15MG/5ML; 6.25MG/5ML	A088864	001	Jan 04, 1985	Feb	CAHN
----	--	------------------	----------------------	---------	-----	--------------	-----	------

DIAZOXIDE CHOLINE

>A> TABLET, EXTENDED RELEASE; ORAL  
>A> VYKAT XR

>A>		+ SOLENO THERAP	25MG	N216665	001	Mar 26, 2025	Mar	NEWA
>A>		+	75MG	N216665	002	Mar 26, 2025	Mar	NEWA
>A>		+	150MG	N216665	003	Mar 26, 2025	Mar	NEWA

DICLOFENAC POTASSIUM

FOR SOLUTION; ORAL  
DICLOFENAC POTASSIUM

AB		TORRENT	50MG	A215891	001	Jan 22, 2025	Jan	NEWA
		TABLET; ORAL						
		DICLOFENAC POTASSIUM						
>D>	AB	! RK PHARMA	50MG	A075463	001	Jul 26, 1999	Mar	CHRS
>A>	AB		50MG	A075463	001	Jul 26, 1999	Mar	CHRS
>D>	AB	RUBICON	50MG	A075229	001	Nov 20, 1998	Mar	CHRS
>A>	AB	!	50MG	A075229	001	Nov 20, 1998	Mar	CHRS

DICLOFENAC SODIUM

GEL; TOPICAL  
DICLOFENAC SODIUM

>D>	AB	ALEMBIC	3%	A212351	001	Jul 27, 2022	Mar	CTEC
>A>	BX		3%	A212351	001	Jul 27, 2022	Mar	CTEC
		SOLUTION; TOPICAL						
		DICLOFENAC SODIUM						
>A>	AB	ENCUBE	2%	A217646	001	Apr 09, 2025	Mar	NEWA

DICYCLOMINE HYDROCHLORIDE

TABLET; ORAL  
DICYCLOMINE HYDROCHLORIDE

>D>	AB	RUBICON	20MG	A216736	001	Dec 14, 2022	Mar	CAHN
>A>	AB	RUBICON RESEARCH	20MG	A216736	001	Dec 14, 2022	Mar	CAHN
>A>		!	40MG	A216736	002	Mar 25, 2025	Mar	NEWA

DIFLUPREDNATE

EMULSION; OPHTHALMIC  
DIFLUPREDNATE

>A>	AB	MYLAN LABS LTD	0.05%	A212566	001	Mar 20, 2025	Mar	NEWA
	AB	UPSHER SMITH LABS	0.05%	A218191	001	Feb 11, 2025	Jan	NEWA

DIHYDROERGOTAMINE MESYLATE

INJECTABLE; INJECTION  
DIHYDROERGOTAMINE MESYLATE  
@ CIPLA 1MG/ML

A212334	001	Sep 20, 2024	Jan	DISC
---------	-----	--------------	-----	------

SPRAY, METERED; NASAL  
DIHYDROERGOTAMINE MESYLATE

AB		AGGREGA	0.5MG/SPRAY	A215228	001	Feb 26, 2025	Feb	NEWA
----	--	---------	-------------	---------	-----	--------------	-----	------

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL  
DILTIAZEM HYDROCHLORIDE

>A>	AB1	AMTA	60MG	A219073	001	Mar 24, 2025	Mar	NEWA
>A>	AB1		90MG	A219073	002	Mar 24, 2025	Mar	NEWA
>A>	AB1		120MG	A219073	003	Mar 24, 2025	Mar	NEWA
>D>	AB3	SUN PHARM	180MG	A203023	002	Jun 08, 2017	Mar	DISC
>A>		@	180MG	A203023	002	Jun 08, 2017	Mar	DISC
>D>	AB3		240MG	A203023	003	Jun 08, 2017	Mar	DISC
>A>		@	240MG	A203023	003	Jun 08, 2017	Mar	DISC
		@	300MG	A203023	004	Jun 08, 2017	Feb	DISC

SOLUTION;INTRAVENOUS

DILTIAZEM HYDROCHLORIDE IN 0.72% SODIUM CHLORIDE

+!	HQ SPCLT PHARMA	100MG/100ML (1MG/ML)	N218038	001	Feb 21, 2025	Feb NEWA
+!		250MG/250ML (1MG/ML)	N218038	002	Feb 21, 2025	Feb NEWA

DIMETHYL FUMARATE

CAPSULE, DELAYED RELEASE;ORAL

DIMETHYL FUMARATE

@	CIPLA	120MG	A210305	001	Sep 24, 2020	Feb DISC
@		240MG	A210305	002	Sep 24, 2020	Feb DISC

DIPHENHYDRAMINE HYDROCHLORIDE

INJECTABLE;INJECTION

DIPHENHYDRAMINE HYDROCHLORIDE

AP	!	NORVIUM BIOSCIENCE	50MG/ML	A040498	001	Jul 12, 2005	Feb CAHN
----	---	--------------------	---------	---------	-----	--------------	----------

DIPYRIDAMOLE

TABLET;ORAL

DIPYRIDAMOLE

>D>	AB	BARR	75MG	A087717	001	Oct 03, 1990	Mar CAHN
>A>	AB	BARR LABS	75MG	A087717	001	Oct 03, 1990	Mar CAHN

DIVALPROEX SODIUM

TABLET, DELAYED RELEASE;ORAL

DIVALPROEX SODIUM

>D>	AB	APOTEX	EQ 125MG VALPROIC ACID	A077615	003	Jul 29, 2008	Mar DISC
>A>		@	EQ 125MG VALPROIC ACID	A077615	003	Jul 29, 2008	Mar DISC
>D>	AB		EQ 250MG VALPROIC ACID	A077615	002	Jul 29, 2008	Mar DISC
>A>		@	EQ 250MG VALPROIC ACID	A077615	002	Jul 29, 2008	Mar DISC
>D>	AB		EQ 500MG VALPROIC ACID	A077615	001	Jul 29, 2008	Mar DISC
>A>		@	EQ 500MG VALPROIC ACID	A077615	001	Jul 29, 2008	Mar DISC

DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

MEMANTINE HYDROCHLORIDE AND DONEPEZIL HYDROCHLORIDE

AB		AMNEAL	10MG;7MG	A208328	003	Feb 27, 2025	Feb NFTG
AB			10MG;21MG	A208328	004	Feb 27, 2025	Feb NEWA
		NAMZARIC					
AB	+	ABBVIE	10MG;7MG	N206439	003	Jul 18, 2016	Feb CFTG

DORZOLAMIDE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

DORZOLAMIDE HYDROCHLORIDE

AT		SOMERSET THERAPS LLC	EQ 2% BASE	A215004	001	Feb 11, 2025	Jan NEWA
----	--	----------------------	------------	---------	-----	--------------	----------

DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE

SOLUTION/DROPS;OPHTHALMIC

DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE

AT2		IDENTIRX	EQ 2% BASE;EQ 0.5% BASE	A216308	001	Feb 18, 2025	Feb NEWA
-----	--	----------	-------------------------	---------	-----	--------------	----------

DOXAZOSIN MESYLATE

TABLET;ORAL

DOXAZOSIN MESYLATE

>A>	AB	APPCO	EQ 1MG BASE	A209013	001	Apr 17, 2018	Mar CAHN
>A>	AB		EQ 2MG BASE	A209013	002	Apr 17, 2018	Mar CAHN
>A>	AB		EQ 4MG BASE	A209013	003	Apr 17, 2018	Mar CAHN
>A>	AB		EQ 8MG BASE	A209013	004	Apr 17, 2018	Mar CAHN
>D>	AB	UPSHER SMITH LABS	EQ 1MG BASE	A209013	001	Apr 17, 2018	Mar CAHN
>D>	AB		EQ 2MG BASE	A209013	002	Apr 17, 2018	Mar CAHN
>D>	AB		EQ 4MG BASE	A209013	003	Apr 17, 2018	Mar CAHN
>D>	AB		EQ 8MG BASE	A209013	004	Apr 17, 2018	Mar CAHN

DOXEPIIN HYDROCHLORIDE

CAPSULE;ORAL

DOXEPIIN HYDROCHLORIDE

>A>	AB	@	ADAPTIS	EQ 150MG BASE	A213796	001	Apr 19, 2022	Jan DISC
>A>	AB		PTS CONSULTING	EQ 10MG BASE	A217975	001	Aug 21, 2023	Mar CAHN
>A>	AB			EQ 25MG BASE	A217975	002	Aug 21, 2023	Mar CAHN
>A>	AB			EQ 50MG BASE	A217975	003	Aug 21, 2023	Mar CAHN
>A>	AB			EQ 75MG BASE	A217975	004	Aug 21, 2023	Mar CAHN
>A>	AB			EQ 100MG BASE	A217975	005	Aug 21, 2023	Mar CAHN
>D>	AB		UNIQUE PHARM	EQ 10MG BASE	A217975	001	Aug 21, 2023	Mar CAHN

## CAPSULE;ORAL

## DOXEPIN HYDROCHLORIDE

>D>	AB		EQ 25MG BASE	A217975	002	Aug 21, 2023	Mar CAHN
>D>	AB		EQ 50MG BASE	A217975	003	Aug 21, 2023	Mar CAHN
>D>	AB		EQ 75MG BASE	A217975	004	Aug 21, 2023	Mar CAHN
>D>	AB		EQ 100MG BASE	A217975	005	Aug 21, 2023	Mar CAHN
>D>	AB	ZYDUS LIFESCIENCES	EQ 10MG BASE	A210700	001	Mar 23, 2023	Mar CTEC
>A>	BX		EQ 10MG BASE	A210700	001	Mar 23, 2023	Mar CTEC
>D>	AB		EQ 25MG BASE	A210700	002	Mar 23, 2023	Mar CTEC
>A>	BX		EQ 25MG BASE	A210700	002	Mar 23, 2023	Mar CTEC
>D>	AB		EQ 50MG BASE	A210700	003	Mar 23, 2023	Mar CTEC
>A>	BX		EQ 50MG BASE	A210700	003	Mar 23, 2023	Mar CTEC
>D>	AB		EQ 75MG BASE	A210700	004	Mar 23, 2023	Mar CTEC
>A>	BX		EQ 75MG BASE	A210700	004	Mar 23, 2023	Mar CTEC
>D>	AB		EQ 100MG BASE	A210700	005	Mar 23, 2023	Mar CTEC
>A>	BX		EQ 100MG BASE	A210700	005	Mar 23, 2023	Mar CTEC
>D>	AB		EQ 150MG BASE	A210140	001	Mar 21, 2023	Mar CTEC
>A>	BX		EQ 150MG BASE	A210140	001	Mar 21, 2023	Mar CTEC

## TABLET;ORAL

## DOXEPIN HYDROCHLORIDE

>D>	AB	MSN	EQ 3MG BASE	A214823	001	Apr 03, 2023	Mar CTEC
>A>	BX		EQ 3MG BASE	A214823	001	Apr 03, 2023	Mar CTEC
>D>	AB		EQ 6MG BASE	A214823	002	Apr 03, 2023	Mar CTEC
>A>	BX		EQ 6MG BASE	A214823	002	Apr 03, 2023	Mar CTEC

DOXYCYCLINE

## CAPSULE;ORAL

## DOXYCYCLINE

>A>	AB	MACLEODS PHARMS LTD	40MG	A210381	001	Mar 27, 2025	Mar NEWA
	AB	PRINSTON INC	40MG	A217098	001	Jan 27, 2025	Jan NEWA

DOXYCYCLINE HYCLATE

## CAPSULE;ORAL

## DOXYCYCLINE HYCLATE

AB	!	HIKMA INTL PHARMS	EQ 100MG BASE	A062396	001	May 07, 1984	Feb CHRS
		VIBRAMYCIN					
	+	@ PFIZER	EQ 100MG BASE	N050007	002		Feb DISC
		INJECTABLE; INJECTION					
		DOXYCYCLINE HYCLATE					
		@ AMNEAL	EQ 100MG BASE/VIAL	A217487	001	Dec 04, 2024	Jan DISC
AP		PRECISION DOSE INC	EQ 100MG BASE/VIAL	A217078	001	Feb 21, 2025	Feb NEWA

EFLORNITHINE HYDROCHLORIDE

## CREAM; TOPICAL

## VANIQA

	+	@ ABBVIE	13.9%	N021145	001	Jul 27, 2000	Feb CAHN
--	---	----------	-------	---------	-----	--------------	----------

ELIGLUSTAT TARTRATE

## CAPSULE;ORAL

## ELIGLUSTAT TARTRATE

		@ APOTEX	EQ 84MG BASE	A212425	001	Jul 10, 2024	Jan DISC
--	--	----------	--------------	---------	-----	--------------	----------

ELTROMBOPAG OLAMINE

## TABLET;ORAL

## ELTROMBOPAG OLAMINE

AB		HETERO LABS LTD V	EQ 12.5MG ACID	A206788	001	Jan 17, 2025	Jan NFTG
AB			EQ 25MG ACID	A206788	002	Jan 17, 2025	Jan NFTG
AB			EQ 50MG ACID	A206788	003	Jan 17, 2025	Jan NFTG
AB			EQ 75MG ACID	A206788	004	Jan 17, 2025	Jan NFTG
		PROMACTA					
AB	+	NOVARTIS	EQ 12.5MG ACID	N022291	004	Oct 20, 2011	Jan CFTG
AB	+		EQ 25MG ACID	N022291	001	Nov 20, 2008	Jan CFTG
AB	+		EQ 50MG ACID	N022291	002	Nov 20, 2008	Jan CFTG
AB	+	!	EQ 75MG ACID	N022291	003	Sep 08, 2009	Jan CFTG

ELUXADOLINE

## TABLET;ORAL

## ELUXADOLINE

>A>	AB	ZYDUS PHARMS	75MG	A213522	001	Mar 14, 2025	Mar NFTG
>A>	AB		100MG	A213522	002	Mar 14, 2025	Mar NFTG
		VIBERZI					
>D>	+	ABBVIE	75MG	N206940	001	May 27, 2015	Mar CFTG

TABLET;ORAL  
VIBERZI

>A>	AB	+	75MG	N206940	001	May 27, 2015	Mar	CFTG
>D>		+!	100MG	N206940	002	May 27, 2015	Mar	CFTG
>A>	AB	+!	100MG	N206940	002	May 27, 2015	Mar	CFTG

EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL  
EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE

AB	HETERO LABS LTD III	100MG;150MG	A201806	002	Mar 03, 2025	Feb	NEWA
AB		133MG;200MG	A201806	003	Mar 03, 2025	Feb	NEWA
AB		167MG;250MG	A201806	004	Mar 03, 2025	Feb	NEWA

>D> ENFUVRTIDE

>D> INJECTABLE;SUBCUTANEOUS  
>D> FUZEON

>D>		+!	ROCHE	90MG/VIAL	N021481	001	Mar 13, 2003	Mar	DISC
>A>		+ @		90MG/VIAL	N021481	001	Mar 13, 2003	Mar	DISC

ENZALUTAMIDE

CAPSULE;ORAL  
ENZALUTAMIDE

	@ ZYDUS PHARMS	40MG	A209667	001	Sep 26, 2024	Feb	DISC
	XTANDI						
	+! ATELLAS	40MG	N203415	001	Aug 31, 2012	Feb	CTEC

EPHEDRINE SULFATE

SOLUTION;INTRAVENOUS  
AKOVAZ

>D>	AP	+!	EXELA PHARMA	25MG/5ML (5MG/ML)	N208289	002	Aug 02, 2021	Mar	CTEC
>A>	AP3	+!		25MG/5ML (5MG/ML)	N208289	002	Aug 02, 2021	Mar	CTEC

EMERPHED

>D>	AP	+!	NEXUS	50MG/10ML (5MG/ML)	N213407	001	Apr 17, 2020	Mar	CTEC
>A>	AP1	+!		50MG/10ML (5MG/ML)	N213407	001	Apr 17, 2020	Mar	CTEC
	AP	+!		50MG/10ML (5MG/ML)	N213407	001	Apr 17, 2020	Jan	CFTG

EPHEDRINE SULFATE

>D>	AP	+!	ENDO OPERATIONS	25MG/5ML (5MG/ML)	N213994	002	Apr 22, 2022	Mar	CTEC
>A>	AP2	+!		25MG/5ML (5MG/ML)	N213994	002	Apr 22, 2022	Mar	CTEC
	AP	+!		25MG/5ML (5MG/ML)	N213994	002	Apr 22, 2022	Feb	CFTG
>D>	AP	+!		50MG/10ML (5MG/ML)	N213994	001	Oct 16, 2020	Mar	CTEC
>A>	AP2	+!		50MG/10ML (5MG/ML)	N213994	001	Oct 16, 2020	Mar	CTEC
	AP	+!		50MG/10ML (5MG/ML)	N213994	001	Oct 16, 2020	Feb	CFTG
>D>	AP		FRESENIUS KABI USA	25MG/5ML (5MG/ML)	A218271	001	Mar 11, 2025	Mar	CTEC
>A>	AP2			25MG/5ML (5MG/ML)	A218271	001	Mar 11, 2025	Mar	CTEC
	AP			25MG/5ML (5MG/ML)	A218271	001	Mar 11, 2025	Feb	NFTG
>D>	AP			50MG/10ML (5MG/ML)	A218271	002	Mar 11, 2025	Mar	CTEC
>A>	AP2			50MG/10ML (5MG/ML)	A218271	002	Mar 11, 2025	Mar	CTEC
	AP			50MG/10ML (5MG/ML)	A218271	002	Mar 11, 2025	Feb	NFTG
>D>	AP		GLAND	50MG/10ML (5MG/ML)	A218211	001	Jan 16, 2025	Mar	CTEC
>A>	AP1			50MG/10ML (5MG/ML)	A218211	001	Jan 16, 2025	Mar	CTEC
	AP			50MG/10ML (5MG/ML)	A218211	001	Jan 16, 2025	Jan	NFTG
>D>	AP		HIKMA	25MG/5ML (5MG/ML)	A217721	001	Oct 11, 2024	Mar	CTEC
>A>	AP3			25MG/5ML (5MG/ML)	A217721	001	Oct 11, 2024	Mar	CTEC

EPINASTINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

	@ RENOVA PHARMS	0.05%	A090870	001	Mar 14, 2011	Feb	CAHN
--	-----------------	-------	---------	-----	--------------	-----	------

EPINEPHRINE

>D> SOLUTION;INTRAMUSCULAR, INTRAOCULAR, SUBCUTANEOUS  
>D> EPINEPHRINE

>D>	AP		GLAND PHARMA LTD	10MG/10ML (1MG/ML)	A219239	001	Feb 06, 2025	Mar	CDFR
	AP			10MG/10ML (1MG/ML)	A219239	001	Feb 06, 2025	Jan	NFTG

SOLUTION;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS  
EPINEPHRINE

	AP	+!	BPI LABS	10MG/10ML (1MG/ML)	N205029	002	Feb 04, 2022	Jan	CFTG
>A>		+!	FRESENIUS KABI USA	30MG/30ML (1MG/ML)	N215425	001	Mar 13, 2025	Mar	NEWA
>A>	AP		GLAND	10MG/10ML (1MG/ML)	A219239	001	Feb 06, 2025	Mar	CDFR

SPRAY;NASAL

NEFFY

>A>		+	ARS PHARMS OPERATION	1MG/SPRAY	N214697	002	Mar 05, 2025	Mar	NEWA
-----	--	---	----------------------	-----------	---------	-----	--------------	-----	------

EPINEPHRINE BITARTRATE

SOLUTION; INTRAVENOUS

EPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE

+!	BAXTER HLTHCARE CORP	EQ 16MG BASE/250ML (EQ 64MCG BASE/ML)	N218475	001	Feb 28, 2025	Feb	NEWA
----	----------------------	---------------------------------------	---------	-----	--------------	-----	------

EPLERENONE

TABLET; ORAL

EPLERENONE

>D>	@ PRASCO	25MG	A203896	001	Feb 02, 2017	Mar	CAHN
>D>	@	50MG	A203896	002	Feb 02, 2017	Mar	CAHN
>A>	@ THINKRX	25MG	A203896	001	Feb 02, 2017	Mar	CAHN
>A>	@	50MG	A203896	002	Feb 02, 2017	Mar	CAHN

ERIBULIN MESYLATE

SOLUTION; INTRAVENOUS

ERIBULIN MESYLATE

AP	CHIA TAI TIANQING	1MG/2ML (0.5MG/ML)	A218743	001	Mar 04, 2025	Feb	NEWA
----	-------------------	--------------------	---------	-----	--------------	-----	------

ERLOTINIB HYDROCHLORIDE

TABLET; ORAL

ERLOTINIB HYDROCHLORIDE

@ APOTEX

EQ 25MG BASE

A208396 001 Nov 05, 2019 Jan DISC

@

EQ 100MG BASE

A208396 002 Nov 05, 2019 Jan DISC

@

EQ 150MG BASE

A208396 003 Nov 05, 2019 Jan DISC

@ SUN PHARM

EQ 25MG BASE

A210300 001 Nov 05, 2019 Jan DISC

@

EQ 100MG BASE

A210300 002 Nov 05, 2019 Feb DISC

@

EQ 150MG BASE

A210300 003 Nov 05, 2019 Jan DISC

ERTUGLIFLOZIN

TABLET; ORAL

ERTUGLIFLOZIN

@ HIKMA

5MG

A216842 001 Jan 21, 2025 Feb DISC

AB

@

15MG

A216842 002 Jan 21, 2025 Jan NEWA

AB

@

15MG

A216842 002 Jan 21, 2025 Feb DISC

ESLICARBAZEPINE ACETATE

TABLET; ORAL

ESLICARBAZEPINE ACETATE

@ LUPIN LTD

200MG

A211246 001 Mar 27, 2024 Mar CMFD

&gt;D&gt;

&gt;A&gt; AB

@

400MG

A211246 002 Mar 27, 2024 Mar CMFD

&gt;D&gt;

&gt;A&gt; AB

@

600MG

A211246 003 Mar 27, 2024 Mar CMFD

&gt;D&gt;

&gt;A&gt; AB

@

800MG

A211246 004 Mar 27, 2024 Mar CMFD

&gt;D&gt;

&gt;A&gt; AB

@

800MG

A211246 004 Mar 27, 2024 Mar CMFD

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED REL PELLETS; ORAL

ESOMEPRAZOLE MAGNESIUM

@ IVAX SUB TEVA PHARMS

EQ 20MG BASE

A078003 001 Jan 26, 2015 Feb DISC

@

EQ 40MG BASE

A078003 002 Jan 26, 2015 Feb DISC

FOR SUSPENSION, DELAYED RELEASE; ORAL

ESOMEPRAZOLE MAGNESIUM

AB TORRENT

EQ 2.5MG BASE/PACKET

A212651 001 Mar 05, 2025 Feb NEWA

AB

EQ 5MG BASE/PACKET

A212651 002 Mar 05, 2025 Feb NEWA

AB

EQ 10MG BASE/PACKET

A212652 001 Mar 05, 2025 Feb NEWA

AB

EQ 20MG BASE/PACKET

A212651 003 Mar 05, 2025 Feb NEWA

AB

EQ 40MG BASE/PACKET

A212651 004 Mar 05, 2025 Feb NEWA

ESOMEPRAZOLE MAGNESIUM; NAPROXEN

TABLET, DELAYED RELEASE; ORAL

NAPROXEN AND ESOMEPRAZOLE MAGNESIUM

@ NORVIUM BIOSCIENCE

EQ 20MG BASE; 375MG

A204920 001 Jul 20, 2021 Feb CAHN

@

EQ 20MG BASE; 500MG

A204920 002 Jul 20, 2021 Feb CAHN



ESOMEPRAZOLE SODIUMINJECTABLE; INTRAVENOUS  
ESOMEPRAZOLE SODIUM

AP	YANGTZE	EQ 40MG BASE/VIAL	A214046	001	Jan 08, 2025	Jan	NEWA
----	---------	-------------------	---------	-----	--------------	-----	------

ESTRADIOLCREAM; VAGINAL  
ESTRADIOL

AB	ENCUBE	0.01%	A209767	001	Mar 05, 2018	Jan	CAHN
----	--------	-------	---------	-----	--------------	-----	------

GEL; TRANSDERMAL  
ESTRADIOL

AB	ENCUBE	0.1% (0.25GM/PACKET)	A218507	001	Mar 05, 2025	Feb	NEWA
AB		0.1% (0.5GM/PACKET)	A218507	002	Mar 05, 2025	Feb	NEWA
AB		0.1% (0.75GM/PACKET)	A218507	003	Mar 05, 2025	Feb	NEWA
AB		0.1% (1.25GM/PACKET)	A218507	005	Mar 05, 2025	Feb	NEWA
AB		0.1% (1GM/PACKET)	A218507	004	Mar 05, 2025	Feb	NEWA

GEL, METERED; TRANSDERMAL  
ELESTRIN

+!	VIATRIS	0.06% (0.87GM/ACTIVATION)	N021813	001	Dec 15, 2006	Feb	CAHN
----	---------	---------------------------	---------	-----	--------------	-----	------

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-28

GENCEPT 10/11-28

>D>	@ BARR	0.035MG; 0.035MG; 0.5MG, 1MG	A072697	001	Feb 28, 1992	Mar	CAHN
>A>	@ BARR LABS	0.035MG; 0.035MG; 0.5MG, 1MG	A072697	001	Feb 28, 1992	Mar	CAHN

NORTREL 0.5/35-28

>D>	AB BARR	0.035MG; 0.5MG	A072695	001	Feb 28, 1992	Mar	CAHN
>A>	AB BARR LABS	0.035MG; 0.5MG	A072695	001	Feb 28, 1992	Mar	CAHN

NORTREL 1/35-28

>D>	AB ! BARR	0.035MG; 1MG	A072696	001	Feb 28, 1992	Mar	CAHN
>A>	AB ! BARR LABS	0.035MG; 1MG	A072696	001	Feb 28, 1992	Mar	CAHN

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE

>A>	AB BARR LABS	0.02MG; 1MG	A090938	001	Dec 01, 2014	Mar	CAHN
>D>	AB BARR LABS INC	0.02MG; 1MG	A090938	001	Dec 01, 2014	Mar	CAHN

TABLET; ORAL-21

JUNEL 1/20

>D>	AB BARR	0.02MG; 1MG	A076380	001	May 30, 2003	Mar	CAHN
>A>	AB BARR LABS	0.02MG; 1MG	A076380	001	May 30, 2003	Mar	CAHN

EVEROLIMUS

TABLET; ORAL

EVEROLIMUS

>A>	AB BIOCON PHARMA	0.25MG	A216140	001	Apr 09, 2025	Mar	NEWA
>A>	AB	0.5MG	A216140	002	Apr 09, 2025	Mar	NEWA
>A>	AB	0.75MG	A216140	003	Apr 09, 2025	Mar	NEWA
>A>	AB	1MG	A216140	004	Apr 09, 2025	Mar	NEWA
>D>	AB MYLAN	2.5MG	A212936	001	Jun 08, 2020	Mar	DISC
>A>	@	2.5MG	A212936	001	Jun 08, 2020	Mar	DISC
>D>	AB	5MG	A212936	002	Jun 08, 2020	Mar	DISC
>A>	@	5MG	A212936	002	Jun 08, 2020	Mar	DISC
>D>	AB	7.5MG	A212936	003	Jun 08, 2020	Mar	DISC
>A>	@	7.5MG	A212936	003	Jun 08, 2020	Mar	DISC
>D>	AB	10MG	A212936	004	Jun 08, 2020	Mar	DISC
>A>	@	10MG	A212936	004	Jun 08, 2020	Mar	DISC

TABLET, FOR SUSPENSION; ORAL

EVEROLIMUS

AB	AMNEAL	2MG	A218863	001	Jan 10, 2025	Jan	NEWA
AB		3MG	A218863	002	Jan 10, 2025	Jan	NEWA
AB		5MG	A218863	003	Jan 10, 2025	Jan	NEWA
AB	NATCO	2MG	A217640	001	Jan 28, 2025	Jan	NEWA
AB		3MG	A217640	002	Jan 28, 2025	Jan	NEWA
AB		5MG	A217640	003	Jan 28, 2025	Jan	NEWA

EXENATIDE SYNTHETIC

>D>	SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS							
>D>	BYDUREON BCISE							
>D>	+! ASTRAZENECA AB	2MG/0.85ML (2MG/0.85ML)	N209210	001	Oct 20, 2017	Mar	DISC	
>A>	+ @	2MG/0.85ML (2MG/0.85ML)	N209210	001	Oct 20, 2017	Mar	DISC	

EZETIMIBE; SIMVASTATIN

	TABLET;ORAL							
	EZETIMIBE AND SIMVASTATIN							
AB	TORRENT	10MG;10MG	A209461	001	Jan 27, 2025	Jan	NEWA	
AB		10MG;20MG	A209461	002	Jan 27, 2025	Jan	NEWA	
AB		10MG;40MG	A209461	003	Jan 27, 2025	Jan	NEWA	
AB		10MG;80MG	A209461	004	Jan 27, 2025	Jan	NEWA	

FAMOTIDINE

	FOR SUSPENSION;ORAL							
	FAMOTIDINE							
>A>	AB APPCO	40MG/5ML	A217655	001	Jun 16, 2023	Mar	CAHN	
>D>	AB UPSHER SMITH LABS	40MG/5ML	A217655	001	Jun 16, 2023	Mar	CAHN	
	TABLET;ORAL							
	FAMOTIDINE							
>D>	AB APOTEX	20MG	A075611	001	Jul 23, 2001	Mar	DISC	
>A>	@	20MG	A075611	001	Jul 23, 2001	Mar	DISC	
>D>	AB	40MG	A075611	002	Jul 23, 2001	Mar	DISC	
>A>	@	40MG	A075611	002	Jul 23, 2001	Mar	DISC	
>A>	AB BEXIMCO PHARMS USA	20MG	A218631	001	Mar 25, 2025	Mar	NEWA	
>A>	AB	40MG	A218631	002	Mar 25, 2025	Mar	NEWA	

FAMOTIDINE; IBUPROFEN

	TABLET;ORAL							
	IBUPROFEN AND FAMOTIDINE							
AB	ENDO OPERATIONS	26.6MG;800MG	A203658	001	Mar 22, 2024	Feb	CTNA	
	@ TORRENT	26.6MG;800MG	A215925	001	Mar 18, 2024	Feb	CTNA	
AB	ZYDUS PHARMS	26.6MG;800MG	A218684	001	Feb 20, 2025	Feb	NEWA	

FEBUXOSTAT

	TABLET;ORAL							
	FEBUXOSTAT							
AB	MSN	40MG	A210461	001	Dec 30, 2019	Jan	CTEC	
AB		80MG	A210461	002	Dec 30, 2019	Jan	CTEC	

FENOFIBRATE

	TABLET;ORAL							
	FENOFIBRATE							
>D>	BX CREEKWOOD PHARMS	40MG	A217732	001	Sep 07, 2023	Mar	CTEC	
>A>	AB	40MG	A217732	001	Sep 07, 2023	Mar	CTEC	
>D>	BX	120MG	A217732	002	Sep 07, 2023	Mar	CTEC	
>A>	AB	120MG	A217732	002	Sep 07, 2023	Mar	CTEC	
	@ MYLAN	54MG	A076520	001	Oct 25, 2007	Feb	DISC	
	@	160MG	A076520	003	Oct 25, 2007	Feb	DISC	
	@ SUN PHARM	48MG	A200884	001	Sep 07, 2017	Jan	DISC	

FINASTERIDE; TADALAFIL

	CAPSULE;ORAL							
	FINASTERIDE AND TADALAFIL							
>A>	NOVITIUM PHARMA	5MG;5MG	A218499	001	Mar 19, 2025	Mar	NEWA	

FITUSIRAN SODIUM

>A>	SOLUTION;SUBCUTANEOUS							
>A>	QFITLIA							
>A>	+! GENZYME CORP	EQ 20MG BASE/0.2ML (EQ 20MG BASE/0.2ML)	N219019	001	Mar 28, 2025	Mar	NEWA	
>A>	+!	EQ 50MG BASE/0.5ML (EQ 50MG BASE/0.5ML)	N219019	002	Mar 28, 2025	Mar	NEWA	

FLUDEOXYGLUCOSE F-18

	INJECTABLE;INTRAVENOUS							
	FLUDEOXYGLUCOSE F18							
AP	BAMF	20-400mCi/ML	A216125	001	Mar 11, 2025	Feb	NEWA	
>D>	AP DECATUR	20-300mCi/ML	A204463	001	Oct 21, 2014	Mar	CAHN	
>A>	AP SOFIE	20-300mCi/ML	A204463	001	Oct 21, 2014	Mar	CAHN	

FLUOCINONIDE

CREAM; TOPICAL		FLUOCINONIDE					
AB1	ENCUBE	0.05%		A211410	001	Oct 16, 2018	Feb CMFD
GEL; TOPICAL		FLUOCINONIDE					
AB	PADAGIS US	0.05%		A209030	001	Jun 19, 2018	Feb CMFD
SOLUTION; TOPICAL		FLUOCINONIDE					
AT	QUAGEN	0.05%		A216389	001	Feb 26, 2025	Feb NEWA
	@ SAPTALIS PHARMS	0.05%		A207554	001	Mar 18, 2019	Feb CAHN

FLUORESCEIN SODIUM

INJECTABLE; INTRAVENOUS		FLUORESCEIN SODIUM					
>A>	AP	NEXUS	EQ 500MG BASE/5ML (EQ 100MG BASE/ML)	A215709	001	Sep 25, 2023	Mar CAHN
>A>	AP		EQ 500MG BASE/2ML (EQ 250MG BASE/ML)	A215709	002	Sep 25, 2023	Mar CAHN
>D>	AP	NEXUS PHARMS	EQ 500MG BASE/5ML (EQ 100MG BASE/ML)	A215709	001	Sep 25, 2023	Mar CAHN
>D>	AP		EQ 500MG BASE/2ML (EQ 250MG BASE/ML)	A215709	002	Sep 25, 2023	Mar CAHN

FLUORODOPA F-18

SOLUTION; INTRAVENOUS		FLUORODOPA F18					
+!	FEINSTEIN	1-40mCi/ML		N200655	001	Oct 10, 2019	Feb CPOT

FLUOROURACIL

CREAM; TOPICAL		FLUOROURACIL					
AB	ENCUBE	5%		A216942	001	Feb 12, 2025	Jan NEWA
INJECTABLE; INJECTION		FLUOROURACIL					
AP	KINDOS	5GM/100ML (50MG/ML)		A215699	001	Feb 06, 2025	Jan NEWA

FLUOXETINE HYDROCHLORIDE

TABLET; ORAL		FLUOXETINE HYDROCHLORIDE					
>D>	@	ADAPTIS	EQ 10MG BASE	A211444	001	Sep 13, 2022	Mar CAHN
>D>	@		EQ 20MG BASE	A211444	002	Sep 13, 2022	Mar CAHN
	@	APPCO	EQ 10MG BASE	A211696	001	Jan 30, 2019	Feb CAHN
	@		EQ 20MG BASE	A211696	002	Jan 30, 2019	Feb CAHN
>A>	@	CHARTWELL RX	EQ 10MG BASE	A211444	001	Sep 13, 2022	Mar CAHN
>A>	@		EQ 20MG BASE	A211444	002	Sep 13, 2022	Mar CAHN

FLUOXETINE HYDROCHLORIDE; OLANZAPINE

CAPSULE; ORAL		SYMBYAX					
+	@	LILLY	EQ 25MG BASE; EQ 3MG BASE	N021520	001	Apr 09, 2007	Feb DISC
+	@		EQ 25MG BASE; EQ 6MG BASE	N021520	002	Dec 24, 2003	Feb DISC
+	@		EQ 25MG BASE; EQ 12MG BASE	N021520	004	Dec 24, 2003	Feb DISC
+	@		EQ 50MG BASE; EQ 6MG BASE	N021520	003	Dec 24, 2003	Feb DISC
+	@		EQ 50MG BASE; EQ 12MG BASE	N021520	005	Dec 24, 2003	Feb DISC

FLUPHENAZINE HYDROCHLORIDE

TABLET; ORAL		FLUPHENAZINE HYDROCHLORIDE					
AB	ZAMEER PHARMS	1MG		A215141	001	Oct 20, 2021	Feb CAHN
AB		2.5MG		A215141	002	Oct 20, 2021	Feb CAHN
AB		5MG		A215141	003	Oct 20, 2021	Feb CAHN
AB		10MG		A215141	004	Oct 20, 2021	Feb CAHN

FLUTICASONE PROPIONATE

OINTMENT; TOPICAL		FLUTICASONE PROPIONATE					
>A>	@	CHARTWELL RX	0.005%	A076300	001	May 14, 2004	Mar CAHN
>D>	@	FOUGERA PHARMS	0.005%	A076300	001	May 14, 2004	Mar CAHN

FOLIC ACID

TABLET; ORAL  
FOLIC ACID

>A>	AA	AIPING PHARM INC	1MG	A091145	001	Jul 12, 2013	Mar	CAHN
>D>	AA	QINGDAO BAHEAL PHARM	1MG	A091145	001	Jul 12, 2013	Mar	CAHN

FORMOTEROL FUMARATE

SOLUTION; INHALATION  
FORMOTEROL FUMARATE

AN		DEVA HOLDING AS	0.02MG/2ML	A218308	001	Feb 11, 2025	Jan	NEWA
AN		DR REDDYS	0.02MG/2ML	A215907	001	Jan 30, 2025	Jan	NEWA
AN	+	VIATRIS SPECIALTY	0.02MG/2ML	N022007	001	May 11, 2007	Feb	CAHN

FOSAPREPITANT DIMEGLUMINE

POWDER; INTRAVENOUS  
FOSAPREPITANT DIMEGLUMINE

@	PRAXGEN	EQ 150MG BASE/VIAL	A213199	001	Oct 04, 2021	Jan	CAHN
---	---------	--------------------	---------	-----	--------------	-----	------

FOSINOPRIL SODIUM

TABLET; ORAL  
FOSINOPRIL SODIUM

>A>		@ APOTEX	10MG	A076906	001	May 17, 2005	Mar	DISC
>A>		@	20MG	A076906	002	May 17, 2005	Mar	DISC
>A>		@	40MG	A076906	003	May 17, 2005	Mar	DISC
>D>	AB	APOTEX INC	10MG	A076906	001	May 17, 2005	Mar	DISC
>D>	AB		20MG	A076906	002	May 17, 2005	Mar	DISC
>D>	AB		40MG	A076906	003	May 17, 2005	Mar	DISC

FUROSEMIDE

TABLET; ORAL  
FUROSEMIDE

@	NORVIUM BIOSCIENCE	80MG	A070082	001	Oct 29, 1986	Feb	CAHN
---	--------------------	------	---------	-----	--------------	-----	------

GABAPENTIN

SOLUTION; ORAL  
GABAPENTIN

AA		AJENAT PHARMS	250MG/5ML	A091286	001	Mar 14, 2016	Jan	CAHN
----	--	---------------	-----------	---------	-----	--------------	-----	------

TABLET; ORAL  
GABAPENTIN

>D>	AB1	APOTEX	100MG	A077894	001	Oct 10, 2006	Mar	DISC
>A>		@	100MG	A077894	001	Oct 10, 2006	Mar	DISC
>D>	AB1		300MG	A077894	002	Oct 10, 2006	Mar	DISC
>A>		@	300MG	A077894	002	Oct 10, 2006	Mar	DISC
>D>	AB1		400MG	A077894	003	Oct 10, 2006	Mar	DISC
>A>		@	400MG	A077894	003	Oct 10, 2006	Mar	DISC
>D>	AB1	IVAX SUB TEVA PHARMS	300MG	A076017	002	Apr 28, 2004	Mar	CTEC
>A>			300MG	A076017	002	Apr 28, 2004	Mar	CTEC

GADOTERIDOL

INJECTABLE; INJECTION  
GADOTERIDOL

AP		HAINAN POLY	279.3MG/ML	A218749	001	Feb 11, 2025	Jan	NFTG
AP	+	BRACCO	279.3MG/ML	N020131	001	Nov 16, 1992	Jan	CFTG

GALLIUM GA-68 GOZETOTIDE

POWDER; INTRAVENOUS  
GOZELLIX

>A>								
>A>	+	TElix INNOVATIONS	N/A	N219592	001	Mar 20, 2025	Mar	NEWA

GEMFIBROZIL

TABLET; ORAL  
GEMFIBROZIL

>D>	AB	APOTEX	600MG	A075034	001	Jul 20, 1998	Mar	DISC
>A>		@	600MG	A075034	001	Jul 20, 1998	Mar	DISC

>A>	<u>GEPOTIDACIN MESYLATE</u>								
>A>	TABLET;ORAL								
>A>	BLUJEPA								
>A>	+!	GLAXOSMITHKLINE	EQ 750MG BASE	N218230	001	Mar 25, 2025	Mar	NEWA	
	<u>GLIMEPIRIDE</u>								
	TABLET;ORAL								
	AMARYL								
	+ @	SANOFI AVENTIS US	1MG	N020496	001	Nov 30, 1995	Feb	DISC	
	+ @		2MG	N020496	002	Nov 30, 1995	Feb	DISC	
	+ @		4MG	N020496	003	Nov 30, 1995	Feb	DISC	
	GLIMEPIRIDE								
AB	!	DR REDDYS LABS LTD	1MG	A077091	001	Oct 06, 2005	Feb	CHRS	
	<u>GLIPIZIDE</u>								
	TABLET;ORAL								
	GLIPIZIDE								
	@	AIPING PHARM INC	5MG	A074305	001	Apr 07, 1995	Jan	CAHN	
	@		10MG	A074305	002	Apr 07, 1995	Jan	CAHN	
	<u>GLUCAGON</u>								
	SOLUTION;INTRAVENOUS								
>A>	GVOKE VIALDX								
>A>	+!	XERIS	1MG/0.2ML (1MG/0.2ML)	N212097	006	Mar 14, 2025	Mar	NEWA	
	<u>GLYCOPYRROLATE</u>								
	INJECTABLE;INJECTION								
	GLYCOPYRROLATE								
	@	XIROMED	0.2MG/ML	A212227	001	Mar 04, 2021	Jan	DISC	
	SOLUTION;ORAL								
	GLYCOPYRROLATE								
>A>	AA	MSN	1MG/5ML	A216084	001	Apr 08, 2025	Mar	NEWA	
	TABLET;ORAL								
	GLYCOPYRROLATE								
AA		CHARTWELL RX	1MG	A040847	001	Mar 21, 2008	Feb	CAHN	
AA			2MG	A040847	002	Mar 21, 2008	Feb	CAHN	
	<u>GRAMICIDIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE</u>								
	SOLUTION/DROPS;OPHTHALMIC								
	NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN								
AT		SAPTALIS PHARMS	0.025MG/ML;EQ 1.75MG BASE/ML;10,000 UNITS/ML	A065187	001	Oct 28, 2005	Feb	CAHN	
	<u>GRANISETRON HYDROCHLORIDE</u>								
	SOLUTION;ORAL								
	GRANISETRON HYDROCHLORIDE								
>A>		INTRA SANA LABS	EQ 2MG BASE/10ML	A219282	001	Mar 17, 2025	Mar	NEWA	
	TABLET;ORAL								
	GRANISETRON HYDROCHLORIDE								
>D>	AB	APOTEX INC	EQ 1MG BASE	A078843	001	Feb 27, 2008	Mar	DISC	
>A>		@	EQ 1MG BASE	A078843	001	Feb 27, 2008	Mar	DISC	
	<u>GUANFACINE HYDROCHLORIDE</u>								
	TABLET;ORAL								
	GUANFACINE HYDROCHLORIDE								
>D>	AB	RUBICON	EQ 1MG BASE	A216762	001	Oct 17, 2023	Mar	CTEC	
>A>	BX		EQ 1MG BASE	A216762	001	Oct 17, 2023	Mar	CTEC	
>D>	AB		EQ 2MG BASE	A216762	002	Oct 17, 2023	Mar	CTEC	
>A>	BX		EQ 2MG BASE	A216762	002	Oct 17, 2023	Mar	CTEC	
	TABLET, EXTENDED RELEASE;ORAL								
	GUANFACINE HYDROCHLORIDE								
>D>		@	FOSUN WANBANG	EQ 1MG BASE	A217638	001	Jun 12, 2024	Mar	CMFD
>A>	AB		EQ 1MG BASE	A217638	001	Jun 12, 2024	Mar	CMFD	
		@	EQ 1MG BASE	A217638	001	Jun 12, 2024	Jan	CAHN	
>D>		@	EQ 2MG BASE	A217638	002	Jun 12, 2024	Mar	CMFD	
>A>	AB		EQ 2MG BASE	A217638	002	Jun 12, 2024	Mar	CMFD	
		@	EQ 2MG BASE	A217638	002	Jun 12, 2024	Jan	CAHN	
>D>		@	EQ 3MG BASE	A217638	003	Jun 12, 2024	Mar	CMFD	
>A>	AB		EQ 3MG BASE	A217638	003	Jun 12, 2024	Mar	CMFD	
		@	EQ 3MG BASE	A217638	003	Jun 12, 2024	Jan	CAHN	
>D>		@	EQ 4MG BASE	A217638	004	Jun 12, 2024	Mar	CMFD	

TABLET, EXTENDED RELEASE;ORAL  
GUANFACINE HYDROCHLORIDE

>A>	AB		EQ 4MG BASE	A217638	004	Jun 12, 2024	Mar	CMFD
		@	EQ 4MG BASE	A217638	004	Jun 12, 2024	Jan	CAHN

HALCINONIDE

SOLUTION;TOPICAL  
HALCINONIDE

>D>		@	ENCUBE	0.1%	A217671	001	May 29, 2024	Mar	CMFD
>A>		!		0.1%	A217671	001	May 29, 2024	Mar	CMFD
		@		0.1%	A217671	001	May 29, 2024	Jan	DISC

HALOBETASOL PROPIONATE

LOTION;TOPICAL  
ULTRAVATE

		+ @	LACER PHARMA	0.05%	N208183	001	Nov 06, 2015	Jan	CAHN
--	--	-----	--------------	-------	---------	-----	--------------	-----	------

HALOPERIDOL

TABLET;ORAL  
HALOPERIDOL

AB			APPCO	0.5MG	A211061	001	Jan 08, 2020	Feb	CAHN
AB				1MG	A211061	002	Jan 08, 2020	Feb	CAHN
AB				2MG	A211061	003	Jan 08, 2020	Feb	CAHN
AB				5MG	A211061	004	Jan 08, 2020	Feb	CAHN
AB				10MG	A211061	005	Jan 08, 2020	Feb	CAHN
AB				20MG	A211061	006	Jan 08, 2020	Feb	CAHN

HALOPERIDOL LACTATE

INJECTABLE;INJECTION  
HALOPERIDOL

		@	FRESENIUS KABI USA	EQ 5MG BASE/ML	A210356	001	Jul 01, 2019	Feb	DISC
--	--	---	--------------------	----------------	---------	-----	--------------	-----	------

HEPARIN SODIUM

INJECTABLE;INJECTION  
HEPARIN SODIUM

		@	B BRAUN MEDICAL INC	5,000 UNITS/0.5ML	A208827	001	Nov 19, 2018	Jan	DISC
			HIKMA	5,000 UNITS/0.5ML	N017037	013	Apr 07, 1986	Jan	CTEC
>A>	AP		PLANO PHARMS	1,000 UNITS/ML	A091682	001	Jun 08, 2011	Mar	CAHN
>A>	AP			5,000 UNITS/ML	A091682	002	Jun 08, 2011	Mar	CAHN
>A>	AP			10,000 UNITS/ML	A201002	001	Jun 08, 2011	Mar	CAHN
>D>	AP		SANDOZ	1,000 UNITS/ML	A091682	001	Jun 08, 2011	Mar	CAHN
>D>	AP			5,000 UNITS/ML	A091682	002	Jun 08, 2011	Mar	CAHN
>D>	AP			10,000 UNITS/ML	A201002	001	Jun 08, 2011	Mar	CAHN
>A>			HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER						
>A>		+!	B BRAUN	5,000 UNITS/100ML	N019953	003	Mar 25, 2025	Mar	NEWA
>A>		+!		10,000 UNITS/100ML	N019953	004	Mar 25, 2025	Mar	NEWA

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

SYRUP;ORAL

HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE

AA			XTTRIUM LABS INC	1.5MG/5ML;5MG/5ML	A088008	001	Mar 03, 1983	Feb	CAHN
----	--	--	------------------	-------------------	---------	-----	--------------	-----	------

HYDROCHLOROTHIAZIDE

FOR SUSPENSION;ORAL  
INZIRQO

		+!	NOVITIUM PHARMA	10MG/ML	N219141	001	Jan 28, 2025	Jan	NEWA
--	--	----	-----------------	---------	---------	-----	--------------	-----	------

TABLET;ORAL

HYDROCHLOROTHIAZIDE

>A>	AB		UNICHEM	12.5MG	A040907	003	Apr 03, 2025	Mar	NEWA
-----	----	--	---------	--------	---------	-----	--------------	-----	------

HYDROCHLOROTHIAZIDE; METOPROLOL TARTRATE

TABLET;ORAL

METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE

AB			SENORES PHARMS	25MG;50MG	A215789	001	Jan 08, 2025	Jan	NEWA
AB				25MG;100MG	A215789	002	Jan 08, 2025	Jan	NEWA

HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE

TABLET; ORAL

QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

@	APOTEX	12.5MG;EQ 10MG BASE	A091524	001	Mar 12, 2013	Jan	DISC
@		12.5MG;EQ 20MG BASE	A091524	002	Mar 12, 2013	Jan	DISC
@		25MG;EQ 20MG BASE	A091524	003	Mar 12, 2013	Jan	DISC

HYDROCHLOROTHIAZIDE; TELMISARTAN

TABLET; ORAL

TELMISARTAN AND HYDROCHLOROTHIAZIDE

AB	MANKIND PHARMA	12.5MG;40MG	A218406	001	Mar 03, 2025	Feb	NEWA
AB		12.5MG;80MG	A218406	002	Mar 03, 2025	Feb	NEWA
AB		25MG;80MG	A218406	003	Mar 03, 2025	Feb	NEWA

HYDROCHLOROTHIAZIDE; TRIAMTERENE

CAPSULE; ORAL

TRIAMTERENE AND HYDROCHLOROTHIAZIDE

AB	MACLEODS PHARMS LTD	25MG;37.5MG	A214611	001	Jan 28, 2025	Jan	NEWA
----	---------------------	-------------	---------	-----	--------------	-----	------

HYDROCORTISONE

LOTION; TOPICAL

ALA-SCALP

>D>		LEGACY PHARMA	2%	A083231	001		Mar	CRLD
>A>	+		2%	A083231	001		Mar	CRLD

HYDROCORTISONE ACETATE

AEROSOL, METERED; RECTAL

CORTIFOAM

+!	VIATRIS	10%	N017351	001	Feb 10, 1982	Feb	CAHN
----	---------	-----	---------	-----	--------------	-----	------

CREAM; TOPICAL

MICORT-HC

@	LEGACY PHARMA	2%	A040398	001	Mar 29, 2002	Jan	CAHN
---	---------------	----	---------	-----	--------------	-----	------

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS; OTIC

NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE

@	SAPTALIS PHARMS	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A065216	001	Oct 31, 2005	Feb	CAHN
---	-----------------	-------------------------------------	---------	-----	--------------	-----	------

SUSPENSION/DROPS; OTIC

NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE

AT	SAPTALIS PHARMS	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A065219	001	May 01, 2006	Feb	CAHN
----	-----------------	-------------------------------------	---------	-----	--------------	-----	------

HYDROXYZINE HYDROCHLORIDE

TABLET; ORAL

HYDROXYZINE HYDROCHLORIDE

>D>	AB	GRAVITI PHARMS	50MG	A217652	003	Aug 17, 2023	Mar	CHRS	
>A>	AB	!	50MG	A217652	003	Aug 17, 2023	Mar	CHRS	
>D>	AB	+!	PLIVA	50MG	A088619	001	Jan 10, 1986	Mar	CHRS
>A>	AB	+		50MG	A088619	001	Jan 10, 1986	Mar	CHRS
>D>		@	STRIDES PHARMA	50MG	A087604	001	Jan 22, 1982	Mar	CRLD
>A>		+ @		50MG	A087604	001	Jan 22, 1982	Mar	CRLD

HYDROXYZINE PAMOATE

CAPSULE; ORAL

HYDROXYZINE PAMOATE

>D>	AB	BARR	EQ 50MG HYDROCHLORIDE	A088487	001	Jun 15, 1984	Mar	CAHN
>D>			EQ 100MG HYDROCHLORIDE	A088488	001	Jun 15, 1984	Mar	CAHN
>A>	AB	BARR LABS	EQ 50MG HYDROCHLORIDE	A088487	001	Jun 15, 1984	Mar	CAHN
>A>			EQ 100MG HYDROCHLORIDE	A088488	001	Jun 15, 1984	Mar	CAHN

ICODextrin

SOLUTION; INTRAPERITONEAL

EXTRANEAL

+!	VANTIVE US HLTHCARE	7.5GM/100ML	N021321	001	Dec 20, 2002	Feb	CAHN
----	---------------------	-------------	---------	-----	--------------	-----	------

IMIQUIMODCREAM; TOPICAL  
IMIQUIMOD

>D>	AB	APOTEX INC	5%	A 091308	001	Apr 06, 2012	Mar	DISC
>A>	@		5%	A 091308	001	Apr 06, 2012	Mar	DISC

INDOMETHACINSUPPOSITORY; RECTAL  
INDOMETHACIN

AB	AMNEAL	50MG	A 215399	001	Feb 24, 2025	Feb	NEWA
----	--------	------	----------	-----	--------------	-----	------

>D> IOMEPROL>D> SOLUTION; INTRA-ARTERIAL  
>D> IOMERVU

>D>	+	!	BRACCO	15GM IODINE/50ML (300MG IODINE/ML)	N 216016	002	Nov 27, 2024	Mar	DISC
>A>	+	@		15GM IODINE/50ML (300MG IODINE/ML)	N 216016	002	Nov 27, 2024	Mar	DISC
>D>	+	!		17.5GM IODINE/50ML (350MG IODINE/ML)	N 216016	006	Nov 27, 2024	Mar	DISC
>A>	+	@		17.5GM IODINE/50ML (350MG IODINE/ML)	N 216016	006	Nov 27, 2024	Mar	DISC
>D>	+	!		20GM IODINE/50ML (400MG IODINE/ML)	N 216016	010	Nov 27, 2024	Mar	DISC
>A>	+	@		20GM IODINE/50ML (400MG IODINE/ML)	N 216016	010	Nov 27, 2024	Mar	DISC
>D>	+	!		25GM IODINE/100ML (250MG IODINE/ML)	N 216016	001	Nov 27, 2024	Mar	DISC
>A>	+	@		25GM IODINE/100ML (250MG IODINE/ML)	N 216016	001	Nov 27, 2024	Mar	DISC
>D>	+	!		30GM IODINE/100ML (300MG IODINE/ML)	N 216016	003	Nov 27, 2024	Mar	DISC
>A>	+	@		30GM IODINE/100ML (300MG IODINE/ML)	N 216016	003	Nov 27, 2024	Mar	DISC
>D>	+	!		35GM IODINE/100ML (350MG IODINE/ML)	N 216016	007	Nov 27, 2024	Mar	DISC
>A>	+	@		35GM IODINE/100ML (350MG IODINE/ML)	N 216016	007	Nov 27, 2024	Mar	DISC
>D>	+	!		40GM IODINE/100ML (400MG IODINE/ML)	N 216016	011	Nov 27, 2024	Mar	DISC
>A>	+	@		40GM IODINE/100ML (400MG IODINE/ML)	N 216016	011	Nov 27, 2024	Mar	DISC
>D>	+	!		60GM IODINE/150ML (400MG IODINE/ML)	N 216016	012	Nov 27, 2024	Mar	DISC
>A>	+	@		60GM IODINE/150ML (400MG IODINE/ML)	N 216016	012	Nov 27, 2024	Mar	DISC
>D>	+	!		45GM IODINE/150ML (300MG IODINE/ML)	N 216016	004	Nov 27, 2024	Mar	DISC
>A>	+	@		45GM IODINE/150ML (300MG IODINE/ML)	N 216016	004	Nov 27, 2024	Mar	DISC
>D>	+	!		52.5GM IODINE/150ML (350MG IODINE/ML)	N 216016	008	Nov 27, 2024	Mar	DISC
>A>	+	@		52.5GM IODINE/150ML (350MG IODINE/ML)	N 216016	008	Nov 27, 2024	Mar	DISC
>D>	+	!		60GM IODINE/200ML (300MG IODINE/ML)	N 216016	005	Nov 27, 2024	Mar	DISC
>A>	+	@		60GM IODINE/200ML (300MG IODINE/ML)	N 216016	005	Nov 27, 2024	Mar	DISC
>D>	+	!		70GM IODINE/200ML (350MG IODINE/ML)	N 216016	009	Nov 27, 2024	Mar	DISC
>A>	+	@		70GM IODINE/200ML (350MG IODINE/ML)	N 216016	009	Nov 27, 2024	Mar	DISC
>D>	+	!		80GM IODINE/200ML (400MG IODINE/ML)	N 216016	013	Nov 27, 2024	Mar	DISC
>A>	+	@		80GM IODINE/200ML (400MG IODINE/ML)	N 216016	013	Nov 27, 2024	Mar	DISC
>D>				SOLUTION; INTRAVENOUS					
>D>				IOMERVU					
>D>	+	!	BRACCO	15GM IODINE/50ML (300MG IODINE/ML)	N 216017	002	Nov 27, 2024	Mar	DISC
>A>	+	@		15GM IODINE/50ML (300MG IODINE/ML)	N 216017	002	Nov 27, 2024	Mar	DISC
>D>	+	!		17.5GM IODINE/50ML (350MG IODINE/ML)	N 216017	006	Nov 27, 2024	Mar	DISC
>A>	+	@		17.5GM IODINE/50ML (350MG IODINE/ML)	N 216017	006	Nov 27, 2024	Mar	DISC
>D>	+	!		20GM IODINE/50ML (400MG IODINE/ML)	N 216017	010	Nov 27, 2024	Mar	DISC
>A>	+	@		20GM IODINE/50ML (400MG IODINE/ML)	N 216017	010	Nov 27, 2024	Mar	DISC
>D>	+	!		25GM IODINE/100ML (250MG IODINE/ML)	N 216017	001	Nov 27, 2024	Mar	DISC
>A>	+	@		25GM IODINE/100ML (250MG IODINE/ML)	N 216017	001	Nov 27, 2024	Mar	DISC
>D>	+	!		30GM IODINE/100ML (300MG IODINE/ML)	N 216017	003	Nov 27, 2024	Mar	DISC



SOLUTION; INTRAVENOUS  
IOMERVU

>A>	+ @	30GM IODINE/100ML (300MG IODINE/ML)	N216017	003	Nov 27, 2024	Mar	DISC
>D>	+!	35GM IODINE/100ML (350MG IODINE/ML)	N216017	007	Nov 27, 2024	Mar	DISC
>A>	+ @	35GM IODINE/100ML (350MG IODINE/ML)	N216017	007	Nov 27, 2024	Mar	DISC
>D>	+!	40GM IODINE/100ML (400MG IODINE/ML)	N216017	011	Nov 27, 2024	Mar	DISC
>A>	+ @	40GM IODINE/100ML (400MG IODINE/ML)	N216017	011	Nov 27, 2024	Mar	DISC
>D>	+!	60GM IODINE/150ML (400MG IODINE/ML)	N216017	012	Nov 27, 2024	Mar	DISC
>A>	+ @	60GM IODINE/150ML (400MG IODINE/ML)	N216017	012	Nov 27, 2024	Mar	DISC
>D>	+!	45GM IODINE/150ML (300MG IODINE/ML)	N216017	004	Nov 27, 2024	Mar	DISC
>A>	+ @	45GM IODINE/150ML (300MG IODINE/ML)	N216017	004	Nov 27, 2024	Mar	DISC
>D>	+!	52.5GM IODINE/150ML (350MG IODINE/ML)	N216017	008	Nov 27, 2024	Mar	DISC
>A>	+ @	52.5GM IODINE/150ML (350MG IODINE/ML)	N216017	008	Nov 27, 2024	Mar	DISC
>D>	+!	60GM IODINE/200ML (300MG IODINE/ML)	N216017	005	Nov 27, 2024	Mar	DISC
>A>	+ @	60GM IODINE/200ML (300MG IODINE/ML)	N216017	005	Nov 27, 2024	Mar	DISC
>D>	+!	70GM IODINE/200ML (350MG IODINE/ML)	N216017	009	Nov 27, 2024	Mar	DISC
>A>	+ @	70GM IODINE/200ML (350MG IODINE/ML)	N216017	009	Nov 27, 2024	Mar	DISC
>D>	+!	80GM IODINE/200ML (400MG IODINE/ML)	N216017	013	Nov 27, 2024	Mar	DISC
>A>	+ @	80GM IODINE/200ML (400MG IODINE/ML)	N216017	013	Nov 27, 2024	Mar	DISC

IPRATROPIUM BROMIDE

SPRAY, METERED; NASAL  
IPRATROPIUM BROMIDE

AB	LUPIN	0.021MG/SPRAY	A217912	001	Feb 07, 2025	Jan	NEWA
AB		0.042MG/SPRAY	A217886	001	Jan 27, 2025	Jan	NEWA
AB	RUBICON	0.021MG/SPRAY	A219222	001	Jan 14, 2025	Jan	NEWA

ISONIAZID

SYRUP; ORAL  
ISONIAZID

AA	CHARTWELL RX	50MG/5ML	A081118	001	Jul 21, 1997	Feb	CMFD
AA	+! CMP PHARMA INC	50MG/5ML	A088235	001	Nov 10, 1983	Feb	CTEC

ISOTRETINOIN

CAPSULE; ORAL  
AMNESTEEM

>A>	AB1	MYLAN PHARMS INC	30MG	A075945	004	Mar 17, 2025	Mar	NEWA
-----	-----	------------------	------	---------	-----	--------------	-----	------

ITRACONAZOLE

CAPSULE; ORAL  
ITRACONAZOLE

AB	RISING	100MG	A205724	001	Dec 13, 2016	Feb	CMFD
----	--------	-------	---------	-----	--------------	-----	------

IVERMECTIN

TABLET; ORAL  
IVERMECTIN

AB	RUBICON	3MG	A215922	001	Jan 22, 2025	Jan	NEWA
		6MG	A215922	002	Jan 22, 2025	Jan	NFTG

KETOCONAZOLE

SHAMPOO; TOPICAL  
KETOCONAZOLE

AB	ZYDUS LIFESCIENCES	2%	A218559	001	Mar 07, 2025	Feb	NEWA
----	--------------------	----	---------	-----	--------------	-----	------

LACOSAMIDESOLUTION;ORAL  
LACOSAMIDE

@ APOTEX	10MG/ML	A206355	001	Sep 26, 2022	Feb DISC
----------	---------	---------	-----	--------------	----------

LACTULOSEFOR SOLUTION;ORAL  
LACTULOSE

>D>	!	CUMBERLAND PHARMS	10GM/PACKET	A074712	001	Dec 10, 1997	Mar CTEC
>A>	AA	!	10GM/PACKET	A074712	001	Dec 10, 1997	Mar CTEC
>D>	!		20GM/PACKET	A074712	002	Dec 10, 1997	Mar CTEC
>A>	AA	!	20GM/PACKET	A074712	002	Dec 10, 1997	Mar CTEC
>A>	AA	PAI HOLDINGS	10GM/PACKET	A217914	001	Mar 14, 2025	Mar NEWA
>A>	AA		20GM/PACKET	A217914	002	Mar 14, 2025	Mar NEWA

SOLUTION;ORAL  
LACTULOSE

@ VISTAPHARM LLC	10GM/15ML	A074138	001	Sep 30, 1992	Jan CAHN
------------------	-----------	---------	-----	--------------	----------

LAMIVUDINETABLET;ORAL  
LAMIVUDINE

>A>	AB	APPCO	150MG	A206974	001	Nov 21, 2016	Mar CAHN
>A>	AB		300MG	A206974	002	Nov 21, 2016	Mar CAHN
		@ NORVIUM BIOSCIENCE	150MG	A078545	001	Mar 05, 2019	Feb CAHN
		@	300MG	A078545	002	Mar 05, 2019	Feb CAHN
>D>	AB	UPSHER SMITH LABS	150MG	A206974	001	Nov 21, 2016	Mar CAHN
>D>	AB		300MG	A206974	002	Nov 21, 2016	Mar CAHN

LAMOTRIGINETABLET;ORAL  
LAMOTRIGINE

@ AIPING PHARM INC	25MG	A078645	001	Jan 27, 2009	Jan CAHN
@	100MG	A078645	002	Jan 27, 2009	Jan CAHN
@	150MG	A078645	003	Jan 27, 2009	Jan CAHN
@	200MG	A078645	004	Jan 27, 2009	Jan CAHN

LANTHANUM CARBONATETABLET, CHEWABLE;ORAL  
LANTHANUM CARBONATE

>A>	AB	ALKEM LABS LTD	EQ 500MG BASE	A202329	001	Mar 13, 2025	Mar NEWA
>A>	AB		EQ 750MG BASE	A202329	002	Mar 13, 2025	Mar NEWA
>A>	AB		EQ 1GM BASE	A202329	003	Mar 13, 2025	Mar NEWA

LEFLUNOMIDETABLET;ORAL  
LEFLUNOMIDE

AB	FOSUN WANBANG	10MG	A077087	001	Sep 13, 2005	Jan CAHN
AB		20MG	A077087	002	Sep 13, 2005	Jan CAHN

LENALIDOMIDECAPSULE;ORAL  
LENALIDOMIDE

AB	AMNEAL	2.5MG	A216213	001	Jan 31, 2025	Jan NEWA
AB		5MG	A216213	002	Jan 31, 2025	Jan NEWA
AB		10MG	A216213	003	Jan 31, 2025	Jan NEWA
AB		15MG	A216213	004	Jan 31, 2025	Jan NEWA
AB		20MG	A216213	005	Jan 31, 2025	Jan NEWA
AB		25MG	A216213	006	Jan 31, 2025	Jan NEWA
AB	BIOCON PHARMA	2.5MG	A215759	001	Mar 03, 2025	Feb NEWA
AB		5MG	A215759	002	Mar 03, 2025	Feb NEWA
AB		10MG	A215759	003	Mar 03, 2025	Feb NEWA
AB		15MG	A215759	004	Mar 03, 2025	Feb NEWA
AB		20MG	A215759	005	Mar 03, 2025	Feb NEWA
AB		25MG	A215759	006	Mar 03, 2025	Feb NEWA

LEVETIRACETAMINJECTABLE;INTRAVENOUS  
LEVETIRACETAM IN SODIUM CHLORIDE

AP	CAPLIN	500MG/100ML (5MG/ML)	A219562	001	Jan 16, 2025	Jan NEWA
AP		1GM/100ML (10MG/ML)	A219562	002	Jan 16, 2025	Jan NEWA
AP		1.5GM/100ML (15MG/ML)	A219562	003	Jan 16, 2025	Jan NEWA

SOLUTION;ORAL		LEVETIRACETAM					
AA	AJENAT PHARMS	100MG/ML		A090461	001	Sep 30, 2010	Jan CAHN
TABLET;ORAL		LEVETIRACETAM					
	@ CHINA RESOURCES	500MG		A205102	004	Dec 16, 2015	Jan CAHN
	@	1GM		A205102	003	Dec 16, 2015	Jan CAHN
TABLET, EXTENDED RELEASE;ORAL		LEVETIRACETAM					
>D>	APOTEX	1GM		A202958	001	Feb 25, 2015	Mar DISC
>A>	@	1GM		A202958	001	Feb 25, 2015	Mar DISC

LEVOCETIRIZINE DIHYDROCHLORIDE

TABLET;ORAL		LEVOCETIRIZINE DIHYDROCHLORIDE					
AB	SYNTHON BV	5MG		A090229	001	Nov 26, 2010	Feb CAHN

LEVODOPA

POWDER; INHALATION		INBRIJA					
+!	MERZ	42MG		N209184	001	Dec 21, 2018	Feb CAHN

LEVOFLOXACIN

TABLET;ORAL		LEVOFLOXACIN					
>D> AB	APOTEX INC	250MG		A090787	001	Sep 29, 2011	Mar DISC
>A>	@	250MG		A090787	001	Sep 29, 2011	Mar DISC
>D> AB		500MG		A090787	002	Sep 29, 2011	Mar DISC
>A>	@	500MG		A090787	002	Sep 29, 2011	Mar DISC
>D> AB		750MG		A090787	003	Sep 29, 2011	Mar DISC
>A>	@	750MG		A090787	003	Sep 29, 2011	Mar DISC

LEVORPHANOL TARTRATE

TABLET;ORAL		LEVORPHANOL TARTRATE					
>D>	NOVITIUM PHARMA	1MG		A213479	003	Jul 20, 2021	Mar CTEC
>A> BX		1MG		A213479	003	Jul 20, 2021	Mar CTEC
>D> AB		2MG		A213479	001	Jul 01, 2020	Mar CTEC
>A> BX		2MG		A213479	001	Jul 01, 2020	Mar CTEC
>D> AB	!	3MG		A213479	002	Jan 12, 2021	Mar CHRS
>A> AB		3MG		A213479	002	Jan 12, 2021	Mar CHRS
>A> BX		3MG		A213479	002	Jan 12, 2021	Mar CTEC
>D> AB	SUN PHARM INDS INC	3MG		A213906	002	Apr 25, 2023	Mar CHRS
>A> AB	!	3MG		A213906	002	Apr 25, 2023	Mar CHRS
>A>	!	3MG		A213906	002	Apr 25, 2023	Mar CTEC

LEVOTHYROXINE SODIUM

POWDER; INTRAVENOUS		LEVOTHYROXINE SODIUM					
AP	STERISCIENCE	100MCG/VIAL		A216729	001	Mar 05, 2025	Feb NEWA
AP		200MCG/VIAL		A216729	002	Mar 05, 2025	Feb NEWA
AP		500MCG/VIAL		A216729	003	Mar 05, 2025	Feb NEWA

LEVOTHYROXINE SODIUM \*\*

\*\*See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium

TABLET;ORAL		LEVOTHYROXINE SODIUM					
	@ AUROBINDO PHARMA	0.137MG		A216414	001	Jul 16, 2024	Jan DISC
	@	0.15MG		A216414	002	Jul 16, 2024	Jan DISC
	@	0.175MG		A216414	003	Jul 16, 2024	Jan DISC
	@	0.2MG		A216414	004	Jul 16, 2024	Jan DISC
	@	0.3MG		A216414	005	Jul 16, 2024	Jan DISC
AB1, AB2, AB3, AB4	MACLEODS PHARMS LTD	0.025MG		A211417	001	Dec 21, 2022	Feb CTEC
AB1, AB2, AB4		0.025MG		A211417	001	Dec 21, 2022	Feb CTEC
AB1, AB2, AB3, AB4		0.05MG		A211417	002	Dec 21, 2022	Feb CTEC

TABLET;ORAL							
LEVOTHYROXINE SODIUM							
AB1, AB2, AB4	0.05MG	A211417	002	Dec 21, 2022	Feb	CTEC	
AB1, AB2, AB3, AB4	0.075MG	A211417	003	Dec 21, 2022	Feb	CTEC	
AB1, AB2, AB4	0.075MG	A211417	003	Dec 21, 2022	Feb	CTEC	
AB1, AB2, AB3, AB4	0.088MG	A211417	004	Dec 21, 2022	Feb	CTEC	
AB1, AB2, AB4	0.088MG	A211417	004	Dec 21, 2022	Feb	CTEC	
AB1, AB2, AB3, AB4	0.1MG	A211417	005	Dec 21, 2022	Feb	CTEC	
AB1, AB2, AB4	0.1MG	A211417	005	Dec 21, 2022	Feb	CTEC	
AB1, AB2, AB3, AB4	0.112MG	A211417	006	Dec 21, 2022	Feb	CTEC	
AB1, AB2, AB4	0.112MG	A211417	006	Dec 21, 2022	Feb	CTEC	
AB1, AB2, AB3, AB4	0.125MG	A211417	007	Dec 21, 2022	Feb	CTEC	
AB1, AB2, AB4	0.125MG	A211417	007	Dec 21, 2022	Feb	CTEC	
AB1, AB2, AB3, AB4	0.137MG	A211417	008	Dec 21, 2022	Feb	CTEC	
AB1, AB2, AB4	0.137MG	A211417	008	Dec 21, 2022	Feb	CTEC	
AB1, AB2, AB3, AB4	0.15MG	A211417	009	Dec 21, 2022	Feb	CTEC	
AB1, AB2, AB4	0.15MG	A211417	009	Dec 21, 2022	Feb	CTEC	
AB1, AB2, AB3, AB4	0.175MG	A211417	010	Dec 21, 2022	Feb	CTEC	
AB1, AB2, AB4	0.175MG	A211417	010	Dec 21, 2022	Feb	CTEC	
AB1, AB2, AB3, AB4	0.2MG	A211417	011	Dec 21, 2022	Feb	CTEC	
AB1, AB2, AB4	0.2MG	A211417	011	Dec 21, 2022	Feb	CTEC	
AB1, AB2, AB3, AB4	0.3MG	A211417	012	Dec 21, 2022	Feb	CTEC	
AB1, AB2, AB4	0.3MG	A211417	012	Dec 21, 2022	Feb	CTEC	

LIDOCAINE

OINTMENT; TOPICAL

LIDOCAINE

>D>	AT	ALEMBIC	5%	A211469	001	Nov 23, 2018	Mar	CTEC
>A>	BX		5%	A211469	001	Nov 23, 2018	Mar	CTEC
		PATCH; TOPICAL						
>A>		LIDOCAINE						
>A>	AB	AVEVA	1.8%	A217221	001	Mar 25, 2025	Mar	NFTG
		ZTLIDO						
>D>		+! SCILEX PHARMS	1.8%	N207962	001	Feb 28, 2018	Mar	CFTG
>A>	AB	+!	1.8%	N207962	001	Feb 28, 2018	Mar	CFTG

LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

LIDOCAINE HYDROCHLORIDE

>A>	AP	ANTHEA PHARMA	1%	A219535	001	Apr 02, 2025	Mar	NEWA
		SOLUTION; ORAL						
		LIDOCAINE HYDROCHLORIDE						
AT		XTTRIUM LABS INC	2%	A087872	001	Nov 18, 1982	Feb	CAHN
		SOLUTION; TOPICAL						
		LIDOCAINE HYDROCHLORIDE						
AT		XTTRIUM LABS INC	4%	A087881	001	Nov 18, 1982	Feb	CAHN

LINEZOLID

SOLUTION; INTRAVENOUS

LINEZOLID

AP		NORVIUM BIOSCIENCE	200MG/100ML (2MG/ML)	A205154	001	Dec 06, 2017	Feb	CAHN
AP			600MG/300ML (2MG/ML)	A205154	002	Dec 06, 2017	Feb	CAHN

LIRAGLUTIDE

SOLUTION; SUBCUTANEOUS

LIRAGLUTIDE

>A>	AP	NANJING KING-FRIEND	18MG/3ML (6MG/ML)	A218115	001	Apr 02, 2025	Mar	NEWA
-----	----	---------------------	-------------------	---------	-----	--------------	-----	------

LISDEXAMFETAMINE DIMESYLATE

CAPSULE; ORAL

LISDEXAMFETAMINE DIMESYLATE

AB		GRANULES	10MG	A218987	001	Jan 29, 2025	Jan	NEWA
AB			20MG	A218987	002	Jan 29, 2025	Jan	NEWA
AB			30MG	A218987	003	Jan 29, 2025	Jan	NEWA
AB			40MG	A218987	004	Jan 29, 2025	Jan	NEWA
AB			50MG	A218987	005	Jan 29, 2025	Jan	NEWA
AB			60MG	A218987	006	Jan 29, 2025	Jan	NEWA
AB			70MG	A218987	007	Jan 29, 2025	Jan	NEWA
AB		SANDOZ	20MG	A202836	001	Jul 26, 2024	Jan	CMFD
AB			30MG	A202836	002	Jul 26, 2024	Jan	CMFD
AB			40MG	A202836	003	Jul 26, 2024	Jan	CMFD
AB			50MG	A202836	004	Jul 26, 2024	Jan	CMFD
AB			60MG	A202836	005	Jul 26, 2024	Jan	CMFD
AB			70MG	A202836	006	Jul 26, 2024	Jan	CMFD

LITHIUM CARBONATE

TABLET, EXTENDED RELEASE; ORAL

LITHIUM CARBONATE

>D>	AB	NORVIUM BIOSCIENCE	450MG	A202219	001	Aug 08, 2012	Mar	DISC
>A>		@	450MG	A202219	001	Aug 08, 2012	Mar	DISC
	AB		450MG	A202219	001	Aug 08, 2012	Feb	CAHN

LOFEXIDINE HYDROCHLORIDE

TABLET; ORAL

LOFEXIDINE HYDROCHLORIDE

AB		MSN	EQ 0.18MG BASE	A218699	001	Feb 24, 2025	Feb	NEWA
----	--	-----	----------------	---------	-----	--------------	-----	------

LOSARTAN POTASSIUM

SUSPENSION; ORAL

ARB LI

>A>		+! SCIENTURE	10MG/ML	N218772	001	Mar 13, 2025	Mar	NEWA
-----	--	--------------	---------	---------	-----	--------------	-----	------

TABLET; ORAL

LOSARTAN POTASSIUM

@ APOTEX

@

			25MG	A218551	001	Jun 04, 2024	Jan	DISC
			50MG	A218551	002	Jun 04, 2024	Jan	DISC

	TABLET;ORAL						
	LOSARTAN POTASSIUM						
	@	100MG	A218551	003	Jun 04, 2024	Jan	DISC
	<u>LOTEPREDNOL ETABONATE</u>						
	SUSPENSION/DROPS;OPHTHALMIC						
	LOTEPREDNOL ETABONATE						
AB	PADAGIS US	0.5%	A215204	001	Jan 29, 2025	Jan	NEWA
	<u>LURASIDONE HYDROCHLORIDE</u>						
	TABLET;ORAL						
	LURASIDONE HYDROCHLORIDE						
>D>	AB	ADAPTIS	20MG	A212091	001	Dec 28, 2020	Mar CAHN
>D>	AB		40MG	A212091	002	Dec 28, 2020	Mar CAHN
>D>	AB		60MG	A212091	003	Dec 28, 2020	Mar CAHN
>D>	AB		80MG	A212091	004	Dec 28, 2020	Mar CAHN
>D>	AB		120MG	A212091	005	Dec 28, 2020	Mar CAHN
>A>	AB	CHARTWELL RX	20MG	A212091	001	Dec 28, 2020	Mar CAHN
>A>	AB		40MG	A212091	002	Dec 28, 2020	Mar CAHN
>A>	AB		60MG	A212091	003	Dec 28, 2020	Mar CAHN
>A>	AB		80MG	A212091	004	Dec 28, 2020	Mar CAHN
>A>	AB		120MG	A212091	005	Dec 28, 2020	Mar CAHN
AB	TORRENT	60MG	A208055	005	Jan 13, 2025	Jan	NEWA
	<u>MEFENAMIC ACID</u>						
	CAPSULE;ORAL						
	MEFENAMIC ACID						
AB	AJENAT PHARMS	250MG	A091608	001	Jun 02, 2014	Jan	CAHN
	<u>MEGESTROL ACETATE</u>						
	SUSPENSION;ORAL						
	MEGACE ES						
	+ @	ENDO OPERATIONS	125MG/ML	N021778	001	Jul 05, 2005	Feb DISC
	MEGESTROL ACETATE						
	!	TWI PHARMS	125MG/ML	A203139	001	Aug 27, 2014	Feb CTEC
AB	!		125MG/ML	A203139	001	Aug 27, 2014	Feb CHRS
	<u>MELOXICAM</u>						
	TABLET;ORAL						
	MELOXICAM						
AB	GRAVITI PHARMS	7.5MG	A077931	001	Jul 25, 2006	Feb	CAHN
AB		15MG	A077931	002	Jul 25, 2006	Feb	CAHN
	<u>MELOXICAM; RIZATRIPTAN BENZOATE</u>						
	TABLET;ORAL						
	SYMBRAVO						
	+!	AXSOME	20MG;EQ 10MG BASE	N215431	001	Jan 30, 2025	Jan NEWA
	<u>MEMANTINE HYDROCHLORIDE</u>						
	CAPSULE, EXTENDED RELEASE;ORAL						
	MEMANTINE HYDROCHLORIDE						
>D>	AB	APOTEX	7MG	A206135	001	Nov 22, 2016	Mar DISC
>A>	@		7MG	A206135	001	Nov 22, 2016	Mar DISC
>D>	AB		14MG	A206135	002	Nov 22, 2016	Mar DISC
>A>	@		14MG	A206135	002	Nov 22, 2016	Mar DISC
>D>	AB		21MG	A206135	003	Nov 22, 2016	Mar DISC
>A>	@		21MG	A206135	003	Nov 22, 2016	Mar DISC
>D>	AB		28MG	A206135	004	Nov 22, 2016	Mar DISC
>A>	@		28MG	A206135	004	Nov 22, 2016	Mar DISC
	<u>MERCAPTOPURINE</u>						
	SUSPENSION;ORAL						
	MERCAPTOPURINE						
AB	HIKMA	20MG/ML	A216418	001	Feb 26, 2025	Feb	NFTG
	PURIXAN						
AB	+!	NOVA LABS LTD	20MG/ML	N205919	001	Apr 28, 2014	Feb CFTG

MESALAMINE

TABLET, DELAYED RELEASE;ORAL  
MESALAMINE

AB	AMNEAL	800MG	A215067	001	Feb 18, 2025	Feb	NEWA
----	--------	-------	---------	-----	--------------	-----	------

MESNA

TABLET;ORAL  
MESNA

AB	RICONPHARMA LLC	400MG	A218871	001	Jan 13, 2025	Jan	NFTG
AB	+! BAXTER HLTHCARE	400MG	N020855	001	Mar 21, 2002	Jan	CFTG

METFORMIN HYDROCHLORIDE

SOLUTION;ORAL

METFORMIN HYDROCHLORIDE

>A>	AB	ANNORA PHARMA	500MG/5ML	A215008	001	Mar 13, 2025	Mar	NEWA
	AB	VISTAPHARM LLC	500MG/5ML	A212677	001	Aug 19, 2022	Jan	CAHN

TABLET;ORAL

METFORMIN HYDROCHLORIDE

>D>	AB	APOTEX	500MG	A075984	001	Apr 23, 2002	Mar	DISC
>A>		@	500MG	A075984	001	Apr 23, 2002	Mar	DISC
>D>	AB		500MG	A090666	001	Dec 07, 2011	Mar	DISC
>A>		@	500MG	A090666	001	Dec 07, 2011	Mar	DISC
>D>	AB		850MG	A075984	002	Apr 23, 2002	Mar	DISC
>A>		@	850MG	A075984	002	Apr 23, 2002	Mar	DISC
>D>	AB		850MG	A090666	002	Dec 07, 2011	Mar	DISC
>A>		@	850MG	A090666	002	Dec 07, 2011	Mar	DISC
>D>	AB		1GM	A075984	003	Apr 23, 2002	Mar	DISC
>A>		@	1GM	A075984	003	Apr 23, 2002	Mar	DISC
>D>	AB		1GM	A090666	003	Dec 07, 2011	Mar	DISC
>A>		@	1GM	A090666	003	Dec 07, 2011	Mar	DISC

TABLET, EXTENDED RELEASE;ORAL

METFORMIN HYDROCHLORIDE

AB1	MEDICAP LABS	500MG	A202306	001	Feb 23, 2017	Feb	CAHN
AB		750MG	A202306	002	Feb 23, 2017	Feb	CAHN
	@ SUN PHARM	500MG	A202917	001	Aug 01, 2016	Jan	DISC
	@	1GM	A202917	002	Aug 01, 2016	Jan	DISC

METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

SAXAGLIPTIN AND METFORMIN HYDROCHLORIDE

AB	DR REDDYS LABS SA	500MG;EQ 5MG BASE	A207678	001	Aug 09, 2023	Jan	CTNA
AB		1GM;EQ 2.5MG BASE	A207678	002	Aug 09, 2023	Jan	CTNA
AB	!	1GM;EQ 5MG BASE	A207678	003	Aug 09, 2023	Jan	CTNA

METHADONE HYDROCHLORIDE

TABLET, FOR SUSPENSION;ORAL

METHADONE HYDROCHLORIDE

AA	VISTAPHARM LLC	40MG	A075082	001	Mar 25, 1998	Jan	CAHN
----	----------------	------	---------	-----	--------------	-----	------

METHENAMINE HIPPURATE

TABLET;ORAL

METHENAMINE HIPPURATE

AB	ZYDUS LIFESCIENCES	1GM	A219661	001	Mar 10, 2025	Feb	NEWA
----	--------------------	-----	---------	-----	--------------	-----	------

METHIMAZOLE

TABLET;ORAL

METHIMAZOLE

>A>	AB	AIPING PHARM INC	5MG	A040547	001	Feb 18, 2005	Mar	CAHN
>A>	AB		10MG	A040547	002	Feb 18, 2005	Mar	CAHN
>A>		@	20MG	A040547	004	Feb 18, 2005	Mar	CAHN
>D>	AB	QINGDAO BAHEAL PHARM	5MG	A040547	001	Feb 18, 2005	Mar	CAHN
>D>	AB		10MG	A040547	002	Feb 18, 2005	Mar	CAHN
>D>		@	20MG	A040547	004	Feb 18, 2005	Mar	CAHN
	AB	SQUARE PHARMS PLC	5MG	A218830	001	Feb 05, 2025	Jan	NEWA
	AB		10MG	A218830	002	Feb 05, 2025	Jan	NEWA

METHYLENE BLUESOLUTION; INTRAVENOUS  
METHYLENE BLUE

AP	HIKMA	50MG/10ML (5MG/ML)	A216959	001	Dec 17, 2024	Jan	CAHN
AP	MEITHEAL	50MG/10ML (5MG/ML)	A217380	001	Jan 23, 2025	Jan	CAHN
AP	NANJING KING-FRIEND	50MG/10ML (5MG/ML)	A217380	001	Jan 23, 2025	Jan	NEWA

METHYLNALTREXONE BROMIDE

SOLUTION; SUBCUTANEOUS

METHYLNALTREXONE BROMIDE

>D>							
>D>	AP	ACTAVIS LLC	8MG/0.4ML (8MG/0.4ML)	A208112	001	Aug 26, 2024	Mar DISC
>A>		@	8MG/0.4ML (8MG/0.4ML)	A208112	001	Aug 26, 2024	Mar DISC
>D>	AP		12MG/0.6ML (12MG/0.6ML)	A208112	002	Aug 26, 2024	Mar DISC
>A>		@	12MG/0.6ML (12MG/0.6ML)	A208112	002	Aug 26, 2024	Mar DISC
		RELISTOR					
>D>	AP	+! SALLIX PHARMS	8MG/0.4ML (8MG/0.4ML)	N021964	002	Sep 27, 2010	Mar CTEC
>A>		+!	8MG/0.4ML (8MG/0.4ML)	N021964	002	Sep 27, 2010	Mar CTEC
>D>	AP	+!	12MG/0.6ML (12MG/0.6ML)	N021964	003	Sep 27, 2010	Mar CTEC
>A>		+!	12MG/0.6ML (12MG/0.6ML)	N021964	003	Sep 27, 2010	Mar CTEC

METHYLPHENIDATE HYDROCHLORIDE

SOLUTION; ORAL

METHYLPHENIDATE HYDROCHLORIDE

	@	ESJAY PHARMA	5MG/5ML	A201466	001	Nov 12, 2013	Feb CAHN
	@		10MG/5ML	A201466	002	Nov 12, 2013	Feb CAHN

METHYLTESTOSTERONE

TABLET; ORAL

ANDROID 25

>A>	BP	BAUSCH	25MG	A087147	001		Mar CAHN
>D>	BP	VALEANT PHARM INTL	25MG	A087147	001		Mar CAHN

METOCLOPRAMIDE HYDROCHLORIDE

SOLUTION; ORAL

METOCLOPRAMIDE HYDROCHLORIDE

	@	VISTAPHARM LLC	EQ 5MG BASE/5ML	A075051	001	Jan 26, 2001	Jan CAHN
--	---	----------------	-----------------	---------	-----	--------------	----------

METOPROLOL TARTRATE

TABLET; ORAL

METOPROLOL TARTRATE

AB	SCIEGEN PHARMS INC	25MG	A208955	001	Feb 05, 2020	Jan	CAHN
AB		50MG	A208955	002	Feb 05, 2020	Jan	CAHN
AB		100MG	A208955	003	Feb 05, 2020	Jan	CAHN

METRONIDAZOLE

CREAM; TOPICAL

METRONIDAZOLE

>D>	AB	ZYDUS LIFESCIENCES	0.75%	A217128	001	Apr 21, 2023	Mar CTEC
>A>	BX		0.75%	A217128	001	Apr 21, 2023	Mar CTEC

GEL; VAGINAL

METRONIDAZOLE

	@	ENCUBE	1.3%	A216795	001	Mar 18, 2024	Jan DISC
--	---	--------	------	---------	-----	--------------	----------

NUVESSA

	+!	CHEMO RESEARCH SL	1.3%	N205223	001	Mar 24, 2014	Jan CTEC
--	----	-------------------	------	---------	-----	--------------	----------

METYROSINE

CAPSULE; ORAL

METYROSINE

>A>	AB	CEROVENE INC	250MG	A218620	001	Apr 09, 2025	Mar NEWA
-----	----	--------------	-------	---------	-----	--------------	----------

MICAFUNGIN SODIUM

INJECTABLE; INTRAVENOUS

MICAFUNGIN SODIUM

>A>	AP	QILU PHARM HAINAN	EQ 50MG BASE/VIAL	A219273	001	Apr 03, 2025	Mar NEWA
>A>	AP		EQ 100MG BASE/VIAL	A219273	002	Apr 03, 2025	Mar NEWA



MIGLUSTATCAPSULE;ORAL  
MIGLUSTAT

>A>	@	CHARTWELL RX	100MG	A209325	001	Feb 03, 2022	Mar	CAHN
>A>	AB	NAVINTA LLC	100MG	A219111	001	Mar 14, 2025	Mar	NEWA
>D>	@	VERANOVA	100MG	A209325	001	Feb 03, 2022	Mar	CAHN
	@		100MG	A209325	001	Feb 03, 2022	Feb	CAHN

MINOCYCLINE HYDROCHLORIDECAPSULE, EXTENDED RELEASE;ORAL  
EMROSI

>D>	+	JOURNEY	40MG	N219015	001	Nov 01, 2024	Mar	CPOT
>A>	+		EQ 40MG BASE	N219015	001	Nov 01, 2024	Mar	CPOT

INJECTABLE;INJECTION  
MINOCYCLINE HYDROCHLORIDE

>A>	AP	NEXUS	EQ 100MG BASE/VIAL	A214934	001	Oct 24, 2024	Mar	CAHN
>D>	AP	NEXUS PHARMS	EQ 100MG BASE/VIAL	A214934	001	Oct 24, 2024	Mar	CAHN

MIRDAMETINIBCAPSULE;ORAL  
GOMEKLI

+	SPRINGWORKS	1MG	N219389	001	Feb 11, 2025	Feb	NEWA
+		2MG	N219389	002	Feb 11, 2025	Feb	NEWA

TABLET, FOR SUSPENSION;ORAL  
GOMEKLI

+	SPRINGWORKS	1MG	N219379	001	Feb 11, 2025	Feb	NEWA
---	-------------	-----	---------	-----	--------------	-----	------

MITOMYCININJECTABLE;INJECTION  
MITOMYCIN

	@	ACCORD HLTHCARE	20MG/VIAL	A064144	002	Apr 30, 1998	Jan	DISC
AP	!	MEITHEAL	20MG/VIAL	A214505	002	Sep 08, 2022	Jan	CHRS

MODAFINILTABLET;ORAL  
PROVIGIL

AB	+	NUVO PHARMS	100MG	N020717	001	Dec 24, 1998	Jan	CAHN
AB	+		200MG	N020717	002	Dec 24, 1998	Jan	CAHN

MOEXIPRIL HYDROCHLORIDETABLET;ORAL  
MOEXIPRIL HYDROCHLORIDE

>D>	AB	APOTEX INC	7.5MG	A078454	001	Jun 02, 2008	Mar	DISC
>A>	@		7.5MG	A078454	001	Jun 02, 2008	Mar	DISC
>D>	AB		15MG	A078454	002	Jun 02, 2008	Mar	DISC
>A>	@		15MG	A078454	002	Jun 02, 2008	Mar	DISC

MOMETASONE FUROATECREAM;TOPICAL  
MOMETASONE FUROATE

@	CHARTWELL MOLECULAR	0.1%	A076591	001	Apr 18, 2007	Feb	CAHN
---	---------------------	------	---------	-----	--------------	-----	------

MORPHINE SULFATESOLUTION;ORAL  
MORPHINE SULFATE

+	HIKMA	20MG/5ML	N022195	002	Mar 17, 2008	Feb	CTEC
@	RHODES PHARMS	10MG/5ML	A206308	001	Jun 22, 2017	Jan	DISC
@		20MG/5ML	A206420	001	Jul 12, 2016	Jan	DISC
@		100MG/5ML	A206308	002	Jun 22, 2017	Jan	DISC
@	WINDER LABS LLC	10MG/5ML	A211454	001	Feb 12, 2021	Feb	DISC
@		20MG/5ML	A211454	002	Feb 12, 2021	Feb	DISC
@		100MG/5ML	A211454	003	Feb 12, 2021	Feb	DISC

TABLET, EXTENDED RELEASE;ORAL

MORPHINE SULFATE

@	NOVEL LABS INC	15MG	A203602	001	Dec 16, 2015	Feb	DISC
@		30MG	A203602	002	Dec 16, 2015	Feb	DISC
@		60MG	A203602	003	Dec 16, 2015	Feb	DISC
@		100MG	A203602	004	Dec 16, 2015	Feb	DISC
@		200MG	A203602	005	Dec 16, 2015	Feb	DISC

MOTIXAFORTIDE ACETATEPOWDER; SUBCUTANEOUS  
APHEXDA

>A>	+	AYRMID PHARMA	EQ 62MG BASE/VIAL	N217159	001	Sep 08, 2023	Mar CAHN
>D>	+	BIOLINERX LTD	EQ 62MG BASE/VIAL	N217159	001	Sep 08, 2023	Mar CAHN

MOXIFLOXACIN HYDROCHLORIDESOLUTION/DROPS; OPHTHALMIC  
MOXIFLOXACIN HYDROCHLORIDE

AT1		MANKIND PHARMA	EQ 0.5% BASE	A217988	001	Jan 27, 2025	Jan NEWA
	@	NORVIUM BIOSCIENCE	EQ 0.5% BASE	A206447	001	Mar 30, 2020	Feb CAHN

MUPIROICIN CALCIUMCREAM; TOPICAL  
MUPIROICIN

>D>	AB	ALEMBIC	EQ 2% BASE	A213053	001	Nov 16, 2021	Mar CTEC
>A>	BX		EQ 2% BASE	A213053	001	Nov 16, 2021	Mar CTEC

MYCOPHENOLATE MOFETILFOR SUSPENSION; ORAL  
MYCOPHENOLATE MOFETIL

AB		VISTAPHARM LLC	200MG/ML	A210370	001	Feb 12, 2019	Jan CAHN
----	--	----------------	----------	---------	-----	--------------	----------

MYCOPHENOLIC SODIUMTABLET, DELAYED RELEASE; ORAL  
MYCOPHENOLIC SODIUM

AB		FOSUN WANBANG	EQ 180MG BASE	A216637	001	May 29, 2024	Jan CAHN
AB			EQ 360MG BASE	A216637	002	May 29, 2024	Jan CAHN

NALBUPHINE HYDROCHLORIDEINJECTABLE; INJECTION  
NALBUPHINE

>D>	@	ABRAXIS PHARM	10MG/ML	A070751	001	Jul 02, 1986	Mar CDFR
>D>	@		20MG/ML	A070752	001	Sep 24, 1986	Mar CDFR
			NALBUPHINE HYDROCHLORIDE				
>D>	@	ABBOTT	20MG/ML	A070917	001	Feb 03, 1989	Mar CDFR
>D>	@	DR REDDYS	10MG/ML	A074471	001	Mar 19, 1998	Mar CDFR
>D>	@		20MG/ML	A074471	002	Mar 19, 1998	Mar CDFR
>D>	AP	!	HOSPIRA	A070914	001	Feb 03, 1989	Mar CDFR
>D>	AP	!		A070915	001	Feb 03, 1989	Mar CDFR
>D>	AP	!		A070916	001	Feb 03, 1989	Mar CDFR
>D>	AP	!		A070918	001	Feb 03, 1989	Mar CDFR
>D>	@	IGI LABS INC	10MG/ML	A072070	001	Apr 10, 1989	Mar CDFR
>D>	@		10MG/ML	A072071	001	Apr 10, 1989	Mar CDFR
>D>	@		10MG/ML	A072072	001	Apr 10, 1989	Mar CDFR
>D>	@		20MG/ML	A072073	001	Apr 10, 1989	Mar CDFR
>D>	@		20MG/ML	A072074	001	Apr 10, 1989	Mar CDFR
>D>	@		20MG/ML	A072075	001	Apr 10, 1989	Mar CDFR
>D>	@	RISING	10MG/ML	A206506	001	Feb 06, 2019	Mar CDFR
>D>	@		10MG/ML	A207595	001	Jan 11, 2019	Mar CDFR
>D>	@		20MG/ML	A206506	002	Feb 06, 2019	Mar CDFR
>D>	@		20MG/ML	A207595	002	Jan 11, 2019	Mar CDFR
>D>	AP	SOMERSET THERAPS LLC	10MG/ML	A216049	001	Sep 19, 2024	Mar CDFR
>D>	AP		10MG/ML	A216050	001	Sep 19, 2024	Mar CDFR
>D>	AP		20MG/ML	A216049	002	Sep 19, 2024	Mar CDFR
>D>	AP		20MG/ML	A216050	002	Sep 19, 2024	Mar CDFR

NUBAIN

>D>	+	@ ENDO OPERATIONS	10MG/ML	N018024	001		Mar CDFR
>D>	+	@	20MG/ML	N018024	002	May 27, 1982	Mar CDFR

SOLUTION; INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS

NALBUPHINE

>A>	@	ABRAXIS PHARM	10MG/ML	A070751	001	Jul 02, 1986	Mar CDFR
>A>	@		10MG/ML (10MG/ML)	A070751	001	Jul 02, 1986	Mar CPOT
>A>	@		20MG/ML	A070752	001	Sep 24, 1986	Mar CDFR
>A>	@		20MG/ML (20MG/ML)	A070752	001	Sep 24, 1986	Mar CPOT
>A>	@		200MG/10ML (20MG/ML)	A070752	002	Sep 24, 1986	Mar NEWA
>A>			NALBUPHINE HYDROCHLORIDE				
>A>	@	ABBOTT	20MG/ML	A070917	001	Feb 03, 1989	Mar CDFR
>A>	@		20MG/ML (20MG/ML)	A070917	001	Feb 03, 1989	Mar CPOT
>A>	@	ABRAXIS PHARM	100MG/10ML (10MG/ML)	A070751	002	Jul 02, 1986	Mar NEWA
>A>	@	DR REDDYS	10MG/ML	A074471	001	Mar 19, 1998	Mar CDFR

>A>	SOLUTION;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS					
>A>	NALBUPHINE HYDROCHLORIDE					
>A>	@	20MG/ML	A074471	002	Mar 19, 1998	Mar CDFR
>A>	@	100MG/10ML (10MG/ML)	A074471	001	Mar 19, 1998	Mar CPOT
>A>	@	200MG/10ML (20MG/ML)	A074471	002	Mar 19, 1998	Mar CPOT
>A>	AP !	HOSPIRA 10MG/ML	A070914	001	Feb 03, 1989	Mar CDFR
>A>	AP !	10MG/ML (10MG/ML)	A070914	001	Feb 03, 1989	Mar CPOT
>A>	AP !	10MG/ML	A070915	001	Feb 03, 1989	Mar CDFR
>A>	AP !	20MG/ML	A070916	001	Feb 03, 1989	Mar CDFR
>A>	AP !	20MG/ML (20MG/ML)	A070916	001	Feb 03, 1989	Mar CPOT
>A>	AP !	20MG/ML	A070918	001	Feb 03, 1989	Mar CDFR
>A>	AP !	100MG/10ML (10MG/ML)	A070915	001	Feb 03, 1989	Mar CPOT
>A>	AP !	200MG/10ML (20MG/ML)	A070918	001	Feb 03, 1989	Mar CPOT
>A>	@	IGI LABS INC 10MG/ML	A072070	001	Apr 10, 1989	Mar CDFR
>A>	@	10MG/ML (10MG/ML)	A072070	001	Apr 10, 1989	Mar CPOT
>A>	@	10MG/ML	A072071	001	Apr 10, 1989	Mar CDFR
>A>	@	10MG/ML (10MG/ML)	A072071	001	Apr 10, 1989	Mar CPOT
>A>	@	10MG/ML	A072072	001	Apr 10, 1989	Mar CDFR
>A>	@	10MG/ML (10MG/ML)	A072072	001	Apr 10, 1989	Mar CPOT
>A>	@	20MG/ML	A072073	001	Apr 10, 1989	Mar CDFR
>A>	@	20MG/ML (20MG/ML)	A072073	001	Apr 10, 1989	Mar CPOT
>A>	@	20MG/ML	A072074	001	Apr 10, 1989	Mar CDFR
>A>	@	20MG/ML (20MG/ML)	A072074	001	Apr 10, 1989	Mar CPOT
>A>	@	20MG/ML	A072075	001	Apr 10, 1989	Mar CDFR
>A>	@	20MG/ML (20MG/ML)	A072075	001	Apr 10, 1989	Mar CPOT
>A>	@	100MG/10ML (10MG/ML)	A072070	002	Apr 10, 1989	Mar NEWA
>A>	@	200MG/10ML (20MG/ML)	A072073	002	Apr 10, 1989	Mar NEWA
>A>	@	RISING 10MG/ML	A206506	001	Feb 06, 2019	Mar CDFR
>A>	@	10MG/ML	A207595	001	Jan 11, 2019	Mar CDFR
>A>	@	10MG/ML (10MG/ML)	A207595	001	Jan 11, 2019	Mar CPOT
>A>	@	20MG/ML	A206506	002	Feb 06, 2019	Mar CDFR
>A>	@	20MG/ML	A207595	002	Jan 11, 2019	Mar CDFR
>A>	@	20MG/ML (20MG/ML)	A207595	002	Jan 11, 2019	Mar CPOT
>A>	@	100MG/10ML (10MG/ML)	A206506	001	Feb 06, 2019	Mar CPOT
>A>	@	200MG/10ML (20MG/ML)	A206506	002	Feb 06, 2019	Mar CPOT
>A>	AP	SOMERSET THERAPS LLC 10MG/ML	A216049	001	Sep 19, 2024	Mar CDFR
>A>	AP	10MG/ML	A216050	001	Sep 19, 2024	Mar CDFR
>A>	AP	10MG/ML (10MG/ML)	A216050	001	Sep 19, 2024	Mar CPOT
>A>	AP	20MG/ML	A216049	002	Sep 19, 2024	Mar CDFR
>A>	AP	20MG/ML	A216050	002	Sep 19, 2024	Mar CDFR
>A>	AP	20MG/ML (20MG/ML)	A216050	002	Sep 19, 2024	Mar CPOT
>A>	AP	100MG/10ML (10MG/ML)	A216049	001	Sep 19, 2024	Mar CPOT
>A>	AP	200MG/10ML (20MG/ML)	A216049	002	Sep 19, 2024	Mar CPOT
>A>	NUBAIN					
>A>	+ @	ENDO OPERATIONS 10MG/ML	N018024	001		Mar CDFR
>A>	+ @	10MG/ML (10MG/ML)	N018024	001		Mar CPOT
>A>	+ @	20MG/ML	N018024	002	May 27, 1982	Mar CDFR
>A>	+ @	20MG/ML (20MG/ML)	N018024	002	May 27, 1982	Mar CPOT
>A>	+ @	20MG/2ML (10MG/ML)	N018024	004		Mar NEWA
>A>	+ @	100MG/10ML (10MG/ML)	N018024	003		Mar NEWA
>A>	+ @	200MG/10ML (20MG/ML)	N018024	005	Mar 02, 1984	Mar NEWA
<u>NALMEFENE HYDROCHLORIDE</u>						
SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS						
ZURNAI (AUTOINJECTOR)						
>A>	+ @	PURDUE PHARMA LP EQ 1.5MG BASE/0.5ML (EQ 1.5MG BASE/0.5ML)	N218590	001	Aug 07, 2024	Jan DISC
<u>NEBIVOLOL HYDROCHLORIDE</u>						
TABLET;ORAL						
NEBIVOLOL HYDROCHLORIDE						
AB	MACLEODS PHARMS LTD EQ 2.5MG BASE		A212661	001	Jan 28, 2025	Jan NEWA
AB	EQ 5MG BASE		A212661	002	Jan 28, 2025	Jan NEWA
AB	EQ 10MG BASE		A212661	003	Jan 28, 2025	Jan NEWA
AB	EQ 20MG BASE		A212661	004	Jan 28, 2025	Jan NEWA
<u>NICARDIPINE HYDROCHLORIDE</u>						
INJECTABLE;INJECTION						
NICARDIPINE HYDROCHLORIDE						
>A>	@	AMNEAL 25MG/10ML (2.5MG/ML)	A215406	001	Oct 31, 2024	Jan DISC

NILOTINIB D-TARTRATE

CAPSULE;ORAL

NILOTINIB D-TARTRATE

+	CIPLA	EQ 50MG BASE	N218922	001	Feb 19, 2025	Feb NEWA
+		EQ 150MG BASE	N218922	002	Feb 19, 2025	Feb NEWA
+	!	EQ 200MG BASE	N218922	003	Feb 19, 2025	Feb NEWA

NIMODIPINE

SOLUTION;ORAL

NIMODIPINE

AB		ALKEM LABS LTD	6MG/ML	A213409	001	Jan 22, 2025	Jan NFTG	
AB	+	!	AZURITY	6MG/ML	N203340	002	Apr 08, 2020	Jan CFTG

NITAZOXANIDE

TABLET;ORAL

NITAZOXANIDE

AB	!	RISING	500MG	A213820	001	Nov 27, 2020	Jan CTEC
AB		ZENARA	500MG	A214844	001	Feb 03, 2025	Jan NEWA

NITROFURANTOIN

SUSPENSION;ORAL

NITROFURANTOIN

AB		APPCO	25MG/5ML	A208909	001	Jan 14, 2025	Jan NEWA
----	--	-------	----------	---------	-----	--------------	----------

NOREPINEPHRINE BITARTRATE

INJECTABLE;INJECTION

NOREPINEPHRINE BITARTRATE

AP		ASPIRO	EQ 1MG BASE/ML	A219163	001	Jan 31, 2025	Jan NEWA
>A>	AP	BIOCON PHARMA	EQ 1MG BASE/ML	A219443	001	Mar 21, 2025	Mar NEWA

NYSTATIN

CREAM;TOPICAL

NYSTATIN

>A>	AT	AUROBINDO PHARMA	100,000 UNITS/GM	A219527	001	Mar 21, 2025	Mar NEWA
-----	----	------------------	------------------	---------	-----	--------------	----------

SUSPENSION;ORAL

NYSTATIN

AA		XTTRIUM LABS INC	100,000 UNITS/ML	A062512	001	Oct 29, 1984	Jan CAHN
----	--	------------------	------------------	---------	-----	--------------	----------

OFLOXACIN

SOLUTION/DROPS;OPHTHALMIC

OFLOXACIN

@	AMNEAL	0.3%	A211524	001	Mar 01, 2024	Feb DISC
---	--------	------	---------	-----	--------------	----------

OLICERIDINE

SOLUTION;INTRAVENOUS

OLINVYK

+	@	TREVENA	1MG/ML (1MG/ML)	N210730	001	Oct 30, 2020	Jan DISC
+	@		2MG/2ML (1MG/ML)	N210730	002	Oct 30, 2020	Jan DISC

OLMESARTAN MEDOXOMIL

TABLET;ORAL

OLMESARTAN MEDOXOMIL

>D>		@	JUBILANT GENERICS	5MG	A205482	001	Apr 24, 2017	Mar CMFD
>A>	AB			5MG	A205482	001	Apr 24, 2017	Mar CMFD
>D>		@		20MG	A205482	002	Apr 24, 2017	Mar CMFD
>A>	AB			20MG	A205482	002	Apr 24, 2017	Mar CMFD
>D>		@		40MG	A205482	003	Apr 24, 2017	Mar CMFD
>A>	AB			40MG	A205482	003	Apr 24, 2017	Mar CMFD

OMAVELOXOLONE

CAPSULE;ORAL

SKYCLARYS

+	!	BIOGEN US	50MG	N216718	001	Feb 28, 2023	Jan CAHN
---	---	-----------	------	---------	-----	--------------	----------

OMEGA-3-ACID ETHYL ESTERSCAPSULE;ORAL  
LOVAZA

AB	+!	WAYLIS THERAP	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	N021654	001	Nov 10, 2004	Feb	CAHN
----	----	---------------	--	---------	-----	--------------	-----	------

ONDANSETRONTABLET, ORALLY DISINTEGRATING;ORAL  
ONDANSETRON

	@	NORVIUM BIOSCIENCE	4MG	A078139	001	Jun 25, 2007	Feb	CAHN
	@		8MG	A078139	002	Jun 25, 2007	Feb	CAHN

ONDANSETRON HYDROCHLORIDEINJECTABLE;INJECTION  
ONDANSETRON HYDROCHLORIDE

>D>	AP	HIKMA FARMACEUTICA	EQ 2MG BASE/ML	A076781	001	Dec 26, 2006	Mar	DISC
>A>		@	EQ 2MG BASE/ML	A076781	001	Dec 26, 2006	Mar	DISC

TABLET;ORAL

ONDANSETRON HYDROCHLORIDE

>D>	AB	APOTEX	EQ 4MG BASE	A077306	001	Jun 25, 2007	Mar	DISC
>A>		@	EQ 4MG BASE	A077306	001	Jun 25, 2007	Mar	DISC
>D>	AB		EQ 8MG BASE	A077306	002	Jun 25, 2007	Mar	DISC
>A>		@	EQ 8MG BASE	A077306	002	Jun 25, 2007	Mar	DISC

OSELTAMIVIR PHOSPHATE

CAPSULE;ORAL

OSELTAMIVIR PHOSPHATE

>D>	AB	HAINAN POLY	EQ 75MG BASE	A218009	001	Nov 24, 2023	Mar	CAHN
>A>	AB	ZHEJIANG POLY PHARM	EQ 75MG BASE	A218009	001	Nov 24, 2023	Mar	CAHN

FOR SUSPENSION;ORAL

OSELTAMIVIR PHOSPHATE

AB		JUBILANT GENERICS	EQ 6MG BASE/ML	A213695	001	Mar 03, 2025	Feb	NEWA
----	--	-------------------	----------------	---------	-----	--------------	-----	------

OXALIPLATININJECTABLE;INTRAVENOUS  
OXALIPLATIN

AP		HETERO LABS LTD VI	50MG/10ML (5MG/ML)	A217925	001	Jan 27, 2025	Jan	NEWA
AP			100MG/20ML (5MG/ML)	A217925	002	Jan 27, 2025	Jan	NEWA

OXAZEPAM

CAPSULE;ORAL

OXAZEPAM

AB		LEADING	10MG	A218261	001	Mar 03, 2025	Feb	NEWA
AB			15MG	A218261	002	Mar 03, 2025	Feb	NEWA
AB			30MG	A218261	003	Mar 03, 2025	Feb	NEWA

OXYCODONE HYDROCHLORIDE

SOLUTION;ORAL

OXYCODONE HYDROCHLORIDE

	@	VISTAPHARM LLC	100MG/5ML	A202537	001	Jul 30, 2012	Jan	CAHN
--	---	----------------	-----------	---------	-----	--------------	-----	------

TABLET;ORAL

OXYCODONE HYDROCHLORIDE

	@	NOVEL LABS INC	5MG	A204021	001	Jun 12, 2017	Feb	DISC
	@		10MG	A204021	002	Jun 12, 2017	Feb	DISC
	@		15MG	A204021	003	Jun 12, 2017	Feb	DISC
	@		20MG	A204021	004	Jun 12, 2017	Feb	DISC
	@		30MG	A204021	005	Jun 12, 2017	Feb	DISC

PACLITAXEL

POWDER;INTRAVENOUS

PACLITAXEL

>A>	AB	CIPLA	100MG/VIAL	A209657	001	Apr 10, 2025	Mar	NEWA
-----	----	-------	------------	---------	-----	--------------	-----	------

PALIPERIDONE

TABLET, EXTENDED RELEASE;ORAL

PALIPERIDONE

AB		DR REDDYS	3MG	A205559	001	Feb 19, 2025	Feb	NEWA
AB			6MG	A205559	002	Feb 19, 2025	Feb	NEWA
AB			9MG	A205559	003	Feb 19, 2025	Feb	NEWA

PANTOPRAZOLE SODIUM

FOR SUSPENSION, DELAYED RELEASE;ORAL  
PANTOPRAZOLE SODIUM

>A>	AB	AUROBINDO PHARMA LTD	EQ 40MG BASE	A217923	001	Mar 31, 2025	Mar	NEWA
>A>	AB	CIPLA	EQ 40MG BASE	A217458	001	Mar 31, 2025	Mar	NEWA
INJECTABLE;INTRAVENOUS								
PANTOPRAZOLE SODIUM								
>A>	AP	ALEMVIC	EQ 40MG BASE/VIAL	A219230	001	Mar 31, 2025	Mar	NEWA
POWDER;INTRAVENOUS								
PANTOPRAZOLE SODIUM								
		@ FRESENIUS KABI USA	EQ 40MG BASE/VIAL	A216021	001	Aug 01, 2024	Feb	DISC
		+! HIKMA	EQ 40MG BASE/VIAL	N209463	001	Jun 30, 2017	Feb	CTEC
TABLET, DELAYED RELEASE;ORAL								
PANTOPRAZOLE SODIUM								
	AB	GRAVITI PHARMS	EQ 20MG BASE	A219087	001	Jan 16, 2025	Jan	NEWA
	AB		EQ 40MG BASE	A219087	002	Jan 16, 2025	Jan	NEWA
		@ INGENUS PHARMS LLC	EQ 40MG BASE	A211368	001	Mar 01, 2019	Jan	DISC

PENCICLOVIR

CREAM;TOPICAL  
PENCICLOVIR

>D>	AB	TORRENT	1%	A216981	001	Aug 07, 2023	Mar	CTEC
>A>	BX		1%	A216981	001	Aug 07, 2023	Mar	CTEC

PERPHENAZINE

TABLET;ORAL  
PERPHENAZINE

>A>	AB	JUBILANT GENERICS	2MG	A213694	001	Mar 18, 2025	Mar	NEWA
>A>	AB		4MG	A213694	002	Mar 18, 2025	Mar	NEWA
>A>	AB		8MG	A213694	003	Mar 18, 2025	Mar	NEWA
>A>	AB		16MG	A213694	004	Mar 18, 2025	Mar	NEWA

PHENDIMETRAZINE TARTRATE

TABLET;ORAL  
BONTRIL PDM

>A>	AA	+! BAUSCH	35MG	A085272	001		Mar	CAHN
>D>	AA	+! VALEANT	35MG	A085272	001		Mar	CAHN

PHENYLEPHRINE HYDROCHLORIDE

SOLUTION;INTRAVENOUS  
BIORPHEN

AP	+!	DR REDDYS LABS SA	0.5MG/5ML (0.1MG/ML)	N212909	001	Oct 21, 2019	Feb	CFTG
PHENYLEPHRINE HYDROCHLORIDE								
AP		SOMERSET THERAPS LLC	0.5MG/5ML (0.1MG/ML)	A215617	001	Feb 14, 2025	Feb	NFTG

PHENYTOIN

SUSPENSION;ORAL  
PHENYTOIN

		@ VISTAPHARM LLC	125MG/5ML	A040342	001	Jan 31, 2001	Jan	CAHN
		@	125MG/5ML	A040342	002	Aug 18, 2005	Jan	CAHN

PHYTONADIONE

TABLET;ORAL  
PHYTONADIONE

		@ HIKMA	5MG	A212112	001	Dec 19, 2024	Feb	DISC
--	--	---------	-----	---------	-----	--------------	-----	------

PITOLISANT HYDROCHLORIDE

TABLET;ORAL  
WAKIX

	+	HARMONY	EQ 4.45MG BASE	N211150	001	Aug 14, 2019	Feb	CAHN
	+	!	EQ 17.8MG BASE	N211150	002	Aug 14, 2019	Feb	CAHN

POMALIDOMIDE

CAPSULE;ORAL  
POMALIDOMIDE

		@ APOTEX	1MG	A210164	001	Jun 11, 2024	Jan	DISC
		@	2MG	A210164	002	Jun 11, 2024	Jan	DISC
		@	3MG	A210164	003	Jun 11, 2024	Jan	DISC
		@	4MG	A210164	004	Jun 11, 2024	Jan	DISC

POSACONAZOLE

TABLET, DELAYED RELEASE;ORAL  
POSACONAZOLE

AB MSN 100MG A218434 001 Feb 24, 2025 Feb NEWA

POTASSIUM CHLORIDE

FOR SOLUTION;ORAL  
POTASSIUM CHLORIDE

AA AJENAT PHARMS 20MEQ A212183 001 May 06, 2019 Jan CAHN  
AA +! GENUS 20MEQ N208019 001 Aug 19, 2015 Jan CHRS  
+ @ 40MEQ N208019 003 Aug 25, 2023 Jan DISC

INJECTABLE;INJECTION  
POTASSIUM CHLORIDE

>A> AP NEXUS 2MEQ/ML A217704 001 Aug 14, 2023 Mar CAHN  
>D> AP NEXUS PHARMS 2MEQ/ML A217704 001 Aug 14, 2023 Mar CAHN

SOLUTION;ORAL

POTASSIUM CHLORIDE

AA AJENAT PHARMS 20MEQ/15ML A216156 001 Mar 07, 2023 Jan CAHN  
AA 40MEQ/15ML A216156 002 Mar 07, 2023 Jan CAHN  
>A> AA ASCENT PHARMS INC 20MEQ/15ML A211992 001 Apr 09, 2025 Mar NEWA  
>A> AA 40MEQ/15ML A211992 002 Apr 09, 2025 Mar NEWA

POTASSIUM PHOSPHATE, DIBASIC; POTASSIUM PHOSPHATE, MONOBASIC

SOLUTION;INTRAVENOUS  
POTASSIUM PHOSPHATES

AP CIPLA 1.18GM/5ML (236MG/ML);1.12GM/5ML (224MG/ML) A217892 001 Jan 24, 2025 Jan NEWA  
AP 3.54GM/15ML (236MG/ML);3.36GM/15ML (224MG/ML) A217892 002 Jan 24, 2025 Jan NEWA  
AP 11.8GM/50ML (236MG/ML);11.2GM/50ML (224MG/ML) A217892 003 Jan 24, 2025 Jan NEWA

PRALATREXATE

SOLUTION;INTRAVENOUS  
FOLOTYN

AP + ACROTECH BIOPHARMA 20MG/ML (20MG/ML) N022468 001 Sep 24, 2009 Feb CFTG  
AP +! 40MG/2ML (20MG/ML) N022468 002 Sep 24, 2009 Feb CFTG  
PRALATREXATE  
AP DR REDDYS 20MG/ML (20MG/ML) A206183 001 Mar 10, 2025 Feb NFTG  
AP 40MG/2ML (20MG/ML) A206183 002 Mar 10, 2025 Feb NFTG

PREDNISONE

TABLET;ORAL  
PREDNISONE

@ AIPING PHARM INC 5MG A080336 002 Jan CAHN

PREGABALIN

CAPSULE;ORAL  
PREGABALIN

AB HLTHCARE 25MG A091222 001 Feb 21, 2025 Feb NEWA  
AB 50MG A091222 002 Feb 21, 2025 Feb NEWA  
AB 75MG A091222 003 Feb 21, 2025 Feb NEWA  
AB 100MG A091222 004 Feb 21, 2025 Feb NEWA  
AB 150MG A091222 005 Feb 21, 2025 Feb NEWA  
AB 200MG A091222 006 Feb 21, 2025 Feb NEWA  
AB 225MG A091222 007 Feb 21, 2025 Feb NEWA  
AB 300MG A091222 008 Feb 21, 2025 Feb NEWA  
AB TORRENT 25MG A206942 001 Feb 21, 2025 Feb NEWA  
AB 50MG A206942 002 Feb 21, 2025 Feb NEWA  
AB 75MG A206942 003 Feb 21, 2025 Feb NEWA  
AB 100MG A206942 004 Feb 21, 2025 Feb NEWA  
AB 150MG A206942 005 Feb 21, 2025 Feb NEWA  
AB 200MG A206942 006 Feb 21, 2025 Feb NEWA  
AB 225MG A206942 007 Feb 21, 2025 Feb NEWA  
AB 300MG A206942 008 Feb 21, 2025 Feb NEWA

TABLET, EXTENDED RELEASE;ORAL

PREGABALIN

@ ALVOGEN 82.5MG A211593 001 Apr 13, 2021 Feb DISC  
@ 165MG A211593 002 Apr 13, 2021 Feb DISC  
@ 330MG A211593 003 Apr 13, 2021 Feb DISC  
@ APOTEX 165MG A213313 001 Apr 13, 2021 Jan DISC  
@ 330MG A213313 002 Apr 13, 2021 Jan DISC

## TABLET, EXTENDED RELEASE;ORAL

## PREGABALIN

AB	HQ PHARMA	330MG	A217857	001	Jan 28, 2025	Jan NEWA
----	-----------	-------	---------	-----	--------------	----------

PROCAINAMIDE HYDROCHLORIDE

## INJECTABLE; INJECTION

## PROCAINAMIDE HYDROCHLORIDE

AP	CAPLIN	100MG/ML	A218674	001	Feb 04, 2025	Jan NEWA
AP		500MG/ML	A218674	002	Feb 04, 2025	Jan NEWA

PROCHLORPERAZINE

## SUPPOSITORY; RECTAL

## COMPAZINE

>D>	@	GLAXOSMITHKLINE	2.5MG	N011127	003	Mar CRLD
>A>	+	@	2.5MG	N011127	003	Mar CRLD
>D>	@		5MG	N011127	001	Mar CRLD
>A>	+	@	5MG	N011127	001	Mar CRLD
>A>	+	@	5MG	N011127	001	Mar CMS1
>D>	@		25MG	N011127	002	Mar CRLD
>A>	+	@	25MG	N011127	002	Mar CRLD
>A>	+	@	25MG	N011127	002	Mar CMS1

PROMETHAZINE HYDROCHLORIDE

## SYRUP; ORAL

## PROMETHAZINE PLAIN

AA	+!	XTTRIUM LABS INC	6.25MG/5ML	A087953	001	Nov 15, 1982	Feb CAHN
----	----	------------------	------------	---------	-----	--------------	----------

QUETIAPINE FUMARATE

## TABLET; ORAL

## QUETIAPINE FUMARATE

AB		GRAVITI PHARMS	EQ 25MG BASE	A077380	001	Mar 27, 2012	Feb CAHN
AB			EQ 50MG BASE	A077380	002	Mar 27, 2012	Feb CAHN
AB			EQ 100MG BASE	A077380	003	Mar 27, 2012	Feb CAHN
AB			EQ 150MG BASE	A077380	004	Mar 27, 2012	Feb CAHN
AB			EQ 200MG BASE	A077380	005	Mar 27, 2012	Feb CAHN
AB			EQ 300MG BASE	A077380	006	Mar 27, 2012	Feb CAHN
AB			EQ 400MG BASE	A077380	007	Mar 27, 2012	Feb CAHN

## SEROQUEL

>D>	AB	+!	ASTRAZENECA	EQ 25MG BASE	N020639	001	Sep 26, 1997	Mar CAHN
>D>	AB	+		EQ 50MG BASE	N020639	007	Oct 04, 2005	Mar CAHN
>D>	AB	+		EQ 100MG BASE	N020639	002	Sep 26, 1997	Mar CAHN
>D>		+	@	EQ 150MG BASE	N020639	004	Dec 20, 1998	Mar CAHN
>D>	AB	+		EQ 200MG BASE	N020639	003	Sep 26, 1997	Mar CAHN
>D>	AB	+!		EQ 300MG BASE	N020639	005	Jul 26, 2000	Mar CAHN
>D>	AB	+		EQ 400MG BASE	N020639	006	Oct 04, 2005	Mar CAHN
>A>	AB	+!	CHEPLAPHARM	EQ 25MG BASE	N020639	001	Sep 26, 1997	Mar CAHN
>A>	AB	+		EQ 50MG BASE	N020639	007	Oct 04, 2005	Mar CAHN
>A>	AB	+		EQ 100MG BASE	N020639	002	Sep 26, 1997	Mar CAHN
>A>		+	@	EQ 150MG BASE	N020639	004	Dec 20, 1998	Mar CAHN
>A>	AB	+		EQ 200MG BASE	N020639	003	Sep 26, 1997	Mar CAHN
>A>	AB	+!		EQ 300MG BASE	N020639	005	Jul 26, 2000	Mar CAHN
>A>	AB	+		EQ 400MG BASE	N020639	006	Oct 04, 2005	Mar CAHN

## TABLET, EXTENDED RELEASE;ORAL

## QUETIAPINE FUMARATE

AB		MEDICAP LABS	EQ 50MG BASE	A202939	001	May 09, 2017	Feb CAHN
AB			EQ 150MG BASE	A202939	002	May 09, 2017	Feb CAHN
AB			EQ 200MG BASE	A202939	003	May 09, 2017	Feb CAHN
AB			EQ 300MG BASE	A202939	004	May 09, 2017	Feb CAHN
AB			EQ 400MG BASE	A202939	005	May 09, 2017	Feb CAHN

## SEROQUEL XR

>D>	AB	+	ASTRAZENECA	EQ 50MG BASE	N022047	001	May 17, 2007	Mar CAHN
>D>	AB	+		EQ 150MG BASE	N022047	005	Aug 11, 2008	Mar CAHN
>D>	AB	+!		EQ 200MG BASE	N022047	002	May 17, 2007	Mar CAHN
>D>	AB	+		EQ 300MG BASE	N022047	003	May 17, 2007	Mar CAHN
>D>	AB	+		EQ 400MG BASE	N022047	004	May 17, 2007	Mar CAHN
>A>	AB	+	CHEPLAPHARM	EQ 50MG BASE	N022047	001	May 17, 2007	Mar CAHN
>A>	AB	+		EQ 150MG BASE	N022047	005	Aug 11, 2008	Mar CAHN
>A>	AB	+!		EQ 200MG BASE	N022047	002	May 17, 2007	Mar CAHN
>A>	AB	+		EQ 300MG BASE	N022047	003	May 17, 2007	Mar CAHN
>A>	AB	+		EQ 400MG BASE	N022047	004	May 17, 2007	Mar CAHN



RALTEGRAVIR POTASSIUMTABLET; ORAL  
ISENTRESS

+!	MSD SUB MERCK	EQ 400MG BASE	N022145	001	Oct 12, 2007	Jan	CTEC
	RALTEGRAVIR POTASSIUM						
@	HETERO LABS LTD III	EQ 400MG BASE	A203540	001	Dec 19, 2024	Jan	DISC

RAMELTEONTABLET; ORAL  
RAMELTEON

>A>	AB	APPCO	8MG	A213815	001	Oct 26, 2020	Mar	CAHN
>D>	AB	AUROBINDO PHARMA LTD	8MG	A215972	001	Jul 10, 2023	Mar	CTEC
>A>	BX		8MG	A215972	001	Jul 10, 2023	Mar	CTEC
>D>	AB	I3 PHARMS	8MG	A212650	001	Apr 10, 2020	Mar	CTEC
>A>	BX		8MG	A212650	001	Apr 10, 2020	Mar	CTEC
>D>	AB	UPSHER SMITH LABS	8MG	A213815	001	Oct 26, 2020	Mar	CAHN
>D>	AB	XIROMED	8MG	A216209	001	Nov 25, 2022	Mar	CTEC
>A>	BX		8MG	A216209	001	Nov 25, 2022	Mar	CTEC

RANITIDINE HYDROCHLORIDETABLET; ORAL  
RANITIDINE HYDROCHLORIDE

>D>	AB	APOTEX	EQ 150MG BASE	A074680	001	Sep 12, 1997	Mar	DISC
>A>	@		EQ 150MG BASE	A074680	001	Sep 12, 1997	Mar	DISC
>D>	AB		EQ 300MG BASE	A074680	002	Sep 12, 1997	Mar	DISC
>A>	@		EQ 300MG BASE	A074680	002	Sep 12, 1997	Mar	DISC

RANOLAZINETABLET, EXTENDED RELEASE; ORAL  
RANOLAZINE

	AB	ARTHUR GRP	500MG	A212781	001	Mar 23, 2020	Jan	CAHN
	AB		1GM	A212781	002	Mar 23, 2020	Jan	CAHN
>D>	AB	CADILA	1GM	A210188	002	Aug 19, 2019	Mar	CHRS
>A>	AB	!	1GM	A210188	002	Aug 19, 2019	Mar	CHRS
>D>	AB	SUN PHARM	500MG	A211707	001	May 28, 2019	Mar	DISC
>A>	@		500MG	A211707	001	May 28, 2019	Mar	DISC
>D>	AB	!	1GM	A211707	002	May 28, 2019	Mar	DISC
>A>	@		1GM	A211707	002	May 28, 2019	Mar	DISC
	AB	TORRENT	500MG	A210407	001	Feb 04, 2025	Jan	NEWA
	AB		1GM	A210407	002	Feb 04, 2025	Jan	NEWA

REGORAFENIBTABLET; ORAL  
REGORAFENIB

	AB	ACTAVIS LABS FL	40MG	A209728	001	Jan 13, 2025	Jan	NFTG
		STIVARGA						
	AB	+! BAYER HLTHCARE	40MG	N203085	001	Sep 27, 2012	Jan	CFTG

REPAGLINIDETABLET; ORAL  
REPAGLINIDE

	@	SUN PHARM INDS INC	1MG	A077571	002	Jul 11, 2013	Feb	DISC
	@		2MG	A077571	003	Jul 11, 2013	Feb	DISC

RILUZOLETABLET; ORAL  
RILUZOLE

	AB	NORVIUM BIOSCIENCE	50MG	A203042	001	Jul 01, 2013	Feb	CAHN
--	----	--------------------	------	---------	-----	--------------	-----	------

RISDIPLAMTABLET; ORAL  
EVRYSDI

+!	GENENTECH INC	5MG	N219285	001	Feb 11, 2025	Feb	NEWA
----	---------------	-----	---------	-----	--------------	-----	------

RISPERIDONESOLUTION; ORAL  
RISPERIDONE

@	LANNETT CO INC	1MG/ML	A079158	001	Dec 03, 2010	Feb	DISC
---	----------------	--------	---------	-----	--------------	-----	------

## TABLET;ORAL

## RISPERIDONE

>D>	AB	APOTEX INC	0.25MG	A077953	001	Sep 15, 2008	Mar	DISC
>A>		@	0.25MG	A077953	001	Sep 15, 2008	Mar	DISC
>D>	AB		0.5MG	A077953	002	Sep 15, 2008	Mar	DISC
>A>		@	0.5MG	A077953	002	Sep 15, 2008	Mar	DISC
>D>	AB		1MG	A077953	003	Sep 15, 2008	Mar	DISC
>A>		@	1MG	A077953	003	Sep 15, 2008	Mar	DISC
>D>	AB		2MG	A077953	004	Sep 15, 2008	Mar	DISC
>A>		@	2MG	A077953	004	Sep 15, 2008	Mar	DISC
>D>	AB		3MG	A077953	005	Sep 15, 2008	Mar	DISC
>A>		@	3MG	A077953	005	Sep 15, 2008	Mar	DISC
>D>	AB		4MG	A077953	006	Sep 15, 2008	Mar	DISC
>A>		@	4MG	A077953	006	Sep 15, 2008	Mar	DISC

RIVAROXABAN

## TABLET;ORAL

## RIVAROXABAN

AB		LUPIN LTD	2.5MG	A208555	001	Mar 03, 2025	Feb	NFTG
AB		TARO	2.5MG	A208557	001	Mar 03, 2025	Feb	NFTG
AB	+	JANSSEN PHARMS	2.5MG	N022406	004	Oct 11, 2018	Feb	CFTG

RIVASTIGMINE

## FILM, EXTENDED RELEASE;TRANSDERMAL

## RIVASTIGMINE

>D>	AB	ALVOGEN	4.6MG/24HR	A204403	001	Sep 03, 2015	Mar	DISC
>A>		@	4.6MG/24HR	A204403	001	Sep 03, 2015	Mar	DISC
>D>	AB		9.5MG/24HR	A204403	002	Sep 03, 2015	Mar	DISC
>A>		@	9.5MG/24HR	A204403	002	Sep 03, 2015	Mar	DISC
>D>	AB		13.3MG/24HR	A204403	003	Aug 31, 2015	Mar	DISC
>A>		@	13.3MG/24HR	A204403	003	Aug 31, 2015	Mar	DISC

RIZATRIPTAN BENZOATE

## TABLET;ORAL

## RIZATRIPTAN BENZOATE

AB		NORVIUM BIOSCIENCE	EQ 5MG BASE	A201993	001	Dec 31, 2012	Feb	CAHN
AB			EQ 10MG BASE	A201993	002	Dec 31, 2012	Feb	CAHN

ROFLUMILAST

## TABLET;ORAL

## ROFLUMILAST

AB		AUROBINDO PHARMA LTD	250MCG	A213298	002	Jan 31, 2025	Jan	NEWA
		@ SENORES PHARMS	250MCG	A208236	002	Oct 19, 2023	Feb	CAHN
		@	500MCG	A208236	001	Oct 03, 2018	Feb	CAHN

ROPIVACAINE HYDROCHLORIDE

## SOLUTION;INJECTION

## ROPIVACAINE HYDROCHLORIDE

>A>	AP	ANTHEA PHARMA	40MG/20ML (2MG/ML)	A219883	001	Mar 21, 2025	Mar	NEWA
>A>	AP		150MG/30ML (5MG/ML)	A219883	002	Mar 21, 2025	Mar	NEWA
>A>	AP		200MG/20ML (10MG/ML)	A219883	003	Mar 21, 2025	Mar	NEWA

ROSUVASTATIN CALCIUM

## TABLET;ORAL

## CRESTOR

AB	+	ASTRAZENECA	EQ 5MG BASE	N021366	002	Aug 12, 2003	Jan	CAHN
AB	+		EQ 10MG BASE	N021366	003	Aug 12, 2003	Jan	CAHN
AB	+		EQ 20MG BASE	N021366	004	Aug 12, 2003	Jan	CAHN
AB	+	!	EQ 40MG BASE	N021366	005	Aug 12, 2003	Jan	CAHN

SACUBITRIL; VALSARTAN

## TABLET;ORAL

## SACUBITRIL AND VALSARTAN

AB		DR REDDYS	24MG;26MG	A213627	001	Jan 13, 2025	Jan	NEWA
AB			49MG;51MG	A213627	002	Jan 13, 2025	Jan	NEWA
AB			97MG;103MG	A213627	003	Jan 13, 2025	Jan	NEWA
AB		LUPIN	24MG;26MG	A213808	001	Jan 08, 2025	Jan	NEWA
AB			49MG;51MG	A213808	002	Jan 08, 2025	Jan	NEWA
AB			97MG;103MG	A213808	003	Jan 08, 2025	Jan	NEWA

SELENIOS ACID

SOLUTION;INTRAVENOUS		SELENIOS ACID					
	+!	AM REGENT	EQ 60MCG SELENIUM/ML (EQ 60MCG SELENIUM/ML)	N209379	002	Jan 25, 2021	Feb CTEC
AP	+!		EQ 60MCG SELENIUM/ML (EQ 60MCG SELENIUM/ML)	N209379	002	Jan 25, 2021	Jan CFTG
AP	+!		EQ 600MCG SELENIUM/10ML (EQ 60MCG SELENIUM/ML)	N209379	001	Apr 30, 2019	Feb CFTG
AP		FRESENIUS KABI USA	EQ 60MCG SELENIUM/ML (EQ 60MCG SELENIUM/ML)	A218779	001	Feb 10, 2025	Jan NFTG
AP			EQ 600MCG SELENIUM/10ML (EQ 60MCG SELENIUM/ML)	A218779	001	Feb 10, 2025	Feb CMS1
AP		SUN PHARM	EQ 600MCG SELENIUM/10ML (EQ 60MCG SELENIUM/ML)	A219547	001	Feb 20, 2025	Feb NEWA

SELINEXOR

TABLET;ORAL		XPOVIO					
>A>	+	KARYOPHARM THERAPS	10MG	N212306	005	Mar 10, 2025	Mar NEWA

SELPERCATINIBCAPSULE;ORAL  
RETEVMO

	+	ELI LILLY AND CO	40MG	N213246	001	May 08, 2020	Jan CAHN
	+!		80MG	N213246	002	May 08, 2020	Jan CAHN

TABLET;ORAL  
RETEVMO

	+	ELI LILLY AND CO	40MG	N218160	001	Apr 10, 2024	Jan CAHN
	+		80MG	N218160	002	Apr 10, 2024	Jan CAHN
	+		120MG	N218160	003	Apr 10, 2024	Jan CAHN
	+!		160MG	N218160	004	Apr 10, 2024	Jan CAHN

SEVELAMER CARBONATEFOR SUSPENSION;ORAL  
SEVELAMER CARBONATE

	@	INVAGEN PHARMS	800MG/PACKET	A206234	001	Jul 12, 2024	Jan DISC
	@		2.4GM/PACKET	A206234	002	Jul 12, 2024	Jan DISC
AB		TORRENT	800MG/PACKET	A215909	001	Feb 27, 2025	Feb NEWA
AB			2.4GM/PACKET	A215909	002	Feb 27, 2025	Feb NEWA

SEVELAMER HYDROCHLORIDETABLET;ORAL  
SEVELAMER HYDROCHLORIDE

>D>	AB	AUROBINDO PHARMA LTD	400MG	A212599	001	Jul 11, 2023	Mar CTEC
>A>	BX		400MG	A212599	001	Jul 11, 2023	Mar CTEC
>D>	AB		800MG	A212599	002	Jul 11, 2023	Mar CTEC
>A>	BX		800MG	A212599	002	Jul 11, 2023	Mar CTEC
	AB	NAVINTA LLC	800MG	A218966	001	Feb 03, 2025	Jan NEWA

SILDENAFIL CITRATEFOR SUSPENSION;ORAL  
SILDENAFIL CITRATE

AB		APPCO	EQ 10MG BASE/ML	A213814	001	Apr 29, 2021	Feb CAHN
AB		CHARTWELL RX	EQ 10MG BASE/ML	A213814	001	Apr 29, 2021	Feb CAHN

TABLET;ORAL  
SILDENAFIL CITRATE

AB		JUBILANT GENERICS	EQ 20MG BASE	A202954	001	Mar 06, 2025	Feb NEWA
----	--	-------------------	--------------	---------	-----	--------------	----------

SILODOSINCAPSULE;ORAL  
SILODOSIN

AB		TORRENT	4MG	A210396	001	Feb 10, 2025	Jan NEWA
AB			8MG	A210396	002	Feb 10, 2025	Jan NEWA

SIMVASTATINTABLET;ORAL  
SIMVASTATIN

AB		GRAVITI PHARMS	5MG	A077752	005	Jan 23, 2008	Feb CAHN
AB			10MG	A077752	001	Dec 20, 2006	Feb CAHN
AB			20MG	A077752	002	Dec 20, 2006	Feb CAHN
AB			40MG	A077752	003	Dec 20, 2006	Feb CAHN

	TABLET;ORAL						
	SIMVASTATIN						
AB		80MG		A077752	004	Dec 20, 2006	Feb CAHN
	<u>SIROLIMUS</u>						
	POWDER;INTRAVENOUS						
	FYARRO						
>D>	+	AADI	100MG/VIAL	N213312	001	Nov 22, 2021	Mar CAHN
>A>	+	AADI SUB	100MG/VIAL	N213312	001	Nov 22, 2021	Mar CAHN
	<u>SITAGLIPTIN HYDROCHLORIDE</u>						
	SOLUTION;ORAL						
	BRYNOVIN						
	+	AZURITY	EQ 25MG BASE/ML	N219122	001	Jan 16, 2025	Jan NEWA
	<u>SODIUM CHLORIDE</u>						
	SOLUTION;INJECTION						
	SODIUM CHLORIDE 0.9%						
>A>	AP	NEXUS	90MG/10ML (9MG/ML)	A217535	001	Aug 23, 2023	Mar CAHN
>A>	AP		180MG/20ML (9MG/ML)	A217535	002	Aug 23, 2023	Mar CAHN
>D>	AP	NEXUS PHARMS	90MG/10ML (9MG/ML)	A217535	001	Aug 23, 2023	Mar CAHN
>D>	AP		180MG/20ML (9MG/ML)	A217535	002	Aug 23, 2023	Mar CAHN
	<u>SODIUM NITROPRUSSIDE</u>						
	INJECTABLE;INJECTION						
	SODIUM NITROPRUSSIDE						
	@	XIROMED	25MG/ML	A211277	001	Oct 29, 2020	Jan DISC
	<u>SODIUM POLYSTYRENE SULFONATE</u>						
	POWDER;ORAL, RECTAL						
	SODIUM POLYSTYRENE SULFONATE						
AA		AJENAT PHARMS	454GM/BOT	A205727	001	Feb 23, 2016	Jan CAHN
	<u>SOLIFENACIN SUCCINATE</u>						
	TABLET;ORAL						
	SOLIFENACIN SUCCINATE						
AB		TORRENT	5MG	A209424	001	Mar 04, 2025	Feb NEWA
AB			10MG	A209424	002	Mar 04, 2025	Feb NEWA
	<u>SORAFENIB TOSYLATE</u>						
	TABLET;ORAL						
	SORAFENIB TOSYLATE						
>D>	AB	APOTEX	EQ 200MG BASE	A212228	001	Jan 27, 2025	Mar DISC
>A>	@		EQ 200MG BASE	A212228	001	Jan 27, 2025	Mar DISC
AB			EQ 200MG BASE	A212228	001	Jan 27, 2025	Jan NEWA
	<u>SPIRONOLACTONE</u>						
	SUSPENSION;ORAL						
	SPIRONOLACTONE						
AB		HETERO LABS LTD III	25MG/5ML	A218085	001	Feb 21, 2025	Feb NEWA
	TABLET;ORAL						
	SPIRONOLACTONE						
AB		GRAVITI PHARMS	25MG	A219494	001	Jan 23, 2025	Jan NEWA
AB			50MG	A219494	002	Jan 23, 2025	Jan NEWA
AB			100MG	A219494	003	Jan 23, 2025	Jan NEWA
	<u>STREPTOZOCIN</u>						
	INJECTABLE;INJECTION						
	ZANOSAR						
	+	@ TEVA PHARMS USA	1GM/VIAL	N050577	001	May 07, 1982	Feb DISC
	<u>SUCCINYLCHOLINE CHLORIDE</u>						
	INJECTABLE;INJECTION						
	SUCCINYLCHOLINE CHLORIDE						
AP		FRESENIUS KABI USA	20MG/ML	A217885	001	Feb 21, 2025	Feb NEWA
	SOLUTION;INTRAMUSCULAR, INTRAVENOUS						
	SUCCINYLCHOLINE CHLORIDE						
AP		FRESENIUS KABI USA	100MG/5ML (20MG/ML)	A217884	001	Feb 11, 2025	Jan NEWA

SULINDACTABLET;ORAL  
SULINDAC

>A>	AB	EPIC PHARMA	150MG	A072711	002	Mar 25, 1991	Mar CMS1
-----	----	-------------	-------	---------	-----	--------------	----------

SUNITINIB MALATECAPSULE;ORAL  
SUNITINIB MALATE

AB		FOSUN WANBANG	EQ 12.5MG BASE	A218012	001	Aug 21, 2023	Jan CAHN
AB			EQ 25MG BASE	A218012	002	Aug 21, 2023	Jan CAHN
AB			EQ 37.5MG BASE	A218012	003	Aug 21, 2023	Jan CAHN
AB			EQ 50MG BASE	A218012	004	Aug 21, 2023	Jan CAHN
AB		MSN	EQ 12.5MG BASE	A214824	001	Feb 14, 2025	Feb NEWA
AB			EQ 25MG BASE	A214824	002	Feb 14, 2025	Feb NEWA
AB			EQ 37.5MG BASE	A214824	003	Feb 14, 2025	Feb NEWA
AB			EQ 50MG BASE	A214824	004	Feb 14, 2025	Feb NEWA

SUZETRIGINETABLET;ORAL  
JOURNAVX

+!		VERTEX PHARMS INC	50MG	N219209	001	Jan 30, 2025	Jan NEWA
----	--	-------------------	------	---------	-----	--------------	----------

TACROLIMUSCAPSULE;ORAL  
TACROLIMUS

AB		AJENAT PHARMS	EQ 0.5MG BASE	A206651	001	Nov 30, 2017	Jan CAHN
AB			EQ 1MG BASE	A206651	002	Nov 30, 2017	Jan CAHN
AB			EQ 5MG BASE	A206651	003	Nov 30, 2017	Jan CAHN

INJECTABLE;INJECTION  
PROGRAF

AP	+!	ASTELLAS	EQ 5MG BASE/ML	N050709	001	Apr 08, 1994	Jan CTEC
AP		NEXUS	EQ 5MG BASE/ML	A217108	001	Feb 12, 2025	Jan NEWA

OINTMENT;TOPICAL  
TACROLIMUS

>D>	AB	ENCUBE	0.1%	A212387	001	Oct 10, 2023	Mar CTEC
>A>	BX		0.1%	A212387	001	Oct 10, 2023	Mar CTEC

TALAZOPARIB TOSYLATECAPSULE;ORAL  
TALZENNA

+ @		PFIZER	EQ 0.1MG BASE	N211651	005	Jun 20, 2023	Feb DISC
+ @			EQ 0.25MG BASE	N211651	001	Oct 16, 2018	Feb DISC
+ @			EQ 0.35MG BASE	N211651	006	Jun 20, 2023	Feb DISC
+ @			EQ 0.5MG BASE	N211651	003	Sep 20, 2021	Feb DISC
+ @			EQ 0.75MG BASE	N211651	004	Sep 20, 2021	Feb DISC
+ @			EQ 1MG BASE	N211651	002	Oct 16, 2018	Feb DISC

TAMOXIFEN CITRATETABLET;ORAL  
TAMOXIFEN CITRATE

>D>	AB	APOTEX	EQ 10MG BASE	A090878	001	Sep 23, 2011	Mar DISC
>A>		@	EQ 10MG BASE	A090878	001	Sep 23, 2011	Mar DISC
>D>	AB		EQ 20MG BASE	A090878	002	Sep 23, 2011	Mar DISC
>A>		@	EQ 20MG BASE	A090878	002	Sep 23, 2011	Mar DISC

TAMSULOSIN HYDROCHLORIDECAPSULE;ORAL  
FLOMAX

+ @		SANOFI	0.4MG	N020579	001	Apr 15, 1997	Feb DISC
AB		ASCENT PHARMS INC	0.4MG	A214730	001	May 04, 2022	Feb CMFD
AB	!	ZYDUS PHARMS USA INC	0.4MG	A078225	001	Apr 27, 2010	Feb CHRS

TAZAROTENECREAM;TOPICAL  
TAZAROTENE

AB		COSETTE	0.05%	A208662	002	Mar 10, 2025	Feb NEWA
----	--	---------	-------	---------	-----	--------------	----------

TECHNETIUM TC-99M MEDRONATE KITINJECTABLE; INJECTION  
OSTEOLITE

@	SUN PHARM INDS INC	N/A	N017972	001			Feb	CAHN
---	--------------------	-----	---------	-----	--	--	-----	------

TECHNETIUM TC-99M PENTETATE KITINJECTABLE; INJECTION  
DRAXIMAGE DTPA

>D>	+	JUBILANT	N/A	N018511	001	Dec 29, 1989	Mar	CFTG
>A>	AP	+	N/A	N018511	001	Dec 29, 1989	Mar	CFTG
>A>		TECHNETIUM TC-99M PENTETATE KIT						
>A>	AP	CURIUM	N/A	A215146	001	Mar 26, 2025	Mar	NFTG

TELMISARTANTABLET; ORAL  
MICARDIS

AB	+	BOEHRINGER INGELHEIM	80MG	N020850	002	Nov 10, 1998	Feb	CHRS
		TELMISARTAN						
AB	!	INVENTIA	80MG	A205150	003	Oct 30, 2015	Feb	CHRS
AB		MACLEODS PHARMS LTD	20MG	A203986	001	Jan 15, 2025	Jan	NEWA
AB			40MG	A203986	002	Jan 15, 2025	Jan	NEWA
AB			80MG	A203986	003	Jan 15, 2025	Jan	NEWA

TEMAZEPAMCAPSULE; ORAL  
TEMAZEPAM

>D>	AB	SUN PHARM INDUSTRIES	7.5MG	A078581	001	Sep 08, 2009	Mar	DISC
>A>		@	7.5MG	A078581	001	Sep 08, 2009	Mar	DISC

TEMOZOLOMIDECAPSULE; ORAL  
TEMOZOLOMIDE

>D>		@	CHARTWELL MOLECULAR	5MG	A203898	001	Feb 10, 2016	Mar	CAHN
>D>		@		20MG	A203898	002	Feb 10, 2016	Mar	CAHN
>D>		@		100MG	A203898	003	Feb 10, 2016	Mar	CAHN
>D>		@		140MG	A203898	004	Feb 10, 2016	Mar	CAHN
>D>		@		180MG	A203898	005	Feb 10, 2016	Mar	CAHN
>D>		@		250MG	A203898	006	Feb 10, 2016	Mar	CAHN
>A>		@	NEXTSOURCE	5MG	A203898	001	Feb 10, 2016	Mar	CAHN
>A>		@		20MG	A203898	002	Feb 10, 2016	Mar	CAHN
>A>		@		100MG	A203898	003	Feb 10, 2016	Mar	CAHN
>A>	AB			100MG	A203898	003	Feb 10, 2016	Mar	CMFD
>A>		@		140MG	A203898	004	Feb 10, 2016	Mar	CAHN
>A>	AB			140MG	A203898	004	Feb 10, 2016	Mar	CMFD
>A>		@		180MG	A203898	005	Feb 10, 2016	Mar	CAHN
>A>	AB			180MG	A203898	005	Feb 10, 2016	Mar	CMFD
>A>		@		250MG	A203898	006	Feb 10, 2016	Mar	CAHN
>A>	AB			250MG	A203898	006	Feb 10, 2016	Mar	CMFD

TERBINAFINE HYDROCHLORIDETABLET; ORAL  
TERBINAFINE HYDROCHLORIDE

>D>	AB	BRECKENRIDGE PHARM	EQ 250MG BASE	A077714	001	Jun 04, 2010	Mar	DISC
>A>		@	EQ 250MG BASE	A077714	001	Jun 04, 2010	Mar	DISC

TERIFLUNOMIDETABLET; ORAL  
TERIFLUNOMIDE

		@	APOTEX	7MG	A209601	001	Nov 02, 2018	Feb	DISC
		@		14MG	A209601	002	Nov 02, 2018	Feb	DISC
>A>	AB		CONCORD BIOTECH LTD	7MG	A218663	001	Apr 07, 2025	Mar	NEWA
>A>	AB			14MG	A218663	002	Apr 07, 2025	Mar	NEWA

TERIPARATIDESOLUTION; SUBCUTANEOUS  
BONSITY

			ALVOGEN	0.56MG/2.24ML (0.25MG/ML)	N211939	001	Oct 04, 2019	Feb	CPOT
			FORTEO						
AP	+	LILLY		0.56MG/2.24ML (0.25MG/ML)	N021318	002	Jun 25, 2008	Feb	CPOT
			TERIPARATIDE						
AP	+	ALMAJECT		0.56MG/2.24ML (0.25MG/ML)	N218771	001	Jun 04, 2024	Feb	CPOT

SOLUTION;SUBCUTANEOUS  
TERIPARATIDE

AP	+		0.6MG/2.4ML (0.25MG/ML)	N218771	001	Jun 04, 2024	Feb CTEC
AP		APOTEX	0.56MG/2.24ML (0.25MG/ML)	A211097	001	Nov 16, 2023	Feb CPOT
AP		TEVA PHARMS USA	0.56MG/2.24ML (0.25MG/ML)	A208569	001	Nov 16, 2023	Feb CPOT

TESTOSTERONE

SOLUTION, METERED;TRANSDERMAL  
TESTOSTERONE

	@	ENCUBE	30MG/1.5ML ACTUATION	A212301	001	Jan 11, 2021	Jan DISC
--	---	--------	----------------------	---------	-----	--------------	----------

THEOPHYLLINE

TABLET, EXTENDED RELEASE;ORAL  
THEOPHYLLINE

>A>	AB	AJANTA PHARMA LTD	300MG	A218401	002	Mar 26, 2025	Mar NEWA
	AB		450MG	A218401	001	Jan 13, 2025	Jan NEWA
		@ RHODES PHARMS	300MG	A214113	001	May 11, 2023	Jan DISC

THIAMINE HYDROCHLORIDE

INJECTABLE;INJECTION  
THIAMINE HYDROCHLORIDE

AP		GLAND	100MG/ML	A217800	001	Feb 24, 2025	Feb NEWA
----	--	-------	----------	---------	-----	--------------	----------

THIOTEPA

SOLUTION;INTRAVENOUS  
TEPYLUTE

>A>	+	SHORLA	100MG/10ML (10MG/ML)	N216984	002	Feb 26, 2025	Mar NEWA
-----	---	--------	----------------------	---------	-----	--------------	----------

TICAGRELOR

TABLET;ORAL  
BRILINTA

>D>	+	ASTRAZENECA	60MG	N022433	002	Sep 03, 2015	Mar CTEC
>A>	AB	+	60MG	N022433	002	Sep 03, 2015	Mar CTEC
		TICAGRELOR					
>D>		@ MSN	90MG	A208596	001	Apr 07, 2020	Mar CMFD
>A>	AB		90MG	A208596	001	Apr 07, 2020	Mar CMFD
		@	90MG	A208596	001	Apr 07, 2020	Feb CAHN
>D>		@ SUNSHINE	90MG	A208508	001	Apr 06, 2020	Mar CMFD
>A>	AB		90MG	A208508	001	Apr 06, 2020	Mar CMFD
>D>		@ WATSON LABS INC	60MG	A208390	001	Sep 04, 2018	Mar CMFD
>A>	AB		60MG	A208390	001	Sep 04, 2018	Mar CMFD
>D>		@	90MG	A208390	002	Sep 04, 2018	Mar CMFD
>A>	AB		90MG	A208390	002	Sep 04, 2018	Mar CMFD

TICLOPIDINE HYDROCHLORIDE

>D>		TABLET;ORAL					
>D>		TICLOPIDINE HYDROCHLORIDE					
>D>	!	APOTEX	250MG	A075089	001	Jul 01, 1999	Mar DISC
>A>		@	250MG	A075089	001	Jul 01, 1999	Mar DISC

TOBRAMYCIN

POWDER;INHALATION  
TOBI PODHALER

	+	VIATRIS	28MG	N201688	001	Mar 22, 2013	Feb CAHN
--	---	---------	------	---------	-----	--------------	----------

SOLUTION;INHALATION  
TOBI

AN	+	VIATRIS	300MG/5ML	N050753	001	Dec 22, 1997	Feb CAHN
----	---	---------	-----------	---------	-----	--------------	----------

TOLTERODINE TARTRATE

TABLET;ORAL  
TOLTERODINE TARTRATE

>A>	AB	PTS CONSULTING	1MG	A204721	001	Jan 24, 2020	Mar CAHN
>A>	AB		2MG	A204721	002	Jan 24, 2020	Mar CAHN
>D>	AB	UNIQUE	1MG	A204721	001	Jan 24, 2020	Mar CAHN
>D>	AB		2MG	A204721	002	Jan 24, 2020	Mar CAHN

TRAMADOL HYDROCHLORIDE

TABLET; ORAL

TRAMADOL HYDROCHLORIDE

AB	APDM PHARMS	50MG	A 090404	001	Jan 31, 2011	Feb CAHN
>D>	AB	APOTEX	A 075981	001	Jul 10, 2002	Mar DISC
>A>	@	50MG	A 075981	001	Jul 10, 2002	Mar DISC
	@ MERRO PHARM USA	50MG	A 206706	001	Jul 02, 2019	Feb DISC

TABLET, EXTENDED RELEASE; ORAL

TRAMADOL HYDROCHLORIDE

AB1	!	LUPIN LTD	100MG	A 200503	001	Aug 29, 2011	Jan CTEC
AB1			200MG	A 200503	002	Aug 29, 2011	Jan CTEC
AB1			300MG	A 200503	003	Aug 29, 2011	Jan CTEC
AB1		MACLEODS PHARMS LTD	100MG	A 209404	001	Jan 31, 2025	Jan NEWA
AB1			200MG	A 209404	002	Jan 31, 2025	Jan NEWA
AB1			300MG	A 209404	003	Jan 31, 2025	Jan NEWA

TRAMETINIB DIMETHYL SULFOXIDE

TABLET; ORAL

TRAMETINIB DIMETHYL SULFOXIDE

@	HIKMA	EQ 0.5MG	A 219002	001	Aug 06, 2024	Feb CAHN
@		EQ 2MG	A 219002	002	Aug 06, 2024	Feb CAHN

TRANEXAMIC ACID

INJECTABLE; INJECTION

TRANEXAMIC ACID

@	FRESENIUS KABI USA	100MG/ML	A 091596	001	Mar 02, 2012	Jan DISC
---	--------------------	----------	----------	-----	--------------	----------

TRAVOPROST

SOLUTION/DROPS; OPHTHALMIC

TRAVATAN Z

AT2	+	SANDOZ	0.004%	N 021994	001	Sep 21, 2006	Feb CTEC
		TRAVOPROST					
	@	ALEMBIC	0.004%	A 210458	001	Dec 20, 2019	Feb DISC
AT2		APOTEX	0.004%	A 203431	001	Jul 10, 2015	Feb CTEC
	!	CHARTWELL RX	0.004%	A 091340	001	Mar 01, 2013	Feb CTEC
AT2		GLAND	0.004%	A 218159	001	Jul 12, 2024	Feb CTEC
AT2		MICRO LABS	0.004%	A 203767	001	Mar 19, 2021	Feb CTEC
AT2		MYLAN	0.004%	A 205050	001	Jul 07, 2017	Feb CTEC
AT2		SOMERSET THERAPS LLC	0.004%	A 217228	001	Sep 23, 2024	Feb CTEC

TREOSULFAN

POWDER; INTRAVENOUS

GRAFAPEX

+	!	MEDEXUS	1GM/VIAL	N 214759	001	Jan 21, 2025	Jan CAHN
+	!		5GM/VIAL	N 214759	002	Jan 21, 2025	Jan CAHN
+	!	MGFKSMB	1GM/VIAL	N 214759	001	Jan 21, 2025	Jan NEWA
+	!		5GM/VIAL	N 214759	002	Jan 21, 2025	Jan NEWA

TREPROSTINIL

POWDER; INHALATION

TYVASO DPI

+	!	UNITED THERAP	0.032MG/INH	N 214324	002	May 23, 2022	Jan CHRS
+	!		0.048MG/INH	N 214324	003	May 23, 2022	Jan CHRS
+	!		0.08MG/INH	N 214324	005	Oct 24, 2024	Jan CHRS

TRETINOIN

CAPSULE; ORAL

TRETINOIN

	@	BARR LABS INC	10MG	A 077684	001	Jun 22, 2007	Feb DISC
AB	!	ENDO OPERATIONS	10MG	A 201687	001	Oct 24, 2012	Feb CHRS

GEL; TOPICAL

RETIN-A

AB	+	!	BAUSCH	0.01%	N 017955	001	Jan CAHN
			TRETINOIN				
AB			AUROBINDO PHARMA LTD	0.01%	A 218246	001	Jan 13, 2025
AB				0.025%	A 218245	001	Feb 27, 2025
AB			ENCUBE	0.01%	A 217588	001	Mar 03, 2025
AB				0.025%	A 217587	001	Mar 03, 2025



TRIAMCINOLONE ACETONIDE

	GEL; TOPICAL							
	ARISTOGEL							
	+ @ ASTELLAS	0.1%		A083380	001			Feb CRLD
	INJECTABLE; INJECTION							
	KENALOG-10							
AB	+ APOTHECON	10MG/ML		N012041	001			Feb CTEC
	TRIAMCINOLONE ACETONIDE							
AB	DR REDDYS	10MG/ML		A218773	001	Mar 12, 2025		Feb NEWA
	LOTION; TOPICAL							
	TRIAMCINOLONE ACETONIDE							
AT	! XTTRIUM LABS INC	0.025%		A088450	001	Apr 01, 1985		Feb CAHN
AT	!	0.1%		A088451	001	Apr 03, 1985		Feb CAHN

TROSPIUM CHLORIDE

	TABLET; ORAL							
	TROSPIUM CHLORIDE							
AB	ZAMEER PHARMS	20MG		A215781	001	Feb 16, 2022		Feb CAHN

VALACYCLOVIR HYDROCHLORIDE

	TABLET; ORAL							
	VALACYCLOVIR HYDROCHLORIDE							
>D>	AB APOTEX	EQ 500MG BASE		A090500	001	Apr 04, 2014		Mar DISC
>A>	@	EQ 500MG BASE		A090500	001	Apr 04, 2014		Mar DISC

VALBENAZINE TOSYLATE

	CAPSULE; ORAL							
	INGREZZA							
	+ NEUROCRINE	EQ 60MG BASE		N209241	003	Apr 23, 2021		Feb CTEC
	VALBENAZINE TOSYLATE							
	@ ZYDUS LIFESCIENCES	EQ 40MG BASE		A216137	001	Aug 07, 2024		Feb DISC
	@	EQ 60MG BASE		A216137	002	Aug 07, 2024		Feb DISC
	@	EQ 80MG BASE		A216137	003	Aug 07, 2024		Feb DISC

VALSARTAN

	TABLET; ORAL							
	VALSARTAN							
	@ RENATA	40MG		A218169	001	Aug 05, 2024		Feb DISC
AB		40MG		A218169	001	Aug 05, 2024		Jan CAHN
	@	80MG		A218169	002	Aug 05, 2024		Feb DISC
AB		80MG		A218169	002	Aug 05, 2024		Jan CAHN
	@	160MG		A218169	003	Aug 05, 2024		Feb DISC
AB		160MG		A218169	003	Aug 05, 2024		Jan CAHN
	@	320MG		A218169	004	Aug 05, 2024		Feb DISC
AB		320MG		A218169	004	Aug 05, 2024		Jan CAHN

VANCOMYCIN HYDROCHLORIDE

	INJECTABLE; INJECTION							
	VANCOMYCIN HYDROCHLORIDE							
AP	MEDIMETRIKS PHARMS	EQ 500MG BASE/VIAL		A065401	001	Jun 30, 2008		Jan CMFD
AP		EQ 1GM BASE/VIAL		A065401	002	Jun 30, 2008		Jan CMFD
>A>	@ PLANO PHARMS	EQ 500MG BASE/VIAL		A090250	001	Apr 27, 2010		Mar CAHN
>A>	@	EQ 1GM BASE/VIAL		A090250	002	Apr 27, 2010		Mar CAHN
>A>	@	EQ 5GM BASE/VIAL		A201048	001	Aug 10, 2012		Mar CAHN
>A>	@	EQ 10GM BASE/VIAL		A201048	002	Aug 10, 2012		Mar CAHN
>D>	@ SANDOZ	EQ 500MG BASE/VIAL		A090250	001	Apr 27, 2010		Mar CAHN
>D>	@	EQ 1GM BASE/VIAL		A090250	002	Apr 27, 2010		Mar CAHN
>D>	@ SANDOZ INC	EQ 5GM BASE/VIAL		A201048	001	Aug 10, 2012		Mar CAHN
>D>	@	EQ 10GM BASE/VIAL		A201048	002	Aug 10, 2012		Mar CAHN
	POWDER; INTRAVENOUS							
	VANCOMYCIN HYDROCHLORIDE							
>A>	AP GLAND	EQ 750MG BASE/VIAL		A218140	001	Mar 21, 2025		Mar NEWA
>A>	AP	EQ 1.25GM BASE/VIAL		A218140	002	Mar 21, 2025		Mar NEWA
>A>	AP	EQ 1.5GM BASE/VIAL		A218140	003	Mar 21, 2025		Mar NEWA
>D>	+! MYLAN LABS LTD	EQ 750MG BASE/VIAL		N209481	002	Jul 10, 2018		Mar CFTG
>A>	AP +!	EQ 750MG BASE/VIAL		N209481	002	Jul 10, 2018		Mar CFTG

VARENICLINE TARTRATE

TABLET; ORAL

VARENICLINE TARTRATE

	@ PIRAMAL	EQ 0.5MG BASE	A217115	001	Jul 23, 2024	Feb	DISC
	@	EQ 1MG BASE	A217115	002	Jul 23, 2024	Feb	DISC
>A>	AB SHILPA	EQ 0.5MG BASE	A216615	001	Apr 08, 2025	Mar	NEWA
>A>	AB	EQ 1MG BASE	A216615	002	Apr 08, 2025	Mar	NEWA

VENLAFAXINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

VENLAFAXINE HYDROCHLORIDE

AB	MEDICAP LABS	EQ 37.5MG BASE	A201272	001	Nov 23, 2018	Feb	CAHN
AB		EQ 75MG BASE	A201272	002	Nov 23, 2018	Feb	CAHN
AB		EQ 150MG BASE	A201272	003	Nov 23, 2018	Feb	CAHN

TABLET, EXTENDED RELEASE; ORAL

VENLAFAXINE HYDROCHLORIDE

AB	ABON PHARMS LLC	EQ 150MG BASE	A217841	001	Feb 07, 2025	Jan	NEWA
AB		EQ 225MG BASE	A217841	002	Feb 07, 2025	Jan	NEWA
AB	TORRENT	EQ 37.5MG BASE	A218180	001	Jan 28, 2025	Jan	NEWA
AB		EQ 75MG BASE	A218180	002	Jan 28, 2025	Jan	NEWA
AB		EQ 150MG BASE	A218180	003	Jan 28, 2025	Jan	NEWA
AB		EQ 225MG BASE	A218180	004	Jan 28, 2025	Jan	NEWA

VIGABATRIN

TABLET; ORAL

VIGABATRIN

	@ AMNEAL PHARMS	500MG	A210042	001	Jun 22, 2022	Feb	DISC
	@ RYAN LABS	500MG	A215519	001	Apr 28, 2023	Jan	DISC

VIMSELTINIB

CAPSULE; ORAL

ROMVIMZA

+	DECIPHERA PHARMS	14MG	N219304	001	Feb 14, 2025	Feb	NEWA
+		20MG	N219304	002	Feb 14, 2025	Feb	NEWA
+	!	30MG	N219304	003	Feb 14, 2025	Feb	NEWA

VORICONAZOLE

FOR SUSPENSION; ORAL

VORICONAZOLE

>D>	AB HAINAN POLY	200MG/5ML	A216805	001	Jan 02, 2024	Mar	CAHN
>A>	AB ZHEJIANG POLY PHARM	200MG/5ML	A216805	001	Jan 02, 2024	Mar	CAHN

ZINC ACETATE

CAPSULE; ORAL

GALZIN

+	ETON	EQ 25MG ZINC	N020458	001	Jan 28, 1997	Jan	CAHN
+	!	EQ 50MG ZINC	N020458	002	Jan 28, 1997	Jan	CAHN

ZOLEDRONIC ACID

INJECTABLE; INTRAVENOUS

ZOLEDRONIC ACID

>D>	AP APOTEX	EQ 5MG BASE/100ML	A204367	001	Dec 24, 2015	Mar	DISC
>A>	@	EQ 5MG BASE/100ML	A204367	001	Dec 24, 2015	Mar	DISC

ZOLPIDEM TARTRATE

TABLET; ORAL

AMBIEN

AB	+ COSETTE	5MG	N019908	001	Dec 16, 1992	Jan	CAHN
AB	+	10MG	N019908	002	Dec 16, 1992	Jan	CAHN

ZOLPIDEM TARTRATE

>D>	AB APOTEX INC	5MG	A077884	001	Apr 23, 2007	Mar	DISC
>A>	@	5MG	A077884	001	Apr 23, 2007	Mar	DISC
>D>	AB	10MG	A077884	002	Apr 23, 2007	Mar	DISC
>A>	@	10MG	A077884	002	Apr 23, 2007	Mar	DISC

TABLET; SUBLINGUAL

EDLUAR

AB	+ VIATRIS	5MG	N021997	001	Mar 13, 2009	Feb	CAHN
AB	+	10MG	N021997	002	Mar 13, 2009	Feb	CAHN

## TABLET, EXTENDED RELEASE;ORAL

## AMBIEN CR

AB	+	COSETTE	6.25MG	N021774	002	Sep 02, 2005	Jan	CAHN
AB	+	!	12.5MG	N021774	001	Sep 02, 2005	Jan	CAHN

## ZOLPIDEM TARTRATE

>D>	AB		APOTEX	6.25MG	A200266	001	Sep 10, 2013	Mar	DISC
>A>		@		6.25MG	A200266	001	Sep 10, 2013	Mar	DISC
>D>	AB			12.5MG	A200266	002	Sep 10, 2013	Mar	DISC
>A>		@		12.5MG	A200266	002	Sep 10, 2013	Mar	DISC

ZONISAMIDE

## CAPSULE;ORAL

## ZONISAMIDE

>A>		@	APOTEX	25MG	A077642	001	Dec 22, 2005	Mar	DISC
>A>		@		50MG	A077642	002	Dec 22, 2005	Mar	DISC
>A>		@		100MG	A077642	003	Dec 22, 2005	Mar	DISC
>D>	AB		APOTEX INC	25MG	A077642	001	Dec 22, 2005	Mar	DISC
>D>	AB			50MG	A077642	002	Dec 22, 2005	Mar	DISC
>D>	AB			100MG	A077642	003	Dec 22, 2005	Mar	DISC

ACETAMINOPHEN; IBUPROFEN

TABLET;ORAL

ACETAMINOPHEN AND IBUPROFEN

STRIDES PHARMA 250MG;125MG

A217241 001 Jan 17, 2025 Jan NEWA

AZELASTINE HYDROCHLORIDE

SPRAY, METERED;NASAL

AZELASTINE HYDROCHLORIDE ALLERGY

AUROBINDO PHARMA 0.2055MG/SPRAY

A216561 001 Jan 27, 2025 Jan NEWA

CIMETIDINE

TABLET;ORAL

CIMETIDINE

>D> APOTEX 100MG

A074948 001 Jun 19, 1998 Mar DISC

>A> @ 100MG

A074948 001 Jun 19, 1998 Mar DISC

>D> 200MG

A074948 002 Jul 26, 2002 Mar DISC

>A> @ 200MG

A074948 002 Jul 26, 2002 Mar DISC

FEXOFENADINE HYDROCHLORIDE

TABLET;ORAL

FEXOFENADINE HYDROCHLORIDE

CONTRACT PHARMACAL 60MG

A219032 001 Feb 28, 2025 Feb NEWA

180MG

A219032 002 Feb 28, 2025 Feb NEWA

LEVOCETIRIZINE DIHYDROCHLORIDE

TABLET;ORAL

LEVOCETIRIZINE DIHYDROCHLORIDE

@ APOTEX 5MG

A211443 001 Apr 21, 2021 Jan DISC

LOPERAMIDE HYDROCHLORIDE

SOLUTION;ORAL

LOPERAMIDE HYDROCHLORIDE

@ PAI HOLDINGS 1MG/5ML

A074352 001 Nov 17, 1995 Feb CAHN

LORATADINE

CAPSULE;ORAL

LORATADINE

CATALENT PHARMA 10MG

A215127 001 Feb 28, 2025 Feb NEWA

OLOPATADINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

OLOPATADINE HYDROCHLORIDE

BAUSCH AND LOMB INC EQ 0.2% BASE

A206087 001 Dec 05, 2017 Feb CMFD

GLENMARK PHARMS INC EQ 0.2% BASE

A219557 001 Feb 28, 2025 Feb NEWA

OMEPRAZOLE

TABLET, DELAYED RELEASE;ORAL

OMEPRAZOLE

@ APOTEX 20MG

A210070 001 Feb 11, 2019 Jan DISC

POTASSIUM IODIDE

TABLET;ORAL

THYROSAFE

>A> BTG INTL 130MG

A076350 002 Apr 02, 2025 Mar NFTG

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT  
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND  
RESEARCH LIST**

**CUMULATIVE SUPPLEMENT NUMBER 3 MARCH 2025**

NO MARCH 2025 APPROVALS

## ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of Orphan Designations and Approvals is available at:

[https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products.](https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products)

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY  
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO MARCH 2025 APPROVALS

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ACALABRUTINIB - CALQUENCE</u>						
N 210259 001	10167291	Jul 01, 2036	DP U-2145		I-960	Jan 16, 2028
	10167291	Jul 01, 2036	DP U-2519			
	10167291	Jul 01, 2036	DP U-2666			
	10167291	Jul 01, 2036	DP U-2667			
	10167291	Jul 01, 2036	DP U-2668			
	10167291	Jul 01, 2036	DP U-2669			
	10167291	Jul 01, 2036	DP U-2670			
	10167291	Jul 01, 2036	DP U-2671			
	10167291	Jul 01, 2036	DP U-2682			
	10167291	Jul 01, 2036	DP U-2683			
	10167291	Jul 01, 2036	DP U-2684			
	10167291	Jul 01, 2036	DP U-2685			
	10167291	Jul 01, 2036	DP U-2686			
	10167291	Jul 01, 2036	DP U-2687			
	10167291	Jul 01, 2036	DP U-4109			
	10272083	Jan 21, 2035	U-2519			
	10272083	Jan 21, 2035	U-2682			
	10272083	Jan 21, 2035	U-2683			
	10272083	Jan 21, 2035	U-2684			
	10272083	Jan 21, 2035	U-2685			
	10272083	Jan 21, 2035	U-2686			
	10272083	Jan 21, 2035	U-2687			
	10272083	Jan 21, 2035	U-4109			
	9758524	Jul 11, 2032	U-2145			
	9758524	Jul 11, 2032	U-4108			
	9796721	Jul 01, 2036	DS DP U-2145			
	9796721	Jul 01, 2036	DS DP U-2666			
	9796721	Jul 01, 2036	DS DP U-2667			
	9796721	Jul 01, 2036	DS DP U-2668			
	9796721	Jul 01, 2036	DS DP U-2669			
	9796721	Jul 01, 2036	DS DP U-2670			
	9796721	Jul 01, 2036	DS DP U-2671			
	9796721	Jul 01, 2036	DS DP U-4108			
<u>ACALABRUTINIB MALEATE - CALQUENCE</u>						
N 216387 001	10272083	Jan 21, 2035	U-2519		I-960	Jan 16, 2028
	10272083	Jan 21, 2035	U-2682			
	10272083	Jan 21, 2035	U-2683			
	10272083	Jan 21, 2035	U-2684			
	10272083	Jan 21, 2035	U-2685			
	10272083	Jan 21, 2035	U-2686			
	10272083	Jan 21, 2035	U-2687			
	10272083	Jan 21, 2035	U-4109			
	11059829	Jul 01, 2036	DS DP U-2145			
	11059829	Jul 01, 2036	DS DP U-2666			
	11059829	Jul 01, 2036	DS DP U-2667			
	11059829	Jul 01, 2036	DS DP U-2668			
	11059829	Jul 01, 2036	DS DP U-2669			
	11059829	Jul 01, 2036	DS DP U-2670			
	11059829	Jul 01, 2036	DS DP U-2671			
	11059829	Jul 01, 2036	DS DP U-4108			
	9758524	Jul 11, 2032	U-2145			
	9758524	Jul 11, 2032	U-4108			
<u>ACORAMIDIS HYDROCHLORIDE - ATTRUBY</u>						
N 216540 001	9913826	May 05, 2031	U-4046		ODE-506	Nov 22, 2031
<u>ALBUTEROL SULFATE - PROAIR HFA</u>						
N 021457 001	>A> 10561808	Jan 01, 2032	DP	Y		
	>A> 11395889	May 18, 2031	DP	Y		
	>A> 8132712	Sep 07, 2028	DP	Y		
	>A> 9463289	May 18, 2031	DP	Y		
	>A> 9808587	May 18, 2031	DP	Y		



## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ALBUTEROL SULFATE; IPRATROPIUM BROMIDE - COMBIVENT RESPIMAT</u>						
N 021747 001	>A> 7396341	Oct 10, 2026	DP	Y		
	>A> 7837235	Mar 13, 2028	DP	Y		
	>A> 8733341	Oct 16, 2030	DP	Y		
	>A> 9027967	Mar 31, 2027	DP	Y		
<u>AMANTADINE HYDROCHLORIDE - GOCOVRI</u>						
N 208944 001	>A> 12233033	Aug 23, 2038	U-2106			
	>A> 12233033	Aug 23, 2038	U-2224			
	>A> 12233033	Aug 23, 2038	U-3180			
<u>AMANTADINE HYDROCHLORIDE - GOCOVRI</u>						
N 208944 002	>A> 12233033	Aug 23, 2038	U-2106			
	>A> 12233033	Aug 23, 2038	U-2224			
	>A> 12233033	Aug 23, 2038	U-3180			
<u>AMIKACIN SULFATE - ARIKAYCE KIT</u>						
N 207356 001	12168021	May 15, 2035	U-2414			
	12168022	May 15, 2035	U-2414			
<u>AMISULPRIDE - BARHEMSYS</u>						
N 209510 001	12005042	Feb 09, 2038	U-1744			
	12005042	Feb 09, 2038	U-2754			
	12005042	Feb 09, 2038	U-3467			
	12194022	Mar 10, 2031	U-1744			
	12194022	Mar 10, 2031	U-3467			
<u>AMISULPRIDE - BARHEMSYS</u>						
N 209510 002	12005042	Feb 09, 2038	U-1744			
	12005042	Feb 09, 2038	U-2754			
	12005042	Feb 09, 2038	U-3467			
	12194022	Mar 10, 2031	U-1744			
	12194022	Mar 10, 2031	U-3467			
<u>AMLODIPINE BESYLATE - NORLIOVA</u>						
N 214439 001	12005141	Feb 24, 2041	DP U-3309			
	12005141	Feb 24, 2041	DP U-3310			
	12005141	Feb 24, 2041	DP U-3311			
	12226528	Feb 24, 2041	DP U-3309			
	12226528	Feb 24, 2041	DP U-3310			
	12226528	Feb 24, 2041	DP U-3311			
<u>ARIPIPRAZOLE LAUROXIL - ARISTADA</u>						
N 207533 001	>A> 12251381	Apr 09, 2039	U-543			
<u>ARIPIPRAZOLE LAUROXIL - ARISTADA</u>						
N 207533 002	>A> 12251381	Apr 09, 2039	U-543			
<u>ARIPIPRAZOLE LAUROXIL - ARISTADA</u>						
N 207533 003	>A> 12251381	Apr 09, 2039	U-543			
<u>ARIPIPRAZOLE LAUROXIL - ARISTADA</u>						
N 207533 004	>A> 12251381	Apr 06, 2039	U-543			
<u>ARIPIPRAZOLE LAUROXIL - ARISTADA INITIO KIT</u>						
N 209830 001	>A> 12251381	Apr 06, 2039	U-543			
<u>ASCIMINIB HYDROCHLORIDE - SCEMBLIX</u>						
N 215358 001	>A> 12252478	May 14, 2040	DP			
	>A> 12252479	May 17, 2040	U-1374			
<u>ASCIMINIB HYDROCHLORIDE - SCEMBLIX</u>						
N 215358 002	>A> 12252478	May 14, 2040	DP			
	>A> 12252479	May 17, 2040	U-1374			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ASCIMINIB HYDROCHLORIDE - SCEMBLIX</u>						
N 215358 002	>A> 12252478	May 14, 2040	DP			
	>A> 12252479	May 17, 2040	U-1374			
<u>ASCIMINIB HYDROCHLORIDE - SCEMBLIX</u>						
N 215358 003	>A> 12252478	May 14, 2040	DP			
	>A> 12252479	May 17, 2040	U-1374			
<u>AVACINCAPTAD PEGOL SODIUM - IZERVAY</u>						
N 217225 001	7579456	Feb 14, 2026	DS			
	9617546	Feb 14, 2026	DS	U-3673		
<u>AVIBACTAM SODIUM; AZTREONAM - EMBLAVEO</u>						
N 217906 001	7112592	Jan 07, 2026	DS DP	U-4147	>A> NP	Feb 07, 2028
	7612087	Nov 12, 2026	DP		>A> GAIN	Feb 07, 2033
	8471025	Aug 12, 2031	DS			
	8835455	Oct 08, 2030	DP			
	8969566	Jun 15, 2032	DS			
	9284314	Jun 15, 2032	DS			
	9695122	Jun 15, 2032	DS DP			
<u>BACLOFEN - BACLOFEN</u>						
A 214445 001					PC	Jul 14, 2025
<u>BALOXAVIR MARBOXIL - XOFLUZA</u>						
N 210854 001					M-187	Dec 19, 2027
<u>BALOXAVIR MARBOXIL - XOFLUZA</u>						
N 210854 002					M-187	Dec 19, 2027
<u>BALOXAVIR MARBOXIL - XOFLUZA</u>						
N 210854 003					M-187	Dec 19, 2027
<u>BALOXAVIR MARBOXIL - XOFLUZA</u>						
N 214410 001					M-187	Dec 19, 2027
<u>BECLOMETHASONE DIPROPIONATE - OVAR 80</u>						
N 020911 001	>A> 10561808	Jan 01, 2032	DP	Y		
	>A> 11395889	May 18, 2031	DP	Y		
	>A> 9463289	May 18, 2031	DP	Y		
	>A> 9808587	May 18, 2031	DP	Y		
<u>BECLOMETHASONE DIPROPIONATE - OVAR 40</u>						
N 020911 002	>A> 10561808	Jan 01, 2032	DP	Y		
	>A> 11395889	May 18, 2031	DP	Y		
	>A> 9463289	May 18, 2031	DP	Y		
	>A> 9808587	May 18, 2031	DP	Y		
<u>BECLOMETHASONE DIPROPIONATE - OVAR REDIHALER</u>						
N 207921 001	>A> 10561808	Jan 01, 2032	DP	Y		
	>A> 11395889	May 18, 2031	DP	Y		
	>A> 8132712	Sep 07, 2028	DP	Y		
<u>BECLOMETHASONE DIPROPIONATE - OVAR REDIHALER</u>						
N 207921 002	>A> 10561808	Jan 01, 2032	DP	Y		
	>A> 11395889	May 18, 2031	DP	Y		
	>A> 8132712	Sep 07, 2028	DP	Y		
<u>BENDAMUSTINE HYDROCHLORIDE - BELRAPZO</u>						
N 205580 001	12138248	Jan 28, 2031	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BENDAMUSTINE HYDROCHLORIDE - BENDEKA</u>						
N 208194 001	12138248	Jan 28, 2031	DP			
<u>BENDAMUSTINE HYDROCHLORIDE - VIVIMUSTA</u>						
N 212209 001	12208086	Jul 29, 2042	DP			
<u>BENZGALANTAMINE GLUCONATE - ZUNVEYL</u>						
N 218549 001	12208176	Feb 26, 2044	DP U-713			
<u>BENZGALANTAMINE GLUCONATE - ZUNVEYL</u>						
N 218549 002	12208176	Feb 26, 2044	DP U-713			
<u>BENZGALANTAMINE GLUCONATE - ZUNVEYL</u>						
N 218549 003	12208176	Feb 26, 2044	DP U-713			
<u>BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - BIKTARVY</u>						
N 210251 001	7390791	Jan 07, 2025	DS DP			
	7390791*PED	Jul 07, 2025				
<u>BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - BIKTARVY</u>						
N 210251 002	7390791	Jan 07, 2025	DS DP			
	7390791*PED	Jul 07, 2025				
<u>BINIMETINIB - MEKTOVI</u>						
N 210498 001	>A> 7777050	Mar 13, 2026	DS DP			
<u>BUDESONIDE - TARPEYO</u>						
N 215935 001	12171882	Jan 23, 2043	U-4085			
	12171882	Jan 23, 2043	U-4086			
	12171883	Jan 23, 2043	DP			
<u>BUPIVACAINE - EXPAREL</u>						
N 022496 001	>A> 12226610	Feb 02, 2043	U-4148			
	>A> 12226610	Feb 02, 2043	U-4149			
	>A> 12226610	Feb 02, 2043	U-4150			
	>A> 12251468	Jul 02, 2044	DP U-4152			
<u>BUPIVACAINE - EXPAREL</u>						
N 022496 002	>A> 12226610	Feb 02, 2043	U-4148			
	>A> 12226610	Feb 02, 2043	U-4149			
	>A> 12226610	Feb 02, 2043	U-4150			
	>A> 12251468	Jul 02, 2044	DP U-4152			
<u>BUPRENORPHINE - SUBLOCADE</u>						
N 209819 001				>A> M-314		Feb 21, 2028
<u>BUPRENORPHINE - SUBLOCADE</u>						
N 209819 002				>A> M-314		Feb 21, 2028
<u>BUPRENORPHINE - BRIXADI</u>						
N 210136 001	12161640	Jul 26, 2032	DP U-4100			
<u>BUPRENORPHINE - BRIXADI</u>						
N 210136 002	12161640	Jul 26, 2032	DP U-4100			
<u>BUPRENORPHINE - BRIXADI</u>						
N 210136 003	12161640	Jul 26, 2032	DP U-4100			
<u>BUPRENORPHINE - BRIXADI</u>						
N 210136 004	12161640	Jul 26, 2032	DP U-4100			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BUPRENORPHINE - BRIXADI</u>						
N 210136 005	12161640	Jul 26, 2032	DP U-4100			
<u>BUPRENORPHINE - BRIXADI</u>						
N 210136 006	12161640	Jul 26, 2032	DP U-4100			
<u>BUPRENORPHINE - BRIXADI</u>						
N 210136 007	12161640	Jul 26, 2032	DP U-4100			
<u>CABOTEGRAVIR; RILPIVIRINE - CABENUVA KIT</u>						
N 212888 001	12178815	Jul 18, 2038	U-3348			
<u>CABOTEGRAVIR; RILPIVIRINE - CABENUVA KIT</u>						
N 212888 002	12178815	Jul 18, 2038	U-3348			
<u>CANAGLIFLOZIN - INVOKANA</u>						
N 204042 001					NPP PED	Dec 18, 2027 Jun 18, 2028
<u>CANAGLIFLOZIN - INVOKANA</u>						
N 204042 002					NPP PED	Dec 18, 2027 Jun 18, 2028
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 001					NPP PED	Dec 18, 2027 Jun 18, 2028
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 002					NPP PED	Dec 18, 2027 Jun 18, 2028
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 003					NPP PED	Dec 18, 2027 Jun 18, 2028
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 004					NPP PED	Dec 18, 2027 Jun 18, 2028
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET XR</u>						
N 205879 001					NPP PED	Dec 18, 2027 Jun 18, 2028
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET XR</u>						
N 205879 002					NPP PED	Dec 18, 2027 Jun 18, 2028
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET XR</u>						
N 205879 003					NPP PED	Dec 18, 2027 Jun 18, 2028
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET XR</u>						
N 205879 004					NPP PED	Dec 18, 2027 Jun 18, 2028
<u>CANTHARIDIN - YCANTH</u>						
N 212905 001	>A> 12233042	Aug 22, 2038	DP U-3663			
<u>CAPIVASERTIB - TRUQAP</u>						
N 218197 001	>A> 12252495	Oct 10, 2028	U-3762			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CAPIVASERTIB - TRUOAP</u>						
N 218197 002	>A> 12252495	Oct 10, 2028	U-3762			
<u>CAPMATINIB HYDROCHLORIDE - TABRECTA</u>						
N 213591 001	10596178	Jul 22, 2035	DP			
	12208101	Jul 22, 2035	DP			
<u>CAPMATINIB HYDROCHLORIDE - TABRECTA</u>						
N 213591 002	10596178	Jul 22, 2035	DP			
	12208101	Jul 22, 2035	DP			
<u>CARBIDOPA; LEVODOPA - CREXONT</u>						
N 217186 001	12194150	Dec 21, 2041	U-219			
	12201596	Dec 21, 2041	U-1649			
	12201596	Dec 21, 2041	U-4004			
	12201596	Dec 21, 2041	U-4005			
<u>CARBIDOPA; LEVODOPA - CREXONT</u>						
N 217186 002	12194150	Dec 21, 2041	U-219			
	12201596	Dec 21, 2041	U-1649			
	12201596	Dec 21, 2041	U-4004			
	12201596	Dec 21, 2041	U-4005			
<u>CARBIDOPA; LEVODOPA - CREXONT</u>						
N 217186 003	12194150	Dec 21, 2041	U-219			
	12201596	Dec 21, 2041	U-1649			
	12201596	Dec 21, 2041	U-4004			
	12201596	Dec 21, 2041	U-4005			
<u>CARBIDOPA; LEVODOPA - CREXONT</u>						
N 217186 004	12194150	Dec 21, 2041	U-219			
	12201596	Dec 21, 2041	U-1649			
	12201596	Dec 21, 2041	U-4004			
	12201596	Dec 21, 2041	U-4005			
<u>CEDAZURIDINE; DECITABINE - INOOVI</u>						
N 212576 001	12195496	Oct 07, 2040	DP			
	>A> 12239653	Feb 24, 2041	U-2865			
	>A> 12239653	Feb 24, 2041	U-2866			
<u>CHENODIOL - CTECLI</u>						
N 219488 001				>A> NP		Feb 21, 2028
<u>CHLOROPROCAINE HYDROCHLORIDE - IHEEZO</u>						
N 216227 001	11969403	May 14, 2039	DP			
<u>COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - GENVOYA</u>						
N 207561 001	7390791	Jan 07, 2025	DS DP			
	7390791*PED	Jul 07, 2025				
<u>COLCHICINE - LODOCO</u>						
N 215727 001	12233035	Nov 01, 2033	U-4132			
<u>COPPER - MIUDELLA</u>						
N 218201 001	>A> 10022264	Mar 22, 2034	DP		>A> NP	Feb 24, 2028
	>A> 10159596	Aug 14, 2032	DP			
	>A> 10166141	Jun 13, 2034	DP			
	>A> 10188546	Aug 14, 2032	DP			
	>A> 10398588	Feb 24, 2034	DP U-4155			
	>A> 10918516	Jan 23, 2037	DP			
	>A> 11207209	Aug 16, 2034	DP			
	>A> 11850181	Aug 14, 2032	DP			
	>A> 12138199	Oct 18, 2033	DP			
	>A> 9089418	Apr 09, 2033	DP			
	>A> 9265652	Apr 28, 2034	U-4155			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>COPPER - MIUDELLA</u>						
N 218201 001	>A> 9427351	Aug 14, 2032	DP			
	>A> 9610191	Feb 24, 2034	U-4155			
<u>COPPER CU-64 DOTATATE - DETECTNET</u>						
N 213227 001	10383961	Jul 02, 2033	U-2951			
<u>CORTICOTROPIN - ACTHAR GEL (AUTOINJECTOR)</u>						
N 008372 003	>A> 11752199	Jul 18, 2041	U-3686			
	>A> 11752199	Jul 18, 2041	U-3687			
	>A> 11752199	Jul 18, 2041	U-3688			
<u>CORTICOTROPIN - ACTHAR GEL (AUTOINJECTOR)</u>						
N 008372 004	>A> 11752199	Jul 18, 2041	U-3686			
	>A> 11752199	Jul 18, 2041	U-3687			
	>A> 11752199	Jul 18, 2041	U-3688			
<u>CORTICOTROPIN - ACTHAR GEL</u>						
N 008372 008	>A> 11752199	Jul 18, 2041	U-3686			
	>A> 11752199	Jul 18, 2041	U-3687			
	>A> 11752199	Jul 18, 2041	U-3688			
<u>CORTICOTROPIN - PURIFIED CORTROPHIN GEL</u>						
N 008975 002	12233105	Oct 27, 2043	U-3904			
	12233105	Oct 27, 2043	U-3905			
	12233105	Oct 27, 2043	U-3906			
	12233105	Oct 27, 2043	U-3907			
	12233105	Oct 27, 2043	U-3908			
	12233105	Oct 27, 2043	U-3909			
	12233105	Oct 27, 2043	U-3910			
	12233105	Oct 27, 2043	U-3911			
	12233105	Oct 27, 2043	U-3912			
	12233105	Oct 27, 2043	U-3913			
	12233105	Oct 27, 2043	U-3914			
	12233105	Oct 27, 2043	U-3915			
	12233105	Oct 27, 2043	U-3916			
	12233105	Oct 27, 2043	U-3917			
	12233105	Oct 27, 2043	U-3918			
	12233105	Oct 27, 2043	U-3919			
	12233105	Oct 27, 2043	U-3920			
	12233105	Oct 27, 2043	U-3921			
	12233105	Oct 27, 2043	U-3922			
	12233105	Oct 27, 2043	U-3923			
	12233105	Oct 27, 2043	U-3924			
	12233105	Oct 27, 2043	U-3925			
	12233105	Oct 27, 2043	U-3926			
<u>CRINECERFONT - CRENESSITY</u>						
N 218808 001	10905690	Jan 21, 2035	U-4049		NCE	Dec 13, 2029
	11311544	Jan 21, 2035	U-4049			
	11730739	Jan 21, 2035	U-4049			
	12128033	Jun 09, 2041	DS U-4049			
<u>CRINECERFONT - CRENESSITY</u>						
N 218808 002	10905690	Jan 21, 2035	U-4049		NCE	Dec 13, 2029
	11311544	Jan 21, 2035	U-4049			
	11730739	Jan 21, 2035	U-4049			
	12128033	Jun 09, 2041	DS U-4049			
<u>CRINECERFONT - CRENESSITY</u>						
N 218808 003	10905690	Jan 21, 2035	U-4049		NCE	Dec 13, 2029
	11311544	Jan 21, 2035	U-4049			
	11730739	Jan 21, 2035	U-4049			
	12128033	Jun 09, 2041	DS U-4049			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CRINECERFONT - CRENESSITY</u>						
N 218820 001	10905690	Jan 21, 2035	U-4049		NCE	Dec 13, 2029
	11311544	Jan 21, 2035	U-4049			
	11730739	Jan 21, 2035	U-4049			
	12128033	Jun 09, 2041	DS U-4049			
<u>DACOMITINIB - VIZIMPRO</u>						
N 211288 001	>A> 7772243	May 05, 2028	DS DP			
<u>DACOMITINIB - VIZIMPRO</u>						
N 211288 002	>A> 7772243	May 05, 2028	DS DP			
<u>DACOMITINIB - VIZIMPRO</u>						
N 211288 003	>A> 7772243	May 05, 2028	DS DP			
<u>DAPAGLIFLOZIN - FARXIGA</u>						
N 202293 002	12213988	Apr 01, 2041	U-4140			
<u>DARIDOREXANT HYDROCHLORIDE - QUVIVIO</u>						
N 214985 001					M-200	Sep 30, 2027
<u>DARIDOREXANT HYDROCHLORIDE - QUVIVIO</u>						
N 214985 002					M-200	Sep 30, 2027
<u>DEOXYCHOLIC ACID - KYBELLA</u>						
N 206333 001	12161653	Feb 17, 2032	U-1940			
<u>DEURUXOLITINIB PHOSPHATE - LEOSELVI</u>						
N 217900 001	>A> 12247034	May 10, 2044	DS DP			
<u>DEUTIVACAFTOR; TEZACAFTOR; VANZACAFTOR CALCIUM - ALYFTREK</u>						
N 218730 001	10022352	Apr 09, 2027	DP U-4081		NCE	Dec 20, 2029
	10047053	May 17, 2032	DS			
	10081621	Mar 25, 2031	DP U-4087			
	10239867	Apr 09, 2027	DS DP U-4090			
	10646481	Aug 13, 2029	DP			
	11066417	Feb 14, 2039	DS DP			
	11564916	Aug 13, 2029	U-4095			
	11578062	Mar 25, 2031	DP U-4096			
	11639347	Apr 09, 2027	DS DP U-4090			
	11866450	Feb 14, 2039	U-4082			
	11873300	Aug 13, 2040	DS DP U-4083			
	7495103	May 20, 2027	DS DP			
	7645789	May 01, 2027	DS DP			
	7776905	Jun 03, 2027	DS DP			
	8324242	Aug 05, 2027	U-4090			
	8354427	Jul 06, 2026	U-4091			
	8410274	Dec 28, 2026	DP			
	8415387	Nov 12, 2027	U-4082			
	8598181	May 01, 2027	U-4090			
	8623905	May 01, 2027	DS DP			
	8629162	Jun 24, 2025	U-4084			
	8754224	Dec 28, 2026	DS DP			
	8865902	May 17, 2032	DS DP			
	9181192	May 17, 2032	DS DP U-4094			
	9512079	May 17, 2032	DS DP U-4098			
	9670163	Dec 28, 2026	DP U-4080			
	9931334	Dec 28, 2026	DP U-4080			
	9974781	Apr 09, 2027	DP U-4082			
<u>DEUTIVACAFTOR; TEZACAFTOR; VANZACAFTOR CALCIUM - ALYFTREK</u>						
N 218730 002	10022352	Apr 09, 2027	DP U-4081		NCE	Dec 20, 2029
	10047053	May 17, 2032	DS			
	10058546	Jul 15, 2033	U-4093			
	10081621	Mar 25, 2031	DP U-4087			
	10206877	Apr 14, 2035	DP U-4092			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DEUTIVACAFTOR; TEZACAFTOR; VANZACAFTOR CALCIUM - ALYFTREK</u>						
N 218730 002	10239867	Apr 09, 2027	DS DP U-4090			
	10646481	Aug 13, 2029	DP			
	11066417	Feb 14, 2039	DS DP			
	11564916	Aug 13, 2029	U-4095			
	11578062	Mar 25, 2031	DP U-4096			
	11639347	Apr 09, 2027	DS DP U-4090			
	11866450	Feb 14, 2039	U-4082			
	11873300	Aug 13, 2040	DS DP U-4083			
	11951212	Apr 14, 2035	DP U-4089			
	12186306	Jan 10, 2043	U-4088			
	7495103	May 20, 2027	DS DP			
	7645789	May 01, 2027	DS DP			
	7776905	Jun 03, 2027	DS DP			
	8324242	Aug 05, 2027	U-4090			
	8354427	Jul 06, 2026	U-4091			
	8410274	Dec 28, 2026	DP			
	8415387	Nov 12, 2027	U-4082			
	8598181	May 01, 2027	U-4090			
	8623905	May 01, 2027	DS DP			
	8629162	Jun 24, 2025	U-4084			
	8754224	Dec 28, 2026	DS DP			
	8865902	May 17, 2032	DS DP			
	9012496	Jul 15, 2033	U-4097			
	9181192	May 17, 2032	DS DP U-4094			
	9512079	May 17, 2032	DS DP U-4098			
	9670163	Dec 28, 2026	DP U-4080			
	9931334	Dec 28, 2026	DP U-4080			
	9974781	Apr 09, 2027	DP U-4082			
<u>DIROXIMEL FUMARATE - VUMERITY</u>						
N 211855 001 >A>	8669281	Oct 29, 2033	DS DP			
<u>DONEPEZIL HYDROCHLORIDE - ADLARITY</u>						
N 212304 001	12161767	Dec 30, 2036	DS DP U-3334			
	12168075	Dec 30, 2036	U-3334			
<u>DONEPEZIL HYDROCHLORIDE - ADLARITY</u>						
N 212304 002	12161767	Dec 30, 2036	DS DP U-3334			
	12168075	Dec 30, 2036	U-3334			
<u>DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - MEMANTINE HYDROCHLORIDE AND DONEPEZIL HYDROCHLORIDE</u>						
A 208328 001					PC	Jul 15, 2025
<u>DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - MEMANTINE HYDROCHLORIDE AND DONEPEZIL HYDROCHLORIDE</u>						
A 208328 002					PC	Jul 15, 2025
<u>DROSPIRENONE; ESTETROL - NEXTSTELLIS</u>						
N 214154 001	12233074	Feb 09, 2043	DP U-3152			
<u>DULOXETINE HYDROCHLORIDE - DRIZALMA SPRINKLE</u>						
N 212516 001	12171742	Apr 13, 2037	DP			
<u>DULOXETINE HYDROCHLORIDE - DRIZALMA SPRINKLE</u>						
N 212516 002	12171742	Apr 13, 2037	DP			
<u>DULOXETINE HYDROCHLORIDE - DRIZALMA SPRINKLE</u>						
N 212516 003	12171742	Apr 13, 2037	DP			
<u>DULOXETINE HYDROCHLORIDE - DRIZALMA SPRINKLE</u>						
N 212516 004	12171742	Apr 13, 2037	DP			
<u>DUVELISIB - COPIKTRA</u>						
N 211155 001	12213983	Apr 26, 2035	U-2412			



## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DUVELISIB - COPIKTRA</u>						
N 211155 002	12213983	Apr 26, 2035	U-2412			
<u>EDARAVONE - RADICAVA ORS</u>						
N 215446 001	12194025	Nov 12, 2041	U-4111			
<u>ELAFIBRANOR - IQIRVO</u>						
N 218860 001	12233038	Mar 30, 2037	U-1854			
<u>ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)</u>						
N 212273 001	10081621	Mar 25, 2031	DP U-3032		M-313	Dec 20, 2027
	10081621	Mar 25, 2031	DP U-3157			
	10081621	Mar 25, 2031	DP U-4075			
	10239867	Apr 09, 2027	DS DP U-3033			
	10239867	Apr 09, 2027	DS DP U-3158			
	10239867	Apr 09, 2027	DS DP U-4056			
	10758534	Oct 06, 2035	DS DP U-3028			
	10758534	Oct 06, 2035	DS DP U-3144			
	10758534	Oct 06, 2035	DS DP U-4073			
	10793547	Dec 08, 2037	DS DP U-3028			
	10793547	Dec 08, 2037	DS DP U-3144			
	10793547	Dec 08, 2037	DS DP U-4073			
	11179367	Dec 08, 2037	DP U-3253			
	11179367	Dec 08, 2037	DP U-4071			
	11426407	Oct 06, 2035	DS DP U-3425			
	11426407	Oct 06, 2035	DS DP U-4070			
	11517564	Dec 08, 2037	DP U-3498			
	11517564	Dec 08, 2037	DP U-4067			
	11564916	Aug 13, 2029	U-3525			
	11564916	Aug 13, 2029	U-4063			
	11578062	Mar 25, 2031	DP U-3544			
	11578062	Mar 25, 2031	DP U-4054			
	11639347	Apr 09, 2027	DS DP U-3587			
	11639347	Apr 09, 2027	DS DP U-4056			
	8324242	Aug 05, 2027	U-3028			
	8324242	Aug 05, 2027	U-3144			
	8324242	Aug 05, 2027	U-4073			
	8415387	Nov 12, 2027	U-3028			
	8415387	Nov 12, 2027	U-3144			
	8415387	Nov 12, 2027	U-4073			
	8598181	May 01, 2027	U-3028			
	8598181	May 01, 2027	U-3144			
	8598181	May 01, 2027	U-4056			
	8629162	Jun 24, 2025	U-3030			
	8629162	Jun 24, 2025	U-3146			
	8629162	Jun 24, 2025	U-4079			
	9670163	Dec 28, 2026	DP U-3031			
	9670163	Dec 28, 2026	DP U-3155			
	9670163	Dec 28, 2026	DP U-4078			
	9931334	Dec 28, 2026	DP U-3031			
	9931334	Dec 28, 2026	DP U-3155			
	9931334	Dec 28, 2026	DP U-4078			
	9974781	Apr 09, 2027	DP U-3028			
	9974781	Apr 09, 2027	DP U-3144			
	9974781	Apr 09, 2027	DP U-4073			
<u>ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)</u>						
N 212273 002	10081621	Mar 25, 2031	DP U-3157		M-313	Dec 20, 2027
	10081621	Mar 25, 2031	DP U-4075			
	10239867	Apr 09, 2027	DS DP U-3158			
	10239867	Apr 09, 2027	DS DP U-4056			
	10758534	Oct 06, 2035	DS DP U-3144			
	10758534	Oct 06, 2035	DS DP U-4073			
	10793547	Dec 08, 2037	DS DP U-3144			
	10793547	Dec 08, 2037	DS DP U-4073			
	11179367	Dec 08, 2037	DP U-3253			
	11179367	Dec 08, 2037	DP U-4071			
	11426407	Oct 06, 2035	DS DP U-3425			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)</u>						
N 212273 002	11426407	Oct 06, 2035	DS DP U-4070			
	11517564	Dec 08, 2037	DP U-3498			
	11517564	Dec 08, 2037	DP U-4069			
	11564916	Aug 13, 2029	U-3525			
	11564916	Aug 13, 2029	U-4063			
	11578062	Mar 25, 2031	DP U-3544			
	11578062	Mar 25, 2031	DP U-4054			
	11639347	Apr 09, 2027	DS DP U-3587			
	11639347	Apr 09, 2027	DS DP U-4056			
	8324242	Aug 05, 2027	U-3144			
	8324242	Aug 05, 2027	U-4073			
	8415387	Nov 12, 2027	U-3144			
	8415387	Nov 12, 2027	U-4073			
	8598181	May 01, 2027	U-3144			
	8598181	May 01, 2027	U-4056			
	8629162	Jun 24, 2025	U-3146			
	8629162	Jun 24, 2025	U-4079			
	9670163	Dec 28, 2026	DP U-3155			
	9670163	Dec 28, 2026	DP U-4078			
	9931334	Dec 28, 2026	DP U-3155			
	9931334	Dec 28, 2026	DP U-4078			
	9974781	Apr 09, 2027	DP U-3144			
	9974781	Apr 09, 2027	DP U-4073			
<u>ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)</u>						
N 217660 001	10081621	Mar 25, 2031	DP U-3600		M-313	Dec 20, 2027
	10081621	Mar 25, 2031	DP U-4065			
	10239867	Apr 09, 2027	DS DP U-3590			
	10239867	Apr 09, 2027	DS DP U-4053			
	10272046	Feb 27, 2033	DP U-3599			
	10272046	Feb 27, 2033	DP U-4062			
	10758534	Oct 06, 2035	DS DP U-3589			
	10758534	Oct 06, 2035	DS DP U-4066			
	10793547	Dec 08, 2037	DS DP U-3588			
	10793547	Dec 08, 2037	DS DP U-4066			
	11147770	Feb 27, 2033	DP U-3598			
	11147770	Feb 27, 2033	DP U-4060			
	11179367	Dec 08, 2037	DP U-3597			
	11179367	Dec 08, 2037	DP U-4059			
	11426407	Oct 06, 2035	DS DP U-3595			
	11426407	Oct 06, 2035	DS DP U-4058			
	11517564	Dec 08, 2037	DP U-3586			
	11517564	Dec 08, 2037	DP U-4057			
	11564916	Aug 13, 2029	U-3585			
	11564916	Aug 13, 2029	U-4055			
	11578062	Mar 25, 2031	DP U-3584			
	11578062	Mar 25, 2031	DP U-4054			
	11639347	Apr 09, 2027	DS DP U-3583			
	11639347	Apr 09, 2027	DS DP U-4053			
	11752106	Feb 27, 2033	DP U-3696			
	11752106	Feb 27, 2033	DP U-4052			
	12214083	Feb 27, 2033	DP U-4141			
	8324242	Aug 05, 2027	U-3589			
	8324242	Aug 05, 2027	U-4066			
	8415387	Nov 12, 2027	U-3589			
	8415387	Nov 12, 2027	U-4066			
	8598181	May 01, 2027	U-3589			
	8598181	May 01, 2027	U-4066			
	8629162	Jun 24, 2025	U-3592			
	8629162	Jun 24, 2025	U-4072			
	9670163	Dec 28, 2026	DP U-3591			
	9670163	Dec 28, 2026	DP U-4068			
	9931334	Dec 28, 2026	DP U-3591			
	9931334	Dec 28, 2026	DP U-4068			
	9974781	Apr 09, 2027	DP U-3589			
	9974781	Apr 09, 2027	DP U-4066			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)</u>						
N 217660 002	10081621	Mar 25, 2031	DP U-3600			
	10081621	Mar 25, 2031	DP U-4065			
	10239867	Apr 09, 2027	DS DP U-3590			
	10239867	Apr 09, 2027	DS DP U-4053			
	10272046	Feb 27, 2033	DP U-3599			
	10272046	Feb 27, 2033	DP U-4062			
	10758534	Oct 06, 2035	DS DP U-3589			
	10758534	Oct 06, 2035	DS DP U-4066			
	10793547	Dec 08, 2037	DS DP U-3588			
	10793547	Dec 08, 2037	DS DP U-4066			
	11147770	Feb 27, 2033	DP U-3598			
	11147770	Feb 27, 2033	DP U-4060			
	11179367	Dec 08, 2037	DP U-3597			
	11179367	Dec 08, 2037	DP U-4059			
	11426407	Oct 06, 2035	DS DP U-3595			
	11426407	Oct 06, 2035	DS DP U-4058			
	11517564	Dec 08, 2037	DP U-3586			
	11517564	Dec 08, 2037	DP U-4057			
	11564916	Aug 13, 2029	U-3585			
	11564916	Aug 13, 2029	U-4055			
	11578062	Mar 25, 2031	DP U-3584			
	11578062	Mar 25, 2031	DP U-4054			
	11639347	Apr 09, 2027	DS DP U-3583			
	11639347	Apr 09, 2027	DS DP U-4053			
	11752106	Feb 27, 2033	DP U-3696			
	11752106	Feb 27, 2033	DP U-4052			
	12214083	Feb 27, 2033	DP U-4141			
	8324242	Aug 05, 2027	U-3589			
	8324242	Aug 05, 2027	U-4066			
	8415387	Nov 12, 2027	U-3589			
	8415387	Nov 12, 2027	U-4066			
	8598181	May 01, 2027	U-3589			
	8598181	May 01, 2027	U-4066			
	8629162	Jun 24, 2025	U-3592			
	8629162	Jun 24, 2025	U-4072			
	9670163	Dec 28, 2026	DP U-3591			
	9670163	Dec 28, 2026	DP U-4068			
	9931334	Dec 28, 2026	DP U-3591			
	9931334	Dec 28, 2026	DP U-4068			
	9974781	Apr 09, 2027	DP U-3589			
	9974781	Apr 09, 2027	DP U-4066			
<u>EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI</u>						
N 206073 001	12178819	May 04, 2027	DP			
<u>EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI</u>						
N 206073 002	12178819	May 04, 2027	DP			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 001	>A> 11666590	Apr 03, 2034			U-4154	
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 002	>A> 11666590	Apr 03, 2034			U-4154	
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 003	>A> 11666590	Apr 03, 2034			U-4154	
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</u>						
N 206111 004	>A> 11666590	Apr 03, 2034			U-4154	
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658 001	>A> 11666590	Apr 03, 2034			U-4154	

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658 002	>A> 11666590	Apr 03, 2034	U-4154			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658 003	>A> 11666590	Apr 03, 2034	U-4154			
<u>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</u>						
N 208658 004	>A> 11666590	Apr 03, 2034	U-4154			
<u>EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR ALAFENAMIDE FUMARATE - ODEFSEY</u>						
N 208351 001	7390791	Jan 07, 2025	DS DP			
	7390791*PED	Jul 07, 2025				
<u>EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - DESCOVY</u>						
N 208215 001	7390791	Jan 07, 2025	DS DP			
	7390791*PED	Jul 07, 2025				
<u>EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - DESCOVY</u>						
N 208215 002	7390791	Jan 07, 2025	DS DP			
	7390791*PED	Jul 07, 2025				
<u>ENCORAFENIB - BRAFTOVI</u>						
N 210496 001					I-957	Dec 20, 2027
<u>ENCORAFENIB - BRAFTOVI</u>						
N 210496 002	10005761	Aug 27, 2030	U-2335		I-957	Dec 20, 2027
	10005761	Aug 27, 2030	U-2802			
	10005761	Aug 27, 2030	U-2803			
	10005761	Aug 27, 2030	U-3738			
	10005761	Aug 27, 2030	U-4051			
	10258622	Nov 21, 2032	U-2802			
	10258622	Nov 21, 2032	U-4051			
	8541575	Feb 26, 2030	DS DP U-2335			
	8541575	Feb 26, 2030	DS DP U-2802			
	8541575	Feb 26, 2030	DS DP U-2803			
	8541575	Feb 26, 2030	DS DP U-3738			
	8541575	Feb 26, 2030	DS DP U-4051			
	9314464	Jul 04, 2031	U-2336			
	9314464	Jul 04, 2031	U-2802			
	9314464	Jul 04, 2031	U-2803			
	9314464	Jul 04, 2031	U-3738			
	9314464	Jul 04, 2031	U-4051			
	9474754	Aug 05, 2033	U-2802			
	9474754	Aug 05, 2033	U-4051			
	9850230	Aug 27, 2030	U-2334			
	9850230	Aug 27, 2030	U-2802			
	9850230	Aug 27, 2030	U-2803			
	9850230	Aug 27, 2030	U-3738			
	9850230	Aug 27, 2030	U-4051			
<u>ENSARTINIB HYDROCHLORIDE - ENSACOVE</u>						
N 218171 001	10899744	Jun 01, 2037	DS U-4099		NCE	Dec 18, 2029
	8551995	Feb 09, 2029	DS			
	9126947	Nov 29, 2031	DS			
	9296724	Jun 18, 2029	DS U-4099			
<u>ENSARTINIB HYDROCHLORIDE - ENSACOVE</u>						
N 218171 002	10899744	Jun 01, 2037	DS U-4099		NCE	Dec 18, 2029
	8551995	Feb 09, 2029	DS			
	9126947	Nov 29, 2031	DS			
	9296724	Jun 18, 2029	DS U-4099			
<u>ENSIFENTRINE - OHTUVAYRE</u>						
N 217389 001	>A> 12251384	Jun 25, 2044	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ENTRECTINIB - ROZLYTREK</u>						
N 218550	001				ODE*	Aug 15, 2026
					ODE*	Aug 15, 2026
<u>ENZALUTAMIDE - XTANDI</u>						
N 203415	001	12161628	Feb 23, 2037	U-4101		
		12161628	Feb 23, 2037	U-4102		
		12161628	Feb 23, 2037	U-4103		
		12161628	Feb 23, 2037	U-4104		
<u>ENZALUTAMIDE - XTANDI</u>						
N 213674	001	12161628	Feb 23, 2037	U-4101		
		12161628	Feb 23, 2037	U-4102		
		12161628	Feb 23, 2037	U-4103		
		12161628	Feb 23, 2037	U-4104		
<u>ENZALUTAMIDE - XTANDI</u>						
N 213674	002	12161628	Feb 23, 2037	U-4101		
		12161628	Feb 23, 2037	U-4102		
		12161628	Feb 23, 2037	U-4103		
		12161628	Feb 23, 2037	U-4104		
<u>EPINEPHRINE - EPINEPHRINE</u>						
A 213708	001				>A> PC	Jun 03, 2025
<u>EPINEPHRINE - EPINEPHRINE</u>						
A 219239	001				>A> CGT	Sep 03, 2025
<u>EPINEPHRINE - NEFFY</u>						
N 214697	002	>A> 10576156	Feb 06, 2038	DP		
		>A> 10682414	Feb 06, 2039	U-3979		
		>A> 11173209	Feb 06, 2038	U-3979		
		>A> 11191838	Feb 06, 2039	DP U-3979		
		>A> 11717571	Feb 06, 2039	U-3979		
		>A> 11744895	Feb 06, 2039	U-3979		
		>A> 11918655	Feb 06, 2039	U-3979		
<u>EPLONTERSEN SODIUM - WAINUA (AUTOINJECTOR)</u>						
N 217388	001	>A> 8101743	Apr 01, 2026	DS DP		
<u>ESKETAMINE HYDROCHLORIDE - SPRAVATO</u>						
N 211243	001	10869844	Sep 10, 2035	U-3034	I-959	Jan 17, 2028
		10869844	Sep 10, 2035	U-3035		
		10869844	Sep 10, 2035	U-3036		
		10869844	Sep 10, 2035	U-4113		
		10869844	Sep 10, 2035	U-4114		
		11173134	Sep 10, 2035	U-3257		
		11173134	Sep 10, 2035	U-3536		
		11173134	Sep 10, 2035	U-4115		
		11311500	Sep 10, 2035	U-3034		
		11311500	Sep 10, 2035	U-3035		
		11311500	Sep 10, 2035	U-3036		
		11311500	Sep 10, 2035	U-4116		
		11311500	Sep 10, 2035	U-4117		
		11446260	Mar 14, 2034	U-3444		
		11446260	Mar 14, 2034	U-3445		
		11446260	Mar 14, 2034	U-3446		
		11446260	Mar 14, 2034	U-4118		
		11446260	Mar 14, 2034	U-4119		
		11883526	Feb 18, 2040	U-3812		
		11883526	Feb 18, 2040	U-3813		
		11883526	Feb 18, 2040	U-4120		
		8785500	Mar 05, 2033	U-2502		
		8785500	Mar 05, 2033	U-4112		
		9592207	Mar 20, 2027	U-2502		
		9592207	Mar 20, 2027	U-4112		

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ESKETAMINE HYDROCHLORIDE - SPRAVATO</u>						
N 211243 001	10869844	Sep 10, 2035	U-3034		I-959	Jan 17, 2028
	10869844	Sep 10, 2035	U-3035			
	10869844	Sep 10, 2035	U-3036			
	10869844	Sep 10, 2035	U-4113			
	10869844	Sep 10, 2035	U-4114			
	11173134	Sep 10, 2035	U-3257			
	11173134	Sep 10, 2035	U-3536			
	11173134	Sep 10, 2035	U-4115			
	11311500	Sep 10, 2035	U-3034			
	11311500	Sep 10, 2035	U-3035			
	11311500	Sep 10, 2035	U-3036			
	11311500	Sep 10, 2035	U-4116			
	11311500	Sep 10, 2035	U-4117			
	11446260	Mar 14, 2034	U-3444			
	11446260	Mar 14, 2034	U-3445			
	11446260	Mar 14, 2034	U-3446			
	11446260	Mar 14, 2034	U-4118			
	11446260	Mar 14, 2034	U-4119			
	11883526	Feb 18, 2040	U-3812			
	11883526	Feb 18, 2040	U-3813			
	11883526	Feb 18, 2040	U-4120			
	8785500	Mar 05, 2033	U-2502			
	8785500	Mar 05, 2033	U-4112			
	9592207	Mar 20, 2027	U-2502			
	9592207	Mar 20, 2027	U-4112			
<u>ETHINYL ESTRADIOL; NORETHINDRONE ACETATE - FEMLYV</u>						
N 218718 001	12178824	Jun 24, 2041	DP			
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 001	7612109	Feb 05, 2026	DS DP			
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 002	7612109	Feb 05, 2026	DS DP			
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 003	7612109	Feb 05, 2026	DS DP			
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 004	7612109	Feb 05, 2026	DS DP			
<u>FLUOCINOLONE ACETONIDE - ILUVIEN</u>						
N 201923 001	>A> 9849027	Nov 07, 2028	DP U-4157			
	>A> 9849027	Nov 07, 2028	DP U-708			
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798 001	>A> 10561808	Jan 01, 2032	DP		Y	
	>A> 10561808*PED	Jul 01, 2032				
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798 002	>A> 10561808	Jan 01, 2032	DP		Y	
	>A> 10561808*PED	Jul 01, 2032				
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798 003	>A> 10561808	Jan 01, 2032	DP		Y	
	>A> 10561808*PED	Jul 01, 2032				
<u>FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER</u>						
N 208798 004	>A> 10561808	Jan 01, 2032	DP		Y	
	>A> 10561808*PED	Jul 01, 2032				
<u>FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER</u>						
N 208798 005	>A> 10561808	Jan 01, 2032	DP		Y	
	>A> 10561808*PED	Jul 01, 2032				

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER</u>						
N 208798 005	>A> 10561808	Jan 01, 2032	DP	Y		
	>A> 10561808*PED	Jul 01, 2032				
<u>FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER</u>						
N 208798 006	>A> 10561808	Jan 01, 2032	DP	Y		
	>A> 10561808*PED	Jul 01, 2032				
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798 007	>A> 10561808	Jan 01, 2032	DP	Y		
	>A> 10561808*PED	Jul 01, 2032				
<u>FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER</u>						
N 208798 008	>A> 10561808	Jan 01, 2032	DP	Y		
	>A> 10561808*PED	Jul 01, 2032				
<u>FOSCARBIDOPA; FOSLEVODOPA - VYALEV</u>						
N 216962 001					NP	Oct 16, 2027
<u>FOSNETUPITANT CHLORIDE HYDROCHLORIDE; PALONOSETRON HYDROCHLORIDE - AKYNZEO</u>						
N 210493 001	12208109	Jun 02, 2037	DP			
<u>FOSNETUPITANT CHLORIDE HYDROCHLORIDE; PALONOSETRON HYDROCHLORIDE - AKYNZEO</u>						
N 210493 002	12208109	Jun 02, 2037	DP			
<u>GALLIUM GA-68 GOZETOTIDE - GOZELLIX</u>						
N 219592 001	>A> 11027031	Jul 28, 2035	U-3317			
<u>HYDROCHLOROTHIAZIDE - INZIROO</u>						
N 219141 001	11878022	Jan 23, 2044	DP U-4138			
	11878022	Jan 23, 2044	DP U-4139			
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 001	8476284	Dec 28, 2026	U-1650			
	8476284	Dec 28, 2026	U-1946			
	8476284*PED	Jun 28, 2027				
	8497277	Dec 28, 2026	U-1491			
	8497277	Dec 28, 2026	U-1650			
	8497277	Dec 28, 2026	U-1946			
	8497277	Dec 28, 2026	U-2241			
	8497277	Dec 28, 2026	U-2242			
	8497277	Dec 28, 2026	U-3422			
	8497277*PED	Jun 28, 2027				
	9540382	Aug 18, 2033	U-1650			
	9540382	Aug 18, 2033	U-1684			
	9540382	Aug 18, 2033	U-1946			
	9540382*PED	Feb 18, 2034				
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 002	8476284	Dec 28, 2026	U-1650			
	8476284	Dec 28, 2026	U-1946			
	8476284*PED	Jun 28, 2027				
	8497277	Dec 28, 2026	U-1491			
	8497277	Dec 28, 2026	U-1650			
	8497277	Dec 28, 2026	U-1946			
	8497277	Dec 28, 2026	U-2241			
	8497277	Dec 28, 2026	U-2242			
	8497277	Dec 28, 2026	U-3422			
	8497277*PED	Jun 28, 2027				
	9540382	Aug 18, 2033	U-1491			
	9540382	Aug 18, 2033	U-1650			
	9540382	Aug 18, 2033	U-1946			
	9540382*PED	Feb 18, 2034				

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IBRUTINIB - IMBRUVICA</u>						
N 217003 001	12201690	Jun 14, 2039	DP			
<u>ICOSAPENT ETHYL - VASCEPA</u>						
N 202057 001	12171738	Feb 09, 2030	U-4105			
<u>ICOSAPENT ETHYL - VASCEPA</u>						
N 202057 002	12171738	Feb 09, 2030	U-4105			
<u>IMETELSTAT SODIUM - RYTELO</u>						
N 217779 001	12171778	Jun 16, 2039	U-3956			
	9388415	Sep 09, 2025	U-3956			
	9388416	Sep 09, 2025	U-3956			
<u>IMETELSTAT SODIUM - RYTELO</u>						
N 217779 002	12171778	Jun 16, 2039	U-3956			
	9388415	Sep 09, 2025	U-3956			
	9388416	Sep 09, 2025	U-3956			
<u>IOMEPROL - IOMERVU</u>						
N 216016 001					NCE	Nov 27, 2029
<u>IOMEPROL - IOMERVU</u>						
N 216016 002					NCE	Nov 27, 2029
<u>IOMEPROL - IOMERVU</u>						
N 216016 003					NCE	Nov 27, 2029
<u>IOMEPROL - IOMERVU</u>						
N 216016 004					NCE	Nov 27, 2029
<u>IOMEPROL - IOMERVU</u>						
N 216016 005					NCE	Nov 27, 2029
<u>IOMEPROL - IOMERVU</u>						
N 216016 006					NCE	Nov 27, 2029
<u>IOMEPROL - IOMERVU</u>						
N 216016 007					NCE	Nov 27, 2029
<u>IOMEPROL - IOMERVU</u>						
N 216016 008					NCE	Nov 27, 2029
<u>IOMEPROL - IOMERVU</u>						
N 216016 009					NCE	Nov 27, 2029
<u>IOMEPROL - IOMERVU</u>						
N 216016 010					NCE	Nov 27, 2029
<u>IOMEPROL - IOMERVU</u>						
N 216016 011					NCE	Nov 27, 2029
<u>IOMEPROL - IOMERVU</u>						
N 216016 012					NCE	Nov 27, 2029
<u>IOMEPROL - IOMERVU</u>						
N 216016 013					NCE	Nov 27, 2029
<u>IOMEPROL - IOMERVU</u>						
N 216017 001					NCE	Nov 27, 2029



## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IOMEPROL - IOMERVU</u>						
N 216017	002				NCE	Nov 27, 2029
<u>IOMEPROL - IOMERVU</u>						
N 216017	003				NCE	Nov 27, 2029
<u>IOMEPROL - IOMERVU</u>						
N 216017	004				NCE	Nov 27, 2029
<u>IOMEPROL - IOMERVU</u>						
N 216017	005				NCE	Nov 27, 2029
<u>IOMEPROL - IOMERVU</u>						
N 216017	006				NCE	Nov 27, 2029
<u>IOMEPROL - IOMERVU</u>						
N 216017	007				NCE	Nov 27, 2029
<u>IOMEPROL - IOMERVU</u>						
N 216017	008				NCE	Nov 27, 2029
<u>IOMEPROL - IOMERVU</u>						
N 216017	009				NCE	Nov 27, 2029
<u>IOMEPROL - IOMERVU</u>						
N 216017	010				NCE	Nov 27, 2029
<u>IOMEPROL - IOMERVU</u>						
N 216017	011				NCE	Nov 27, 2029
<u>IOMEPROL - IOMERVU</u>						
N 216017	012				NCE	Nov 27, 2029
<u>IOMEPROL - IOMERVU</u>						
N 216017	013				NCE	Nov 27, 2029
<u>IPRATROPIUM BROMIDE - ATROVENT HFA</u>						
N 021527	001	>A> 8474447	Jan 17, 2030	DP	Y	
<u>IVABRADINE HYDROCHLORIDE - IVABRADINE HYDROCHLORIDE</u>						
A 214051	001				PC	Jan 11, 2025
<u>IVABRADINE HYDROCHLORIDE - IVABRADINE HYDROCHLORIDE</u>						
A 214051	002				PC	Jan 11, 2025
<u>IVACAFTOR - KALYDECO</u>						
N 203188	001	10646481	Aug 13, 2029	DP		
		10646481*PED	Feb 13, 2030			
		11564916	Aug 13, 2029		U-3530	
		11564916*PED	Feb 13, 2030			
		8410274	Dec 28, 2026	DP		
		8410274*PED	Jun 28, 2027			
		8754224	Dec 28, 2026	DS DP		
		8754224*PED	Jun 28, 2027			
		9670163	Dec 28, 2026	DP	U-1311	
		9670163*PED	Jun 28, 2027			
<u>IVACAFTOR - KALYDECO</u>						
N 207925	001	10646481	Aug 13, 2029	DP		
		10646481*PED	Feb 13, 2030			
		11564916	Aug 13, 2029		U-3528	
		11564916*PED	Feb 13, 2030			
		12214083	Feb 27, 2033	DP	U-4126	

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IVACAFTOR - KALYDECO</u>						
N 207925 001	7495103	May 20, 2027	DS DP			
	7495103*PED	Nov 20, 2027				
	8324242	Aug 05, 2027			U-1311	
	8324242	Aug 05, 2027			U-1906	
	8324242	Aug 05, 2027			U-2527	
	8324242*PED	Feb 05, 2028				
	8410274	Dec 28, 2026	DP			
	8410274*PED	Jun 28, 2027				
	8754224	Dec 28, 2026	DS DP			
	8754224*PED	Jun 28, 2027				
	9670163	Dec 28, 2026	DP		U-1311	
	9670163	Dec 28, 2026	DP		U-2530	
	9670163*PED	Jun 28, 2027				
<u>IVACAFTOR - KALYDECO</u>						
N 207925 002	10646481	Aug 13, 2029	DP			
	10646481*PED	Feb 13, 2030				
	11564916	Aug 13, 2029			U-3528	
	11564916*PED	Feb 13, 2030				
	12214083	Feb 27, 2033	DP		U-4126	
	7495103	May 20, 2027	DS DP			
	7495103*PED	Nov 20, 2027				
	8324242	Aug 05, 2027			U-1311	
	8324242	Aug 05, 2027			U-1906	
	8324242	Aug 05, 2027			U-2527	
	8324242*PED	Feb 05, 2028				
	8410274	Dec 28, 2026	DP			
	8410274*PED	Jun 28, 2027				
	8754224	Dec 28, 2026	DS DP			
	8754224*PED	Jun 28, 2027				
	9670163	Dec 28, 2026	DP		U-1311	
	9670163	Dec 28, 2026	DP		U-2530	
	9670163*PED	Jun 28, 2027				
<u>IVACAFTOR - KALYDECO</u>						
N 207925 003	10646481	Aug 13, 2029	DP			
	10646481*PED	Feb 13, 2030				
	11564916	Aug 13, 2029			U-3528	
	11564916*PED	Feb 13, 2030				
	12214083	Feb 27, 2033	DP		U-4128	
	7495103	May 20, 2027	DS DP			
	7495103*PED	Nov 20, 2027				
	8324242	Aug 05, 2027			U-1311	
	8324242	Aug 05, 2027			U-1906	
	8324242	Aug 05, 2027			U-2963	
	8324242*PED	Feb 05, 2028				
	8410274	Dec 28, 2026	DP			
	8410274*PED	Jun 28, 2027				
	8754224	Dec 28, 2026	DS DP			
	8754224*PED	Jun 28, 2027				
	9670163	Dec 28, 2026	DP		U-1311	
	9670163	Dec 28, 2026	DP		U-2966	
	9670163*PED	Jun 28, 2027				
<u>IVACAFTOR - KALYDECO</u>						
N 207925 004	10646481	Aug 13, 2029	DP			
	10646481*PED	Feb 13, 2030				
	11564916	Aug 13, 2029			U-3603	
	11564916*PED	Feb 13, 2030				
	12214083	Feb 27, 2033	DP		U-4127	
	7495103	May 20, 2027	DS DP			
	7495103*PED	Nov 20, 2027				
	8324242	Aug 05, 2027			U-3609	
	8324242*PED	Feb 05, 2028				
	8410274	Dec 28, 2026	DP			
	8410274*PED	Jun 28, 2027				
	8754224	Dec 28, 2026	DS DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IVACAFTOR - KALYDECO</u>						
N 207925 004	8754224*PED	Jun 28, 2027				
	9670163	Dec 28, 2026	DP U-3606			
	9670163*PED	Jun 28, 2027				
<u>IVACAFTOR - KALYDECO</u>						
N 207925 005	10646481	Aug 13, 2029	DP			
	10646481*PED	Feb 13, 2030				
	11564916	Aug 13, 2029	U-3603			
	11564916*PED	Feb 13, 2030				
	12214083	Feb 27, 2033	DP U-4127			
	7495103	May 20, 2027	DS DP			
	7495103*PED	Nov 20, 2027				
	8324242	Aug 05, 2027	U-3609			
	8324242*PED	Feb 05, 2028				
	8410274	Dec 28, 2026	DP			
	8410274*PED	Jun 28, 2027				
	8754224	Dec 28, 2026	DS DP			
	8754224*PED	Jun 28, 2027				
	9670163	Dec 28, 2026	DP U-3606			
	9670163*PED	Jun 28, 2027				
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 206038 001	10076513	Dec 04, 2028	DP U-2411			
	10076513*PED	Jun 04, 2029				
	10597384	Dec 04, 2028	DS DP U-2777			
	10597384*PED	Jun 04, 2029				
	10646481	Aug 13, 2029	DP			
	10646481*PED	Feb 13, 2030				
	11052075	Dec 04, 2028	DP U-3181			
	11052075*PED	Jun 04, 2029				
	11564916	Aug 13, 2029	U-3529			
	11564916*PED	Feb 13, 2030				
	12065432	Dec 04, 2028	U-3984			
	12065432*PED	Jun 04, 2029				
	7495103	May 20, 2027	DS DP			
	7495103*PED	Nov 20, 2027				
	7973038	Nov 08, 2026	U-1973			
	7973038*PED	May 08, 2027				
	8324242	Aug 05, 2027	U-1311			
	8324242	Aug 05, 2027	U-1911			
	8324242*PED	Feb 05, 2028				
	8410274	Dec 28, 2026	DP			
	8410274*PED	Jun 28, 2027				
	8507534	Sep 20, 2030	DS DP			
	8507534*PED	Mar 20, 2031				
	8653103	Dec 04, 2028	DP			
	8653103*PED	Jun 04, 2029				
	8716338	Sep 20, 2030	DP U-1718			
	8716338	Sep 20, 2030	DP U-1910			
	8716338*PED	Mar 20, 2031				
	8741933	Nov 08, 2026	U-1717			
	8741933	Nov 08, 2026	U-1909			
	8741933*PED	May 08, 2027				
	8754224	Dec 28, 2026	DS DP			
	8754224*PED	Jun 28, 2027				
	8846718	Jul 02, 2029	U-1717			
	8846718	Jul 02, 2029	U-1908			
	8846718*PED	Jan 02, 2030				
	8993600	Dec 11, 2030	DP			
	8993600*PED	Jun 11, 2031				
	9150552	Dec 04, 2028	U-1908			
	9150552*PED	Jun 04, 2029				
	9192606	Sep 29, 2029	DP U-1912			
	9192606*PED	Mar 29, 2030				
	9216969	Nov 08, 2026	DS DP			
	9216969*PED	May 08, 2027				
	9670163	Dec 28, 2026	DP U-1911			
	9670163*PED	Jun 28, 2027				

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 206038 001	9931334	Dec 28, 2026	DP U-2276			
	9931334*PED	Jun 28, 2027				
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 206038 002	10597384	Dec 04, 2028	DS DP U-2777			
	10597384*PED	Jun 04, 2029				
	10646481	Aug 13, 2029	DP			
	10646481*PED	Feb 13, 2030				
	11052075	Dec 04, 2028	DP U-3181			
	11052075*PED	Jun 04, 2029				
	11564916	Aug 13, 2029	U-3529			
	11564916*PED	Feb 13, 2030				
	12065432	Dec 04, 2028	U-3984			
	12065432*PED	Jun 04, 2029				
	7495103	May 20, 2027	DS DP			
	7495103*PED	Nov 20, 2027				
	7973038	Nov 08, 2026	U-1973			
	7973038*PED	May 08, 2027				
	8324242	Aug 05, 2027	U-1911			
	8324242*PED	Feb 05, 2028				
	8410274	Dec 28, 2026	DP			
	8410274*PED	Jun 28, 2027				
	8507534	Sep 20, 2030	DS DP			
	8507534*PED	Mar 20, 2031				
	8653103	Dec 04, 2028	DP			
	8653103*PED	Jun 04, 2029				
	8716338	Sep 20, 2030	DP U-1910			
	8716338*PED	Mar 20, 2031				
	8741933	Nov 08, 2026	U-1909			
	8741933*PED	May 08, 2027				
	8754224	Dec 28, 2026	DS DP			
	8754224*PED	Jun 28, 2027				
	8846718	Jul 02, 2029	U-1908			
	8846718*PED	Jan 02, 2030				
	8993600	Dec 11, 2030	DP			
	8993600*PED	Jun 11, 2031				
	9150552	Dec 04, 2028	U-1908			
	9150552*PED	Jun 04, 2029				
	9192606	Sep 29, 2029	DP U-1912			
	9192606*PED	Mar 29, 2030				
	9216969	Nov 08, 2026	DP			
	9216969*PED	May 08, 2027				
	9670163	Dec 28, 2026	DP U-1911			
	9670163*PED	Jun 28, 2027				
	9931334	Dec 28, 2026	DP U-2276			
	9931334*PED	Jun 28, 2027				
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 211358 001	10597384	Dec 04, 2028	DS DP U-2778		M-14	Dec 13, 2027
	10597384*PED	Jun 04, 2029			ODE-408	Sep 02, 2029
	10646481	Aug 13, 2029	DP		PED	Jun 13, 2028
	10646481*PED	Feb 13, 2030			PED	Mar 02, 2030
	11564916	Aug 13, 2029	U-3526			
	11564916*PED	Feb 13, 2030				
	12065432	Dec 04, 2028	U-3983			
	12065432*PED	Jun 04, 2029				
	7495103	May 20, 2027	DS DP			
	7495103*PED	Nov 20, 2027				
	7973038	Nov 08, 2026	U-2374			
	7973038*PED	May 08, 2027				
	8324242	Aug 05, 2027	U-2374			
	8324242*PED	Feb 05, 2028				
	8410274	Dec 28, 2026	DP			
	8410274*PED	Jun 28, 2027				
	8507534	Sep 20, 2030	DS DP			
	8507534*PED	Mar 20, 2031				
	8653103	Dec 04, 2028	DP			
	8653103*PED	Jun 04, 2029				

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 211358 001	8716338	Sep 20, 2030	DP U-2396			
	8716338*PED	Mar 20, 2031				
	8741933	Nov 08, 2026			U-2374	
	8741933*PED	May 08, 2027				
	8754224	Dec 28, 2026	DS DP			
	8754224*PED	Jun 28, 2027				
	8846718	Jul 02, 2029			U-2375	
	8846718*PED	Jan 02, 2030				
	8993600	Dec 11, 2030		DP		
	8993600*PED	Jun 11, 2031				
	9150552	Dec 04, 2028			U-2375	
	9150552*PED	Jun 04, 2029				
	9192606	Sep 29, 2029	DP U-2397			
	9192606*PED	Mar 29, 2030				
	9216969	Nov 08, 2026		DP		
	9216969*PED	May 08, 2027				
	9670163	Dec 28, 2026	DP U-2376			
	9670163*PED	Jun 28, 2027				
	9931334	Dec 28, 2026	DP U-2376			
	9931334*PED	Jun 28, 2027				
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 211358 002	10597384	Dec 04, 2028	DS DP U-2778		M-14	Dec 13, 2027
	10597384*PED	Jun 04, 2029			ODE-408	Sep 02, 2029
	10646481	Aug 13, 2029		DP	PED	Jun 13, 2028
	10646481*PED	Feb 13, 2030			PED	Mar 02, 2030
	11564916	Aug 13, 2029			U-3526	
	11564916*PED	Feb 13, 2030				
	12065432	Dec 04, 2028			U-3983	
	12065432*PED	Jun 04, 2029				
	7495103	May 20, 2027	DS DP			
	7495103*PED	Nov 20, 2027				
	7973038	Nov 08, 2026			U-2374	
	7973038*PED	May 08, 2027				
	8324242	Aug 05, 2027			U-2374	
	8324242*PED	Feb 05, 2028				
	8410274	Dec 28, 2026		DP		
	8410274*PED	Jun 28, 2027				
	8507534	Sep 20, 2030	DS DP			
	8507534*PED	Mar 20, 2031				
	8653103	Dec 04, 2028		DP		
	8653103*PED	Jun 04, 2029				
	8716338	Sep 20, 2030	DP U-2396			
	8716338*PED	Mar 20, 2031				
	8741933	Nov 08, 2026			U-2374	
	8741933*PED	May 08, 2027				
	8754224	Dec 28, 2026	DS DP			
	8754224*PED	Jun 28, 2027				
	8846718	Jul 02, 2029			U-2375	
	8846718*PED	Jan 02, 2030				
	8993600	Dec 11, 2030		DP		
	8993600*PED	Jun 11, 2031				
	9150552	Dec 04, 2028			U-2375	
	9150552*PED	Jun 04, 2029				
	9192606	Sep 29, 2029	DP U-2397			
	9192606*PED	Mar 29, 2030				
	9216969	Nov 08, 2026		DP		
	9216969*PED	May 08, 2027				
	9670163	Dec 28, 2026	DP U-2376			
	9670163*PED	Jun 28, 2027				
	9931334	Dec 28, 2026	DP U-2376			
	9931334*PED	Jun 28, 2027				
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 211358 003	10597384	Dec 04, 2028	DS DP U-3430		M-14	Dec 13, 2027
	10597384*PED	Jun 04, 2029			ODE-408	Sep 02, 2029
	10646481	Aug 13, 2029		DP	PED	Jun 13, 2028
	10646481*PED	Feb 13, 2030			PED	Mar 02, 2030

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 211358 003	11564916	Aug 13, 2029	U-3526			
	11564916*PED	Feb 13, 2030				
	12065432	Dec 04, 2028	U-3983			
	12065432*PED	Jun 04, 2029				
	7495103	May 20, 2027	DS DP			
	7495103*PED	Nov 20, 2027				
	7973038	Nov 08, 2026	U-3424			
	7973038*PED	May 08, 2027				
	8324242	Aug 05, 2027	U-3424			
	8324242*PED	Feb 05, 2028				
	8410274	Dec 28, 2026	DP			
	8410274*PED	Jun 28, 2027				
	8507534	Sep 20, 2030	DS DP			
	8507534*PED	Mar 20, 2031				
	8653103	Dec 04, 2028	DP			
	8653103*PED	Jun 04, 2029				
	8716338	Sep 20, 2030	DP U-3426			
	8716338*PED	Mar 20, 2031				
	8741933	Nov 08, 2026	U-3424			
	8741933*PED	May 08, 2027				
	8754224	Dec 28, 2026	DS DP			
	8754224*PED	Jun 28, 2027				
	8846718	Jul 02, 2029	U-3427			
	8846718*PED	Jan 02, 2030				
	8993600	Dec 11, 2030	DP			
	8993600*PED	Jun 11, 2031				
	9150552	Dec 04, 2028	U-3427			
	9150552*PED	Jun 04, 2029				
	9192606	Sep 29, 2029	DP U-3428			
	9192606*PED	Mar 29, 2030				
	9216969	Nov 08, 2026	DP			
	9216969*PED	May 08, 2027				
	9670163	Dec 28, 2026	DP U-3429			
	9670163*PED	Jun 28, 2027				
	9931334	Dec 28, 2026	DP U-3429			
	9931334*PED	Jun 28, 2027				
<u>LACTULOSE - LACTULOSE</u>						
A 217914 001				>A> CGT		Sep 13, 2025
<u>LACTULOSE - LACTULOSE</u>						
A 217914 002				>A> CGT		Sep 13, 2025
<u>LAROTRECTINIB SULFATE - VITRAKVI</u>						
N 210861 001	11337967	May 16, 2037	U-4123			
	11974998	May 16, 2037	U-4124			
<u>LAROTRECTINIB SULFATE - VITRAKVI</u>						
N 210861 002	11337967	May 16, 2037	U-4123			
	11974998	May 16, 2037	U-4124			
<u>LAROTRECTINIB SULFATE - VITRAKVI</u>						
N 211710 001	11337967	May 16, 2037	U-4123			
	11974998	May 16, 2037	U-4124			
<u>LAZERTINIB MESYLATE - LAZCLUZE</u>						
N 219008 001	12138351	Apr 13, 2041	DP			
<u>LAZERTINIB MESYLATE - LAZCLUZE</u>						
N 219008 002	12138351	Apr 13, 2041	DP			
<u>LENVATINIB MESYLATE - LENVIMA</u>						
N 206947 001	12226409	May 15, 2038	U-4146			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LENVATINIB MESYLATE - LENVIMA</u>						
N 206947 002	12226409	May 15, 2038	U-4146			
<u>LEVOKETOCONAZOLE - RECORLEV</u>						
N 214133 001					NCE*	Dec 30, 2026
<u>LINAGLIPTIN - TRADJENTA</u>						
N 201280 001	12178819	May 04, 2027	DP			
<u>LISINAPRIL - OBRELIS</u>						
N 208401 001	12186360	Nov 06, 2035	DP			
<u>LOSARTAN POTASSIUM - ARBLI</u>						
N 218772 001	>A> 11890273	Oct 07, 2041	DP			
	>A> 12156869	Oct 07, 2041	DP U-4158			
	>A> 12156869	Oct 07, 2041	DP U-4159			
	>A> 12156869	Oct 07, 2041	DP U-4160			
<u>LOTILANER - XDEMVY</u>						
N 217603 001	12171750	Dec 14, 2038	U-3674			
	12213964	Dec 14, 2038	DP			
<u>LUTETIUM LU-177 VIPIVOTIDE TETRAJETAN - PLUVICTO</u>						
N 215833 001	12208102	Sep 18, 2041	U-3345			
<u>MACITENTAN - OPSUMIT</u>						
N 204410 001					>A> M-187	Feb 28, 2028
<u>MAGNESIUM SULFATE; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM SULFATE - SUFLAVE</u>						
N 215344 001	12239659	Jun 14, 2044	U-4143			
<u>MARIBAVIR - LIVTENCITY</u>						
N 215596 001	12213989	Nov 18, 2042	U-4137			
<u>MELOXICAM; RIZATRIPTAN BENZOATE - SYMBRAVO</u>						
N 215431 001	10029010	Apr 11, 2036	U-4133		NP	Jan 30, 2028
	10058614	Apr 11, 2036	DP			
	10137131	Apr 11, 2036	DP U-1719			
	10195278	Apr 11, 2036	U-1719			
	10265324	Apr 11, 2036	U-1719			
	10363312	Apr 11, 2036	U-1719			
	10369224	Apr 11, 2036	U-4134			
	10426839	Apr 11, 2036	U-4135			
	10463736	Apr 11, 2036	DP			
	10471014	Apr 11, 2036	U-1719			
	10471069	Apr 11, 2036	U-1719			
	10512692	Apr 11, 2036	U-1719			
	10512693	Apr 11, 2036	U-1719			
	10517950	Apr 11, 2036	U-1719			
	10532101	Apr 11, 2036	U-1719			
	10537642	Apr 11, 2036	U-1719			
	10561664	Apr 11, 2036	U-1719			
	10583144	Apr 11, 2036	U-1719			
	10653777	Apr 11, 2036	U-1719			
	10688102	Apr 11, 2036	U-1719			
	10688185	Apr 11, 2036	U-1719			
	10695429	Apr 11, 2036	U-1719			
	10695430	Apr 11, 2036	U-1719			
	10702535	Apr 11, 2036	U-4136			
	10702602	Apr 11, 2036	U-1719			
	10722583	Apr 11, 2036	U-1719			
	10729696	Apr 11, 2036	U-1719			
	10729697	Apr 11, 2036	U-1719			
	10729773	Apr 11, 2036	U-1719			
	10758617	Apr 11, 2036	U-1719			
	10758618	Apr 11, 2036	U-1719			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MELOXICAM; RIZATRIPTAN BENZOATE - SYMBRAVO</u>						
N 215431 001	10780165	Apr 11, 2036	U-1719			
	10780166	Apr 11, 2036	U-1719			
	10799588	Apr 11, 2036	U-1719			
	10821181	Apr 11, 2036	U-1719			
	10821182	Apr 11, 2036	U-1719			
	10894053	Apr 11, 2036	U-1719			
	10905693	Apr 11, 2036	U-1719			
	10918722	Apr 11, 2036	U-1719			
	10933136	Apr 11, 2036	U-1719			
	10933137	Apr 11, 2036	U-1719			
	10940153	Apr 11, 2036	U-1719			
	10987358	Apr 11, 2036	U-1719			
	11013805	Apr 11, 2036	U-1719			
	11013806	Apr 11, 2036	U-1719			
	11020483	Apr 11, 2036	U-1719			
	11045549	Apr 11, 2036	U-1719			
	11135295	Apr 11, 2036	U-1719			
	11207328	Apr 11, 2036	U-1719			
	11219626	Apr 11, 2036	U-1719			
	11285213	Apr 11, 2036	U-1719			
	11331323	Apr 11, 2036	U-1719			
	11369684	Apr 11, 2036	U-1719			
	11426414	Apr 11, 2036	U-1719			
	11471464	Apr 11, 2036	U-1719			
	11471465	Apr 11, 2036	U-1719			
	11504429	Apr 11, 2036	U-1719			
	11510927	Apr 11, 2036	U-1719			
	11571428	Apr 11, 2036	U-1719			
	11602563	Apr 11, 2036	U-1719			
	11607456	Apr 11, 2036	U-1719			
	11617755	Apr 11, 2036	U-1719			
	11617756	Apr 11, 2036	U-1719			
	11617791	Apr 11, 2036	U-1719			
	11628173	Apr 11, 2036	U-1719			
	11712441	Apr 11, 2036	U-1719			
	11738085	Apr 11, 2036	U-1719			
	11759522	Apr 11, 2036	U-1719			
	11801250	Apr 11, 2036	U-1719			
	11806354	Apr 11, 2036	U-1719			
	11826370	Apr 11, 2036	U-1719			
	11865117	Apr 11, 2036	U-1719			
	12128052	May 28, 2040	U-1719			
	9821075	Apr 11, 2036	DP U-1719			
<u>MERCAPTOPURINE - MERCAPTOPURINE</u>						
A 216418 001					CGT	Aug 25, 2025
<u>MESNA - MESNA</u>						
A 218871 001					CGT	Jul 13, 2025
<u>METOCLOPRAMIDE HYDROCHLORIDE - GIMOTI</u>						
N 209388 001	12194008	Dec 22, 2029	U-2843			
	12194009	Dec 22, 2029	U-2843			
<u>MIGLUSTAT - OPFOLDA</u>						
N 215211 001	>A> 12246062	Sep 16, 2038	U-3726			
<u>MIRDAMETINIB - GOMEKLI</u>						
N 219379 001	11066358	Feb 17, 2041	DS		NCE	Feb 11, 2030
	11084780	Feb 17, 2041	DS		>A> ODE-488	Feb 11, 2032
	11453641	Feb 17, 2041				
	11571402	Feb 17, 2041	DP			
	11806321	Feb 17, 2041	U-4130			
	11806322	Mar 16, 2043	U-4130			
	11819487	Feb 17, 2041	U-4130			
	11839595	Mar 16, 2043	U-4130			
	11883375	Mar 16, 2043	U-4130			



## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MIRDAMETINIB - GOMEKLI</u>						
N 219379 001	12011424	Feb 17, 2041	U-4130			
	12029711	Mar 15, 2044	DP U-4130			
	12037306	Feb 17, 2041	U-4130			
	12090128	Feb 17, 2041	DP U-4130			
	12220390	Mar 16, 2043	U-4130			
	>A> 12257215	Mar 16, 2043	U-4130			
	>A> 12263146	Feb 17, 2041	U-4130			
<u>MIRDAMETINIB - GOMEKLI</u>						
N 219389 001	11066358	Feb 17, 2041	DS		NCE	Feb 11, 2030
	11084780	Feb 17, 2041	DS		>A> ODE-488	Feb 11, 2032
	11453641	Feb 17, 2041	U-4130			
	11806321	Feb 17, 2041	U-4130			
	11806322	Mar 16, 2043	U-4130			
	11819487	Feb 17, 2041	U-4130			
	11839595	Mar 16, 2043	U-4130			
	11883375	Mar 16, 2043	U-4131			
	12011424	Feb 17, 2041	U-4130			
	12029711	Mar 15, 2044	DP U-4130			
	12037306	Feb 17, 2041	U-4130			
	12220390	Mar 16, 2043	U-4130			
	>A> 12257215	Mar 16, 2043	U-4130			
	>A> 12263146	Feb 17, 2041	U-4130			
<u>MIRDAMETINIB - GOMEKLI</u>						
N 219389 002	11066358	Feb 17, 2041	DS		NCE	Feb 11, 2030
	11084780	Feb 17, 2041	DS		>A> ODE-488	Feb 11, 2032
	11453641	Feb 17, 2041	U-4130			
	11806321	Feb 17, 2041	U-4130			
	11806322	Mar 16, 2043	U-4130			
	11819487	Feb 17, 2041	U-4130			
	11839595	Mar 16, 2043	U-4130			
	11883375	Mar 16, 2043	U-4131			
	12029711	Mar 15, 2044	DP U-4130			
	12037306	Feb 17, 2041	U-4130			
	12220390	Mar 16, 2043	U-4130			
	>A> 12257215	Mar 16, 2043	U-4130			
	>A> 12263146	Feb 17, 2041	U-4130			
<u>MOXIDECTIN - MOXIDECTIN</u>						
N 210867 001					>A> NPP	Feb 07, 2028
<u>MYCOPHENOLATE MOFETIL - MYHIBBIN</u>						
N 216482 001	12194143	Aug 16, 2039	DP U-1752			
	12226526	Aug 16, 2039	DP U-1752			
<u>NIMODIPINE - NYMALIZE</u>						
N 203340 002	12186308	Apr 16, 2038	DP U-2804			
<u>NIRAPARIB TOSYLATE - ZEJULA</u>						
N 214876 001	11730725	Jan 25, 2039	DP			
<u>NIRAPARIB TOSYLATE - ZEJULA</u>						
N 214876 002	11730725	Jan 25, 2039	DP			
<u>NIRAPARIB TOSYLATE - ZEJULA</u>						
N 214876 003	11730725	Jan 25, 2039	DP			
<u>NIRMATRELVIR; RITONAVIR - PAXLOVID (COPACKAGED)</u>						
N 217188 001					D-195	Jan 31, 2028
<u>NIROGACESTAT HYDROBROMIDE - OGSIVEO</u>						
N 217677 001	>A> 12234210	Jul 08, 2042	DP			
	>A> 12247012	Jul 08, 2042	DP			
	>A> 7951958	Mar 11, 2026	DS			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>NIROGACESTAT HYDROBROMIDE - OGSIVEO</u>						
N 217677 001	>A> 12234210	Jul 08, 2042	DP			
	>A> 12247012	Jul 08, 2042	DP			
	>A> 7951958	Mar 11, 2026	DS			
<u>NIROGACESTAT HYDROBROMIDE - OGSIVEO</u>						
N 217677 002	>A> 12234210	Jul 08, 2042	DP			
	>A> 12247012	Jul 08, 2042	DP			
	>A> 7951958	Mar 11, 2026	DS			
<u>NIROGACESTAT HYDROBROMIDE - OGSIVEO</u>						
N 217677 003	>A> 12234210	Jul 08, 2042	DP			
	>A> 12247012	Jul 08, 2042	DP			
	>A> 7951958	Mar 11, 2026	DS			
<u>NOREPINEPHRINE BITARTRATE - NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE</u>						
N 214628 001	>A> 12245996	Jan 30, 2038	DP			
<u>NOREPINEPHRINE BITARTRATE - NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE</u>						
N 214628 002	>A> 12245996	Jan 30, 2038	DP			
<u>NOREPINEPHRINE BITARTRATE - NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE</u>						
N 214628 003	>A> 12245996	Jan 30, 2038	DP			
<u>NOREPINEPHRINE BITARTRATE - NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE</u>						
N 215700 001	>A> RE49422	Feb 26, 2035	DP			
<u>NOREPINEPHRINE BITARTRATE - NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE</u>						
N 215700 002	>A> RE49422	Feb 26, 2035	DP			
<u>NOREPINEPHRINE BITARTRATE - NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE</u>						
N 215700 003	>A> 10251848	Feb 26, 2035	DP			
	>A> RE49422	Feb 26, 2035	DP			
	>A> RE49443	Feb 26, 2035	DP			
<u>OCTREOTIDE ACETATE - MYCAPSSA</u>						
N 208232 001	>A> 12246054	Feb 03, 2036	U-2857			
	>A> 12251418	Feb 03, 2036	U-2857			
<u>ODEVIXIBAT - BYLVAY</u>						
N 215498 001	12187812	Nov 08, 2031	U-3186			
	12187812	Nov 08, 2031	U-3648			
<u>ODEVIXIBAT - BYLVAY</u>						
N 215498 002	12187812	Nov 08, 2031	U-3186			
	12187812	Nov 08, 2031	U-3648			
<u>ODEVIXIBAT - BYLVAY</u>						
N 215498 003	12187812	Nov 08, 2031	U-3186			
	12187812	Nov 08, 2031	U-3648			
<u>ODEVIXIBAT - BYLVAY</u>						
N 215498 004	12187812	Nov 08, 2031	U-3186			
	12187812	Nov 08, 2031	U-3648			
<u>OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI</u>						
N 213378 001	12194035	Aug 23, 2031	U-3141			
<u>OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI</u>						
N 213378 002	12194035	Aug 23, 2031	U-3141			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI</u>						
N 213378 003	12194035	Aug 23, 2031	U-3141			
<u>OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI</u>						
N 213378 004	12194035	Aug 23, 2031	U-3141			
<u>OLAPARIB - LYNPARZA</u>						
N 208558 001	12178816	Oct 07, 2029	DP			
<u>OLAPARIB - LYNPARZA</u>						
N 208558 002	12178816	Oct 07, 2029	DP			
<u>OLEZARSEN SODIUM - TRYNGOLZA (AUTOINJECTOR)</u>						
N 218614 001	9127276	May 01, 2034	DS			
	9157082	Apr 27, 2032	U-4050			
	9163239	May 01, 2034	DS			
	9181549	May 01, 2034	DS			
	9593333	Feb 14, 2034	U-4050			
<u>OLODATEROL HYDROCHLORIDE; TIOTROPIUM BROMIDE - STIOLTO RESPIMAT</u>						
N 206756 001	>A> 7396341	Oct 10, 2026	DP	Y		
	>A> 7396341*PED	Apr 10, 2027				
	>A> 7837235	Mar 13, 2028	DP	Y		
	>A> 7837235*PED	Sep 13, 2028				
	>A> 8733341	Oct 16, 2030	DP	Y		
	>A> 9027967	Mar 31, 2027	DP	Y		
<u>OMADACYCLINE TOSYLATE - NUZYRA</u>						
N 209816 001	9265740	Oct 24, 2030	DP U-1569			
<u>OMADACYCLINE TOSYLATE - NUZYRA</u>						
N 209817 001	9265740	Oct 24, 2030	DP			
<u>OMAVELOXOLONE - SKYCLARYS</u>						
N 216718 001					M-270	Dec 20, 2027
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 001	>A> 12246094	Aug 24, 2027	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 002	>A> 12246094	Aug 24, 2027	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 003	>A> 12246094	Aug 24, 2027	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 004	>A> 12246094	Aug 24, 2027	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 005	>A> 12246094	Aug 24, 2027	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 006	>A> 12246094	Aug 24, 2027	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 007	>A> 12246094	Aug 24, 2027	DP			
<u>OZANIMOD HYDROCHLORIDE - ZEPOSIA</u>						
N 209899 001	>A> 8481573	Mar 24, 2033	DS DP U-2774			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OZANIMOD HYDROCHLORIDE - ZEPOSIA</u>						
N 209899 002 >A>	8481573	Mar 24, 2033	DS DP U-2774			
<u>OZANIMOD HYDROCHLORIDE - ZEPOSIA</u>						
N 209899 003 >A>	8481573	Mar 24, 2033	DS DP U-2774			
<u>PALIPERIDONE PALMITATE - INVEGA HAFYERA</u>						
N 207946 005	12208100	May 07, 2041	U-3359			
	12208100	May 07, 2041	U-4110			
<u>PALIPERIDONE PALMITATE - INVEGA HAFYERA</u>						
N 207946 006	12208100	May 07, 2041	U-3359			
	12208100	May 07, 2041	U-4110			
<u>PALOPEGTERIPARATIDE - YORVIPATH</u>						
N 216490 001					NCE	Aug 09, 2029
<u>PALOPEGTERIPARATIDE - YORVIPATH</u>						
N 216490 002					NCE	Aug 09, 2029
<u>PALOPEGTERIPARATIDE - YORVIPATH</u>						
N 216490 003					NCE	Aug 09, 2029
<u>PALOVAROTENE - SOHONOS</u>						
N 215559 001	12201614	Jun 08, 2037	U-4031			
<u>PALOVAROTENE - SOHONOS</u>						
N 215559 002	12201614	Jun 08, 2037	U-4031			
<u>PALOVAROTENE - SOHONOS</u>						
N 215559 003	12201614	Jun 08, 2037	U-4031			
<u>PALOVAROTENE - SOHONOS</u>						
N 215559 004	12201614	Jun 08, 2037	U-4031			
<u>PALOVAROTENE - SOHONOS</u>						
N 215559 005	12201614	Jun 08, 2037	U-4031			
<u>PATISIRAN SODIUM - ONPATRO</u>						
N 210922 001	8168775	Aug 10, 2032	DS DP U-2378			
<u>PEGULICIANINE ACETATE - LUMISIGHT</u>						
N 214511 001	11592396	Sep 01, 2030	DS			
<u>PHENTOLAMINE MESYLATE - RYZUMVI</u>						
N 217064 001	12201615	Dec 25, 2039	U-3804			
	12201616	Oct 25, 2039	U-3804			
<u>PHYTONADIONE - PHYTONADIONE</u>						
A 214966 001					CGT	Sep 06, 2025
<u>PIRTOBRUTINIB - JAYPIRCA</u>						
N 216059 001	12220401	Dec 16, 2036	DS DP U-3518			
	12220401	Dec 16, 2036	DS DP U-4144			
<u>PIRTOBRUTINIB - JAYPIRCA</u>						
N 216059 002	12220401	Dec 16, 2036	DS DP U-3518			
	12220401	Dec 16, 2036	DS DP U-4144			
<u>PONESIMOD - PONVORY</u>						
N 213498 001	RE43728	Nov 16, 2029	DS DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PONESIMOD - PONVORY</u>						
N 213498 002	RE43728	Nov 16, 2029	DS DP			
<u>PONESIMOD - PONVORY</u>						
N 213498 003	RE43728	Nov 16, 2029	DS DP			
<u>PONESIMOD - PONVORY</u>						
N 213498 004	RE43728	Nov 16, 2029	DS DP			
<u>PONESIMOD - PONVORY</u>						
N 213498 005	RE43728	Nov 16, 2029	DS DP			
<u>PONESIMOD - PONVORY</u>						
N 213498 006	RE43728	Nov 16, 2029	DS DP			
<u>PONESIMOD - PONVORY</u>						
N 213498 007	RE43728	Nov 16, 2029	DS DP			
<u>PONESIMOD - PONVORY</u>						
N 213498 008	RE43728	Nov 16, 2029	DS DP			
<u>PONESIMOD - PONVORY</u>						
N 213498 009	RE43728	Nov 16, 2029	DS DP			
<u>PONESIMOD - PONVORY</u>						
N 213498 010	RE43728	Nov 16, 2029	DS DP			
<u>PYRIDOSTIGMINE BROMIDE - PYRIDOSTIGMINE BROMIDE</u>						
N 217604 001 >A>	12233166	Jun 18, 2038	DP			
<u>REPOTRECTINIB - AUGTYRO</u>						
N 218213 001	12187739	Jul 05, 2036	DP		ODE-483	Jun 13, 2031
<u>REPOTRECTINIB - AUGTYRO</u>						
N 218213 002	12187739	Jul 05, 2036	DP		ODE-483	Jun 13, 2031
<u>REVUMENIB CITRATE - REVUFORJ</u>						
N 218944 001					ODE-504 ODE-505	Nov 15, 2031 Nov 15, 2031
<u>REVUMENIB CITRATE - REVUFORJ</u>						
N 218944 002					ODE-504 ODE-505	Nov 15, 2031 Nov 15, 2031
<u>REVUMENIB CITRATE - REVUFORJ</u>						
N 218944 003					ODE-504 ODE-505	Nov 15, 2031 Nov 15, 2031
<u>RIFAXIMIN - XIFAXAN</u>						
N 021361 002	8309569	Jul 18, 2029	U-1707	Y		
	8309569	Jul 18, 2029	U-1708	Y		
<u>RIPRETINIB - QINLOCK</u>						
N 213973 001	12213967	Dec 30, 2040	DP			
	12213968	Dec 30, 2040	DP			
	12226406	Dec 30, 2040	DP			
<u>RISDIPLAM - EVRYSDI</u>						
N 219285 001	11534444	Oct 04, 2038	U-1943		M-270	Oct 03, 2026
	11827646	Jan 25, 2036	U-1943		NCE	Aug 07, 2025
	12122789	Apr 15, 2041	DS DP			
	9586955	Feb 08, 2033	DS DP			
	9969754	May 11, 2035	DS DP U-1943			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>RISDIPLAM - EVRYSDI</u>						
N 219285 001	11534444	Oct 04, 2038	U-1943		M-270	Oct 03, 2026
	11827646	Jan 25, 2036	U-1943		NCE	Aug 07, 2025
	12122789	Apr 15, 2041	DS DP			
	9586955	Feb 08, 2033	DS DP			
	9969754	May 11, 2035	DS DP U-1943			
<u>ROFLUMILAST - ZORYVE</u>						
N 215985 001	12220409	Jun 07, 2037	DP			
<u>ROFLUMILAST - ZORYVE</u>						
N 215985 002	12220409	Jun 07, 2037	DP			
<u>ROFLUMILAST - ZORYVE</u>						
N 217242 001	12220409	Jun 07, 2037	DP			
<u>RUXOLITINIB PHOSPHATE - OPZELURA</u>						
N 215309 001	>A> 12226419	May 20, 2031	DP			
	>A> 12233067	Jul 28, 2040	U-4151			
<u>SELINEXOR - XPOVIO</u>						
N 212306 005	>A> 10519139	Aug 14, 2035	DS DP U-2584			
	>A> 10519139	Aug 14, 2035	DS DP U-2855			
	>A> 10519139	Aug 14, 2035	DS DP U-3018			
	>A> 10544108	Jul 26, 2032	U-2584			
	>A> 10544108	Jul 26, 2032	U-3018			
	>A> 11034660	Jul 26, 2032	U-2584			
	>A> 11034660	Jul 26, 2032	U-3018			
	>A> 11746102	Aug 14, 2035	U-2584			
	>A> 11746102	Aug 14, 2035	U-2855			
	>A> 11746102	Aug 14, 2035	U-3018			
	>A> 11753401	Aug 14, 2035	DP U-2584			
	>A> 11753401	Aug 14, 2035	DP U-2855			
	>A> 11753401	Aug 14, 2035	DP U-3018			
	>A> 11787771	Jul 26, 2032	U-2584			
	>A> 11787771	Jul 26, 2032	U-2855			
	>A> 11787771	Jul 26, 2032	U-3018			
	>A> 11807629	Aug 14, 2035	DS			
	>A> 8999996	Jul 03, 2033	DS DP			
	>A> 9079865	Jul 26, 2032	U-2584			
	>A> 9079865	Jul 26, 2032	U-2855			
	>A> 9079865	Jul 26, 2032	U-3018			
	>A> 9714226	Jul 26, 2032	DS DP			
<u>SELPERCATINIB - RETEVMO</u>						
N 213246 001					M-311	Sep 27, 2027
					M-312	Sep 27, 2027
<u>SELPERCATINIB - RETEVMO</u>						
N 213246 002					M-311	Sep 27, 2027
					M-312	Sep 27, 2027
<u>SELPERCATINIB - RETEVMO</u>						
N 218160 001					M-311	Sep 27, 2027
					M-312	Sep 27, 2027
<u>SELPERCATINIB - RETEVMO</u>						
N 218160 002					M-311	Sep 27, 2027
					M-312	Sep 27, 2027
<u>SELPERCATINIB - RETEVMO</u>						
N 218160 003					M-311	Sep 27, 2027
					M-312	Sep 27, 2027

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SELPERCATINIB - RETEVMO</u>						
N 218160 004					M-311 M-312	Sep 27, 2027 Sep 27, 2027
<u>SELUMETINIB SULFATE - KOSELUGO</u>						
N 213756 001	12220403	Mar 26, 2029	DP			
	7425637	Mar 13, 2026	DS			
	>A> 8178693	Mar 13, 2026	DS DP			
<u>SELUMETINIB SULFATE - KOSELUGO</u>						
N 213756 002	12220403	Mar 26, 2029	DP			
	7425637	Mar 13, 2026	DS			
	>A> 8178693	Mar 13, 2026	DS DP			
<u>SEMAGLUTIDE - OZEMPIC</u>						
N 209637 001	>A> 10220155	Jul 17, 2026	DP	Y	I-961	Jan 28, 2028
	>A> 10357616	Jan 20, 2026	DP	Y		
	>A> 10376652	Jan 20, 2026	DP	Y		
	>A> 11097063	Jul 17, 2026	DP	Y		
	>A> 11311679	Jan 20, 2026	DP	Y		
	>A> 11446443	Oct 20, 2025	DP	Y		
	>A> 8684969	Oct 20, 2025	DP	Y		
	>A> 8920383	Jul 17, 2026	DP	Y		
	>A> 9108002	Jan 20, 2026	DP	Y		
	>A> 9132239	Feb 01, 2032	DP	Y		
	>A> 9457154	Sep 27, 2027	DP	Y		
	>A> 9616180	Jan 20, 2026	DP	Y		
	>A> 9687611	Feb 27, 2027	DP	Y		
	>A> 9775953	Jul 17, 2026	DP	Y		
	>A> 9861757	Jan 20, 2026	DP	Y		
	>A> RE46363	Aug 03, 2026	DP	Y		
<u>SEMAGLUTIDE - OZEMPIC</u>						
N 209637 002	>A> 10220155	Jul 17, 2026	DP	Y	I-961	Jan 28, 2028
	>A> 10357616	Jan 20, 2026	DP	Y		
	>A> 10376652	Jan 20, 2026	DP	Y		
	>A> 11097063	Jul 17, 2026	DP	Y		
	>A> 11311679	Jan 20, 2026	DP	Y		
	>A> 11446443	Oct 20, 2025	DP	Y		
	>A> 8684969	Oct 20, 2025	DP	Y		
	>A> 8920383	Jul 17, 2026	DP	Y		
	>A> 9108002	Jan 20, 2026	DP	Y		
	>A> 9132239	Feb 01, 2032	DP	Y		
	>A> 9457154	Sep 29, 2027	DP	Y		
	>A> 9616180	Jan 20, 2026	DP	Y		
	>A> 9687611	Feb 27, 2027	DP	Y		
	>A> 9775953	Jul 17, 2026	DP	Y		
	>A> 9861757	Jan 20, 2026	DP	Y		
	>A> RE46363	Aug 03, 2026	DP	Y		
<u>SEMAGLUTIDE - OZEMPIC</u>						
N 209637 003	>A> 10220155	Jul 17, 2026	DP	Y	I-961	Jan 28, 2028
	>A> 10357616	Jan 20, 2026	DP	Y		
	>A> 10376652	Jan 20, 2026	DP	Y		
	>A> 11097063	Jul 17, 2026	DP	Y		
	>A> 11311679	Jan 20, 2026	DP	Y		
	>A> 11446443	Oct 20, 2025	DP	Y		
	>A> 8684969	Oct 20, 2025	DP	Y		
	>A> 8920383	Jul 17, 2026	DP	Y		
	>A> 9108002	Jan 20, 2026	DP	Y		
	>A> 9132239	Feb 01, 2032	DP	Y		
	>A> 9457154	Sep 29, 2027	DP	Y		
	>A> 9616180	Jan 20, 2026	DP	Y		
	>A> 9687611	Feb 27, 2027	DP	Y		
	>A> 9775953	Jul 17, 2026	DP	Y		
	>A> 9861757	Jan 20, 2026	DP	Y		
	>A> RE46363	Aug 03, 2026	DP	Y		

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SEMAGLUTIDE - OZEMPIC</u>						
N 209637 003	>A> 10220155	Jul 17, 2026	DP	Y	I-961	Jan 28, 2028
	>A> 10357616	Jan 20, 2026	DP	Y		
	>A> 10376652	Jan 20, 2026	DP	Y		
	>A> 11097063	Jul 17, 2026	DP	Y		
	>A> 11311679	Jan 20, 2026	DP	Y		
	>A> 11446443	Oct 20, 2025	DP	Y		
	>A> 8684969	Oct 20, 2025	DP	Y		
	>A> 8920383	Jul 17, 2026	DP	Y		
	>A> 9108002	Jan 20, 2026	DP	Y		
	>A> 9132239	Feb 01, 2032	DP	Y		
	>A> 9457154	Sep 29, 2027	DP	Y		
	>A> 9616180	Jan 20, 2026	DP	Y		
	>A> 9687611	Feb 27, 2027	DP	Y		
	>A> 9775953	Jul 17, 2026	DP	Y		
	>A> 9861757	Jan 20, 2026	DP	Y		
	>A> RE46363	Aug 03, 2026	DP	Y		
<u>SEMAGLUTIDE - OZEMPIC</u>						
N 209637 004	>A> 10220155	Jul 17, 2026	DP	Y	I-961	Jan 28, 2028
	>A> 10357616	Jan 20, 2026	DP	Y		
	>A> 10376652	Jan 20, 2026	DP	Y		
	>A> 11097063	Jul 17, 2026	DP	Y		
	>A> 11311679	Jan 20, 2026	DP	Y		
	>A> 11446443	Oct 20, 2025	DP	Y		
	>A> 8684969	Oct 20, 2025	DP	Y		
	>A> 8920383	Jul 17, 2026	DP	Y		
	>A> 9108002	Jan 20, 2026	DP	Y		
	>A> 9132239	Feb 01, 2032	DP	Y		
	>A> 9457154	Sep 29, 2027	DP	Y		
	>A> 9616180	Jan 20, 2026	DP	Y		
	>A> 9687611	Feb 27, 2027	DP	Y		
	>A> 9775953	Jul 17, 2026	DP	Y		
	>A> 9861757	Jan 20, 2026	DP	Y		
	>A> RE46363	Aug 03, 2026	DP	Y		
<u>SEMAGLUTIDE - RYBELSUS</u>						
N 213051 001	10278923	May 02, 2034	U-2628			
	9278123	Dec 16, 2031	DP U-2628			
<u>SEMAGLUTIDE - RYBELSUS</u>						
N 213051 002	10278923	May 02, 2034	U-2628			
	9278123	Dec 16, 2031	DP U-2628			
<u>SEMAGLUTIDE - RYBELSUS</u>						
N 213051 003	10278923	May 02, 2034	U-2628			
	9278123	Dec 16, 2031	DP U-2628			
<u>SEMAGLUTIDE - RYBELSUS</u>						
N 213051 004	10278923	May 02, 2034	DS DP U-2628			
	11382957	Dec 16, 2031	DS DP			
<u>SEMAGLUTIDE - RYBELSUS</u>						
N 213051 005	10278923	May 02, 2034	DS DP U-2628			
	11382957	Dec 16, 2031	DS DP			
<u>SEMAGLUTIDE - RYBELSUS</u>						
N 213051 006	10278923	May 02, 2034	DS DP U-2628			
	11382957	Dec 16, 2031	DS DP			
	9278123	Dec 16, 2031	DS DP U-2628			
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256 001	12214017	Aug 24, 2038	DP U-3162			



## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256 002	12214017	Aug 24, 2038	DP U-3162			
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256 003	12214017	Aug 24, 2038	DP U-3162			
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256 004	12214017	Aug 24, 2038	DP U-3162			
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256 005	12214017	Aug 24, 2038	DP U-3162			
<u>SETMELANOTIDE ACETATE - IMCIVREE</u>						
N 213793 001	>A> 8039435	Aug 21, 2032	DS DP		NPP >A> ODE-508 >A> ODE-509	Dec 20, 2027 Dec 20, 2031 Dec 20, 2031
<u>SILDENAFIL CITRATE - LIOREV</u>						
N 214952 001	12186321	Dec 24, 2038	DP U-3582			
<u>SIPONIMOD - MAYZENT</u>						
N 209884 001	>A> 11944602	Apr 23, 2036	U-3889			
<u>SIPONIMOD - MAYZENT</u>						
N 209884 002	>A> 11944602	Apr 23, 2036	U-3889			
<u>SIPONIMOD - MAYZENT</u>						
N 209884 003	>A> 11944602	Apr 23, 2036	U-3889			
<u>SITAGLIPTIN HYDROCHLORIDE - BRYNOVIN</u>						
N 219122 001	11944621	Oct 23, 2040	DP			
<u>SODIUM OXYBATE - LUMRYZ</u>						
N 214755 001	12226377	Jul 21, 2037	DP			
<u>SODIUM OXYBATE - LUMRYZ</u>						
N 214755 002	12226377	Jul 21, 2037	DP			
<u>SODIUM OXYBATE - LUMRYZ</u>						
N 214755 003	12226377	Jul 21, 2037	DP			
<u>SODIUM OXYBATE - LUMRYZ</u>						
N 214755 004	12226377	Jul 21, 2037	DP			
<u>SOLRIAMFETOL HYDROCHLORIDE - SUNOSI</u>						
N 211230 001	12194016	Mar 19, 2040	U-4106			
	12209059	Jun 07, 2026	U-2548			
<u>SOLRIAMFETOL HYDROCHLORIDE - SUNOSI</u>						
N 211230 002	12194016	Mar 19, 2040	U-4106			
	12209059	Jun 07, 2026	U-2548			
<u>SOTORASIB - LUMAKRAS</u>						
N 214665 001	11236091	May 20, 2040	DS DP U-3306		I-962	Jan 16, 2028
	11236091	May 20, 2040	DS DP U-4107		>A> ODE-507	Jan 16, 2032
	11426404	Sep 15, 2040	U-3306			
	11426404	Sep 15, 2040	U-4107			
	11827635	May 20, 2040	DS DP U-3306			
	11827635	May 20, 2040	DS DP U-4107			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SOTORASIB - LUMAKRAS</u>						
N 214665 002	11236091	May 20, 2040	DS DP U-3306		I-962	Jan 16, 2028
	11236091	May 20, 2040	DS DP U-4107		>A> ODE-507	Jan 16, 2032
	11426404	Sep 15, 2040	U-3306			
	11426404	Sep 15, 2040	U-4107			
	11827635	May 20, 2040	DS DP U-3306			
	11827635	May 20, 2040	DS DP U-4107			
<u>SOTORASIB - LUMAKRAS</u>						
N 214665 003	11236091	May 20, 2040	DS DP U-3306		I-962	Jan 16, 2028
	11236091	May 20, 2040	DS DP U-4107		>A> ODE-507	Jan 16, 2032
	11426404	Sep 15, 2040	U-3306			
	11426404	Sep 15, 2040	U-4107			
	11827635	May 20, 2040	DS DP U-3306			
	11827635	May 20, 2040	DS DP U-4107			
<u>SUGAMMADEX SODIUM - BRIDION</u>						
N 022225 001					NPP PED	Dec 12, 2027 Jun 12, 2028
<u>SUGAMMADEX SODIUM - BRIDION</u>						
N 022225 002					NPP PED	Dec 12, 2027 Jun 12, 2028
<u>SUZETRIGINE - JOURNAVX</u>						
N 219209 001	11834441	Dec 04, 2040	DS DP U-4125		NCE	Jan 30, 2030
<u>TADALAFIL - TADLIO</u>						
N 214522 001	12186322	Dec 24, 2038	DP U-3397			
<u>TAPINAROF - VTAMA</u>						
N 215272 001	10426743	May 19, 2036	U-2625		I-956	Dec 12, 2027
	10426743	May 19, 2036	U-4048			
	11497718	Nov 13, 2039	U-4048			
	11612573	May 19, 2036	U-2625			
	11612573	May 19, 2036	U-4048			
	11938099	Nov 13, 2039	U-4048			
<u>TASIMELTEON - HETLIOZ</u>						
N 205677 001	12201604	Jan 25, 2033	U-3003			
	12201604	Jan 25, 2033	U-3865			
<u>TASIMELTEON - HETLIOZ LQ</u>						
N 214517 001	12201604	Jan 25, 2033	U-3003			
<u>TAZEMETOSTAT HYDROBROMIDE - TAZVERIK</u>						
N 211723 001	12161645	Sep 12, 2031	U-2853			
	12162865	May 21, 2034	U-2736			
	12168014	May 03, 2038	U-2736			
	12168014	May 03, 2038	U-2852			
	12168014	May 03, 2038	U-2853			
	12168015	Sep 12, 2031	DS DP			
	12168016	Sep 12, 2031	U-2736			
	12168016	Sep 12, 2031	U-2853			
<u>TENOFOVIR ALAFENAMIDE FUMARATE - VEMLIDY</u>						
N 208464 001	7390791	Jan 07, 2025	DS DP			
	7390791*PED	Jul 07, 2025				
<u>TETRACAINE HYDROCHLORIDE - TETRACAINE HYDROCHLORIDE</u>						
A 217227 001					CGT	Jun 25, 2025

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>THIOTEPA - TEPYLUTE</u>						
N 216984 002	11975013	Aug 16, 2041	DP			
<u>TIOTROPIUM BROMIDE - SPIRIVA RESPIMAT</u>						
N 021936 001	>A> 7396341	Oct 10, 2026	DP	Y		
	>A> 7396341*PED	Apr 10, 2027				
	>A> 7837235	Mar 13, 2028	DP	Y		
	>A> 7837235*PED	Sep 13, 2028				
	>A> 7896264	May 26, 2025	DP	Y		
	>A> 7896264*PED	Nov 26, 2025				
	>A> 8733341	Oct 16, 2030	DP	Y		
	>A> 8733341*PED	Apr 16, 2031				
	>A> 9027967	Mar 31, 2027	DP	Y		
	>A> 9027967*PED	Sep 30, 2027				
<u>TIOTROPIUM BROMIDE - SPIRIVA RESPIMAT</u>						
N 021936 002	>A> 7396341	Oct 10, 2026	DP	Y		
	>A> 7396341*PED	Apr 10, 2027				
	>A> 7837235	Mar 13, 2028	DP	Y		
	>A> 7837235*PED	Sep 13, 2028				
	>A> 7896264	May 26, 2025	DP	Y		
	>A> 7896264*PED	Nov 26, 2025				
	>A> 8733341	Oct 16, 2030	DP	Y		
	>A> 8733341*PED	Apr 16, 2031				
	>A> 9027967	Mar 31, 2027	DP	Y		
	>A> 9027967*PED	Sep 30, 2027				
<u>TIRZEPATIDE - ZEPBOUND (AUTOINJECTOR)</u>						
N 217806 001					I-958	Dec 20, 2027
<u>TIRZEPATIDE - ZEPBOUND (AUTOINJECTOR)</u>						
N 217806 002					I-958	Dec 20, 2027
<u>TIRZEPATIDE - ZEPBOUND (AUTOINJECTOR)</u>						
N 217806 003					I-958	Dec 20, 2027
<u>TIRZEPATIDE - ZEPBOUND (AUTOINJECTOR)</u>						
N 217806 004					I-958	Dec 20, 2027
<u>TIRZEPATIDE - ZEPBOUND (AUTOINJECTOR)</u>						
N 217806 005					I-958	Dec 20, 2027
<u>TIRZEPATIDE - ZEPBOUND (AUTOINJECTOR)</u>						
N 217806 006					I-958	Dec 20, 2027
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 007					I-958	Dec 20, 2027
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 008					I-958	Dec 20, 2027
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 009					I-958	Dec 20, 2027
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 010					I-958	Dec 20, 2027
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 011					I-958	Dec 20, 2027
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 012					I-958	Dec 20, 2027

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TIVOZANIB HYDROCHLORIDE - FOTIVDA</u>						
N 212904 001	7166722	Nov 16, 2028	DS DP			
<u>TIVOZANIB HYDROCHLORIDE - FOTIVDA</u>						
N 212904 002	7166722	Nov 16, 2028	DS DP			
<u>TOFACITINIB CITRATE - XELJANZ</u>						
N 203214 001	RE41783	Dec 08, 2025	DS	>A> M-14		Feb 21, 2028
	RE41783*PED	Jun 08, 2026		>A> PED		Aug 21, 2028
<u>TOFACITINIB CITRATE - XELJANZ</u>						
N 203214 002	RE41783	Dec 08, 2025	DS			
	RE41783*PED	Jun 08, 2026				
<u>TOFACITINIB CITRATE - XELJANZ XR</u>						
N 208246 001	11253523	Mar 14, 2034			U-3326	
	11253523	Mar 14, 2034			U-3327	
	11253523	Mar 14, 2034			U-3328	
	11253523	Mar 14, 2034			U-3329	
	11253523*PED	Sep 14, 2034				
	9937181	Mar 14, 2034	DP			
	9937181*PED	Sep 14, 2034				
	RE41783	Dec 08, 2025	DS			
	RE41783*PED	Jun 08, 2026				
<u>TOFACITINIB CITRATE - XELJANZ XR</u>						
N 208246 002	10639309	Mar 14, 2034	DP			
	10639309*PED	Sep 14, 2034				
	11253523	Mar 14, 2034			U-3326	
	11253523	Mar 14, 2034			U-3327	
	11253523	Mar 14, 2034			U-3328	
	11253523	Mar 14, 2034			U-3329	
	11253523*PED	Sep 14, 2034				
	RE41783	Dec 08, 2025	DS			
	RE41783*PED	Jun 08, 2026				
<u>TOFACITINIB CITRATE - XELJANZ</u>						
N 213082 001	RE41783	Dec 08, 2025	DS	>A> M-14		Feb 21, 2028
	RE41783*PED	Jun 08, 2026		>A> PED		Aug 21, 2028
<u>TRAVOPROST - IDOSE TR</u>						
N 218010 001	12201555	Feb 14, 2031	DS DP			
	12201557	Jun 18, 2030	DS DP U-4129			
<u>TREOSULFAN - GRAFAPEX</u>						
N 214759 001	7199162	Oct 12, 2025	U-4142		NCE	Jan 21, 2030
<u>TREOSULFAN - GRAFAPEX</u>						
N 214759 002	7199162	Oct 12, 2025	U-4142		NCE	Jan 21, 2030
<u>TRILACICLIB DIHYDROCHLORIDE - COSELA</u>						
N 214200 001	12168666	Nov 13, 2040	DS DP			
<u>TUCATINIB - TUKYSA</u>						
N 213411 001	>A> 7452895	Nov 16, 2025	DS DP U-2788			
	>A> 7452895	Nov 16, 2025	DS DP U-4153			
<u>TUCATINIB - TUKYSA</u>						
N 213411 002	>A> 7452895	Nov 16, 2025	DS DP U-2788			
	>A> 7452895	Nov 16, 2025	DS DP U-4153			
<u>UBROGEPANT - UBRELVY</u>						
N 211765 001	12168004	Jan 30, 2035	DP			
	12194030	Dec 22, 2041	U-4121			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>UBROGEPANT - UBRELVY</u>						
N 211765 001	12194030	Dec 22, 2041	U-4122			
	>A> 12220408	Jan 30, 2035	DP			
<u>UBROGEPANT - UBRELVY</u>						
N 211765 002	12168004	Jan 30, 2035	DP			
	>A> 12220408	Jan 30, 2035	DP			
<u>VAMOROLONE - AGAMREE</u>						
N 215239 001	12201639	Mar 17, 2040	DS DP U-3747			
<u>VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE</u>						
N 211962 001	12161690	Nov 06, 2035	DP			
<u>VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE</u>						
N 211962 002	12161690	Nov 06, 2035	DP			
<u>VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE</u>						
N 211962 003	12161690	Nov 06, 2035	DP			
<u>VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE</u>						
N 211962 004	12161690	Nov 06, 2035	DP			
<u>VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE</u>						
N 211962 005	12161690	Nov 06, 2035	DP			
<u>VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE</u>						
N 211962 006	12161690	Nov 06, 2035	DP			
<u>VANCOMYCIN HYDROCHLORIDE - VANCOMYCIN HYDROCHLORIDE</u>						
N 211962 007	12161690	Nov 06, 2035	DP			
<u>VASOPRESSIN - VASOSTRICT</u>						
N 204485 005	12186362	Jan 30, 2035	DP			
<u>VIBEGRON - GEMTESA</u>						
N 213006 001	12180219	Mar 12, 2034	DS DP		I-955	Dec 18, 2027
<u>VILOXAZINE HYDROCHLORIDE - QELBREE</u>						
N 211964 001	9662338	Apr 02, 2035	DP			
<u>VILOXAZINE HYDROCHLORIDE - QELBREE</u>						
N 211964 002	9662338	Apr 02, 2035	DP			
<u>VILOXAZINE HYDROCHLORIDE - QELBREE</u>						
N 211964 003	9662338	Apr 02, 2035	DP			
<u>VIMSELTINIB - ROMVIMZA</u>						
N 219304 001	11103507	Feb 03, 2040	U-4145		NCE	Feb 14, 2030
	11679110	Feb 03, 2040	U-4145			
	9181223	Mar 14, 2034	DS DP			
<u>VIMSELTINIB - ROMVIMZA</u>						
N 219304 002	11103507	Feb 03, 2040	U-4145		NCE	Feb 14, 2030
	11679110	Feb 03, 2040	U-4145			
	9181223	Mar 14, 2034	DS DP			
<u>VIMSELTINIB - ROMVIMZA</u>						
N 219304 003	11103507	Feb 03, 2040	U-4145		NCE	Feb 14, 2030
	11679110	Feb 03, 2040	U-4145			
	9181223	Mar 14, 2034	DS DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2025

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>VOSORITIDE - VOXZOGO</u>						
N 214938 001 >A>	12233106	Jul 11, 2042	U-3927			
<u>VOSORITIDE - VOXZOGO</u>						
N 214938 002 >A>	12233106	Jul 11, 2042	U-3927			
<u>VOSORITIDE - VOXZOGO</u>						
N 214938 003 >A>	12233106	Jul 11, 2042	U-3927			
<u>ZURANOLONE - ZURZUVAE</u>						
N 217369 001	11884696	Aug 23, 2037	U-2552			
<u>ZURANOLONE - ZURZUVAE</u>						
N 217369 002	11884696	Aug 23, 2037	U-2552			
<u>ZURANOLONE - ZURZUVAE</u>						
N 217369 003	11884696	Aug 23, 2037	U-2552			

## PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 45<sup>TH</sup> Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at [http://www.accessdata.fda.gov/scripts/cder/ob/results\\_patent.cfm](http://www.accessdata.fda.gov/scripts/cder/ob/results_patent.cfm)

The current complete list of exclusivity terms is available at [http://www.accessdata.fda.gov/scripts/cder/ob/results\\_exclusivity.cfm](http://www.accessdata.fda.gov/scripts/cder/ob/results_exclusivity.cfm)